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Summary 
Liquid chromatography - mass spectrometry (LC-MS) is the ultimate combination of 
gentle separation and the unrivalled specificity of a mass spectrometer. Finally compounds 
not suited to gas chromatography (GC) can be analysed without compromising the 
extensive qualitative data the mass spectrometer provides. The aim of this project was to 
evaluate the use of LC-MS in the forensic toxicology setting. To investigate if its use 
could solve problems encountered while using other instrumentation including downtime, 
limits of detection, chromatography and specificity. 
Benzodiazepines as a class, are known for their undesirable chromatographic behaviour 
when using GC. One way to improve their chromatographic behaviour is to derivatise. 
This is not only time consuming but uses harmful chemicals. Even with derivatisation, 
these drugs can decompose in the injection port, before they are even applied to the 
column. Routinely, diazepam and its metabolites are analysed by high pressure liquid 
chromatography (HPLC) with ultraviolet (UV) detection. The chromatography is 
improved, but specificity is compromised. The use of LC-MS was investigated as an 
alternative to classical HPLC. 
Using LC-MS two methods were developed for the analysis of these drugs in whole blood. 
Increasing awareness of drug facilitated sexual assault, has led to an increase in the number 
of cases to be analysed for drugs such as Rohypnolill• This prompted the development and 
validation of a sensitive and specific method for its detection in blood using solid phase 
extraction and liquid chromatography - mass spectrometry. 
To enhance the qualitative data and cope with degraded samples, the use LC-MS was used 
in the analysis of diazepam and its three metabolites. A method was developed and 
validated and is now used in the routine analysis of blood samples in the laboratory. 
The LC-MS proved invaluable in the analysis of sildenafil, Viagra®, in a post-mortem 
blood sample received in the laboratory. A single quadrupole mass spectrometer was used 
to develop and validate a method to determine if the dose was therapeutic or toxic. 
Summary xv 
The use of oral fluid as an alternative specimen to blood or urine was investigated. This 
was through the British Roadside Impairment Test Evaluation (BRITE) project, evaluating 
the field impairment test (FIT), and the IMMORTAL project, analysing oral fluid from a 
random selection of drivers around the city of Glasgow. LC-MS in combination with GC-
MS was used to screen for over 50 licit and illicit drugs in ImL of oral fluid. LC-MS-MS 
was then used to identify and quantitate 21 drugs of abuse and their metabolites using a 
similar sample size. The use of one extraction and the reliability of LC-MS proved 
invaluable in these projects. 
Currently urine is used to assess recent drug use in rehabilitation centres. The use of oral 
fluid as an alternative was evaluated. Blood, urine and oral fluid, collected using two 
different devices, were volunteered from patients on admission to a residential 
rehabilitation centre for 5 consecutive days. Opiates and benzodiazepines were monitored, 
to assess the detection window of past heroin use. Oral fluid concentrations were 
compared with respective blood samples to give and an indication oflevels likely to be 
found. 
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1 Introduction 
The use of LC-MS in all sectors of analytical chemistry has been increasing at an 
exponential rate in recent years 1• After mastering how to couple liquid chromatography to 
mass spectrometry with the development of atmospheric pressure ionisation (API), LC-MS 
has revolutionised the way routine forensic toxicology is carried out. Before the advent of 
LC-MS the compromise would be the use ofUV spectra for drugs not amenable to Ge-
MS. Now these drugs can have both the qualitative data ofMS with the chromatography 
of HPLC. LC-MS is also ideal for developing and validating a method quickly, downtime 
is much less compared to GC-MS, and analytes are easily identified initially by their 
pseudo-molecular ion. 
One class of drugs found to chromatograph well by HPLC are the benzodiazepines. In 
forensic toxicology, post-mortem blood is often used for analysis, and since this can be 
substantially degraded, the products can cause increased interference in the detector signal. 
Diazepam and its metabolites N-desmethyldiazepam, temazepam and oxazepam are 
routinely analysed in whole blood. If a mass spectrometer could be used for detection, 
specificity would be greater leading to a decrease in the background noise and hence better 
detection limits and less interferents to be concerned about. 
Flunitrazepam is becoming renowned as a "date rape" drug, and its identification in bodily 
fluids increasingly requested. By using LC-MS, flunitrazepam and its metabolite 7-
aminoflunitrazepam can be chromatographed easily and positively identified, to very low 
concentrations. This is essential when the memory of the victim may be affected, the 
report of a crime may be delayed, and the amount administered may be only 1 or 2 mg. 
Oral fluid has gained much interest in recent years. Being an ultrafiltrate of blood, oral 
fluid drug concentrations are related to the unbound, pharmacologically active fraction in 
blood. This has resulted in its use for therapeutic drug monitoringl03• However, recently its 
use as a roadside specimen, to identify impaired drivers, has been of utmost interest. 
Projects have been carried out to evaluate the impairment effects of drugs on driving and 
their detection and subsequent presentation to the judicial system, such as ROSITA 4• The 
use of field impairment tests (FIT) have also been of interest to objectively assess the 
ability of the driver at the roadside. As part of the evaluation of FIT, oral fluid was taken 
when the driver was found not to be impaired by FIT. Only 1 mL of oral fluid was 
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obtained and had to be screened for a wide range of drugs of abuse, prescription and over 
the counter drugs. The use of GC-MS for its screening ability of unknowns, as well as the 
reliability of LC-MS would complement each other, and cover an extensive range of 
analytes. 
Using an LC-MS-MS gives even greater specificity, and can produce mass spectra that 
look similar to GC-MS spectra with many qualitative ions. 
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2 Liquid Chromatography - Mass Spectrometry 
2.1 Introduction 
The technique of separating compounds using chromatography has been in practice since 
the beginning of the 20th century. Tswett described the separation of plant pigments by 
percolating an extract through a glass column packed with calcium carbonate in 19035• 
Chromatography relies on two phases, a stationary and mobile phase. The stationary phase 
can be solid spheres packed into a column or a liquid coated onto a capillary wall. The 
mobile phase can be liquid or gas and flows through and around the stationary phase. 
When compounds are introduced to this environment, they will behave differently 
depending on the types of stationary and mobile phases present. Different analytes are 
retained on the stationary phases for varying amounts of time. The two most common 
methods used to encourage the elution of all analytes are raising the temperature, as in gas 
chromatography, or increasing the percentage of organic solvent as in reverse phase liquid 
chromatography. 
2.1.1 Gas Chromatography 
In Capillary Gas Chromatography (CGC), the stationary phase consists of a liquid coated 
onto the inside wall of a silica capillary. The capillary can be up to 30 m in length and as 
little as 0.1 mm in internal diameter. The mobile phase is an inert gas such as helium, 
which carries the compounds through the column and on to the detector. To separate a 
mixture, the temperature of the column is increased over time to an upper limit e.g. 300 °C. 
Volatile and inert compounds with few polar functional groups elute first. Compounds 
with many functionalities are preferentially attracted to the stationary phase and therefore 
require higher temperatures to elute them. They are retained for different lengths of time, 
dictated by their structure. Analytes which elute quickly have short retention times and 
more complex molecules are retained for longer. 
To observe analytes eluting from the column a detector is needed. Typically a flame 
ionisation detector (Fill) is used for organic compounds. This is a non-specific detector as 
it gives quantitative but not qualitative information about the analyte. Other detectors 
include nitrogen phosphorous detector (NPD) or electron capture detector (BCD). Neither 
of these gives detailed structural information about the analyte. All rely on unique 
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retention times as qualitative data. Using mass spectrometry as a detector can give an 
enormous amount of structural information making it very specific and almost negating the 
need for resolution in the CGC. The gaseous effluent from the gas chromatograph makes it 
a relatively simple process to attach the end of the column to a mass spectrometer ion 
source. As the gas enters the mass spectrometer, it is bombarded with electrons as with 
electron impact ionisation, EI. This ionisation is referred to as "hard ionisation" as it 
fragments the analyte into many unique daughter ions. This technique gives immense 
structural information and very specific qualitative data. Thus Gas Chromatography -
Mass Spectrometry (GC-MS) has become the standard analytical technique for forensic 
toxicology. 
Nonetheless, there are some compounds for which GC-MS is not completely satisfactory. 
If a compound is thermally labile, it may decompose in the GC injection port e.g. 
temazepam. This problem can be overcome by changing the functional groups, making 
them more stable and less reactive with the stationary phase. However, derivatisation adds 
a step onto the extraction method and the chemicals used can be toxic. It introduces 
another source of possible error and consumes more time and reagents. 
2.1.2 Liquid Chromatography 
In benzodiazepine analysis, reversed phase high pressure liquid chromatography, RP-
HPLC, is commonly used. Liquid chromatography uses columns packed with small 
spheres, 3 ~ in diameter, as the stationary phase, and a composition of aqueous and 
organic solvents as the mobile phase. 
When using reversed phase liquid chromatography, increasing the organic content of the 
mobile phase has the same effect as increasing the temperature in gas chromatography. In 
this way even extremely polar drugs are eluted from the column. HPLC is typically 
coupled with ultraviolet (UV) detectors, measuring the changes in absorbance at different 
wavelengths, as different compounds elute off the column and flow through the detector 
cell. This technique relies on compounds being UV absorbent The UV detector works 
well for the benzodiazepines, as they have specific absorbency wavelengths. 
In order to use mass spectrometry with liquid chromatography, the mobile phase must be 
removed in such a way as to allow the anaIytes to enter the mass spectrometer which is 
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kept under vacuum. This has only become possible in the last two decades therefore 
allowing the successful interface of liquid chromatography with mass spectrometry. 
2.2 Liquid Chromatography - Mass Spectrometry 
2.2. 1 The Mobile Phase 
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The mobile phase in LC-MS is very important for both the separation and ionisation of 
analytes. It usually comprises of two parts, the organic phase and the aqueous phase. 
Routinely in HPLC the aqueous part is made up of phosphate buffers at varying molarities 
and pH's. Phosphate buffers cannot be used in LC-MS because they are not volatile and 
will block the entrance to the source, by crystallising out. The main alternatives are acetate 
or formate buffers. Salts present in the mobile phase can affect the spectra by forming 
adducts with the analyte. In toxicology, buffers are commonly used to control the pH of a 
sample for efficient extraction. It is important to have not only good recovery in the 
extraction used, but also a clean extract with no buffer present, to minimise adduct 
formation. If adducts are formed then the number of analyte molecules remaining to 
produce the pseudo molecular ion, [M+Ht, is reduced therefore decreasing sensitivity. 
Buffers or additives can be used but there are conflicting views on how changing the 
mobile phase in this way affects the fragmentation patterns. One group showed that 
changes in acetonitrile concentration did not cause dramatic variation in spectra, except 
that the acetonitrile adduct was more often visible at high concentrations ofacetonitrile6• 
In an earlier paper, the authors commented that the extent of fragmentation ofmorphine-3-
glucuronide and morphine-6-glucuronide was greatly dependent on the acetonitrile 
concentration, i.e. fragmentation increased with increasing acetonitrile concentration7• A 
second group opposed this theory of fragmentation increasing with acetonitrile 
concentration. They carried out controlled experiments that showed fragmentation was 
stable and independent of the composition of the mobile phase, ranging from 0-90% 
acetonitrile8• A third group argued that the different batches of mobile phase used had 
varied their fragmentation of LSD9• 
Another reason for the use of buffers in the mobile phase is to increase the response of the 
analyte. Formic acid is used routinely, with varying concentrations, especially when 
analysing basic drugs. One group used both ammonium acetate (SmM) and formic acid 
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(0.1 %) in the mobile phase for optimal sensitivity and separation of their analyteslO. They 
also noted that the addition of formic acid was essential in preventing the hydrolysis of 
cocaine. Another group claims that the lowest possible concentration of formic acid was 
best for ion production, but too Iowa concentration would result in insufficient control of 
separation pH and thus a less robust methodll • With respect to analysing 1,4-
benzodiazepines, one group found the addition of traces of acid e.g. 0.05% trifluoroacetic 
acid did not enhance the ion yield'2• Using trifluoroacetic acid as a buffer is uncommon in 
LC-MS and the authors do not comment on any other acids tested. 
The addition of a buffer has also been seen to be preferential for more reproducible 
retention times'3 • Another reason for using a buffer in the mobile phase is to ionise the 
analytes before they are injected onto the system by reconstituting samples in the mobile 
phase. It has been demonstrated that electro spray ionisation is most efficient with 
compounds already ionised in solution'4• For example using a moderately acidic mobile 
phase for basic compounds of interest. The acid mobile phase had an excess oflt" ions 
encouraging the addition of a proton on to a basic drug. 
The many differing opinions on the cause of spectral variation suggest that the reasons for 
these variations exist in each system to some extent, and are dependent on the analyte 
concerned. System history has its part to play in spectra variation, especially if the 
instrument is being used for a variety of analytes and mobile phase systems. 
2.2.2 The Column 
Columns used in HPLC are between 200 and 300 mm in length with an internal diameter 
of 4.6 mm. The flow rate is usually -1 mUmin. When using LC-MS the interface dictates 
that the flow rate must be lower so that there is less mobile phase to evaporate in the 
source, but the high pressure must still be present. Smaller columns are therefore used 
with a maximum length of 150 mm and an internal diameter of2.1 mm. 
2.2.3 The Interface 
In general, LC-MS uses atmospheric pressure ionisation, API, to interface the liquid 
chromatograph with the mass spectrometer. As the LC flow emerges from the column it is 
directed through a capillary to the ion source of the mass spectrometer. The interface is 
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positioned orthogonally to the source entrance in order to avoid excess contamination of 
the source. The source is under vacuum, however the interface is at atmospheric pressure. 
As the effluent sprays out of the interface a high percentage of it is lost while the rest is 
drawn into the source through the entrance cone. 
The probe is set at a high temperature e.g. 300°C, which is dependent on the flow-rate. 
This high temperature and the nitrogen flow helps to desolvate the liquid emerging from 
the capillary. Source conditions can be optimised for varying mobile phases, flow-rates 
and analytes used. 
In LC-MS there are two common interfaces used, atmospheric pressure chemical 
ionisation, APCI and electro spray ionisation, ESI. In most instruments the interfaces can 
be interchanged easily, allowing the use of either. 
Both ESI and APCI use soft ionisation to ionise the analytes as opposed to the hard 
ionisation used in GC-EI-MS. By using soft ionisation, the analyte is not exposed to such 
forces and often only the pseudo molecular ion is formed. If it is a basic compound then a 
proton is added [M+H]+, or if an acidic compound a proton is removed [M-Hr. When 
using buffers in the mobile phase there is an increased chance of adduct formation with the 
analyte molecules. Ammonium, sodium and potassium are common adducts resulting in 
the analyte molecular weight plus 18, 23, and 39 respectively, these are denoted as 
[M+18]+mi/, [M+23]~a+ and [M+39]"1(+. 
One study showed that in APCI mode, using a single quadrupole mass spectrometer, 
spectra are dependent on the system history. A 6-MAM standard was analysed and four 
adducts were found, when analysed eight months later there were no adducts. The authors 
suggest that the heated vaporiser used in the APeI interface is a possible source of 
variability in fragmentation and adduct formation. They found that ESI showed better 
long-term reproducibility6. 
2.2.3.1 Atmospheric Pressure Chemical Ionisation 
When using APe!, the probe is inserted into a heated nebulizer. The capillary, which 
carries the liquid from the HPLC column and into the probe, is situated in a second 
cylinder. Nitrogen gas is passed between the cylinders to aid the conversion ofliquid out 
of the capillary end into a stream of droplets. The mobile phase is evaporated quickly and 
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the analytes are charged while in the gaseous state. This process is shown in Figure 2-1. A 
corona discharge pin is located just at the opening of the probe. A potential is applied to 
this, aiding ionisation of the buffer molecules present in the mobile phase. These ionised 
buffer molecules collide with the analyte molecules and protons are transferred. As high 
temperatures are involved, APCI is not suitable for compounds that are thermally labile as 
there may be thermal degradation . 
• •• 
•• • ,  Charo-e n Heat .... . ~:.~: to 
• • • ~oed ~ • 
[ • • • • ~~~ge~t gas • • • 
c.orona .' • formed •• 
pm Analyte ions 
formed 
Figure 2-1 : Atmospheric pressure chemical ion isation process 
2.2.3.2 Electrospray Ionisation 
Electrospray ionisation has been used more frequently than APCI, probably because of its 
ability to ionise larger molecules, such as proteins and more polar molecules. The ESI 
interface has been used to analyse benzodiazepines 15, 16, 12.13 , cannabinoids 17.18 , cocaine I9,20.2 1, 
lysergic acid diethylamide9.l\ and opiates7.ll ,22 . One group, using ESI, has developed a 
broad drug screening method which can be used to identify seventeen basic drugs from a 
variety of c1asses23. 
In contrast to the APCI interface, ESI ionises the analytes in the effluent as they spray out 
of the interface followed by the evaporation of the solvent. Since the analytes are ionised 
in solution and then desolvated, thermally labile molecules can be ionised without 
degradation24. The ESI probe has a voltage applied, which charges the molecules as they 
exit the probe. This probe voltage can be varied from 0 to 5 kY. 
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As droplets flow out of the ESI probe they are full of charged ions. As the solvent 
evaporates the droplets become smaller and the charges are brought closer together. When 
the repulsive forces of the charged species on the surface of the droplet are sufficient to 
overcome the cohesive forces of surface tension, columbic explosions occur which split the 
droplets into smaller droplets. This cycle continues until the analyte ion is sufficiently 
desolvated to enter the source, refer to Figure 2-2 . 
.: .. 
• •• • 
• ••• 
• • • •• 
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RayleighL 
Limit 
reached 
• Basic analyte 
• Solvent molecules 
Figure 2-2 : Electrospray ionisation process 
2.2.4 The Ion Source 
Solvent ion 
cluster 
@ 
n 
• Analyte ion 
On leaving the probe the analytes will be charged but will not necessarily have formed the 
pseudo molecular ion. The charged molecules enter the source via the skimmer or 
entrance cone, shown in Figure 2-3. In-source fragmentation can be achieved by applying 
a voltage to the skimmer cone. It can be varied from 0 to 100 V. The aim of this voltage is 
to fragment the analyte further, to obtain more qualitative information or to knock off any 
adducts from the molecular ion. Increasing the voltage applied to the skimmer cone will 
increase fragmentation. In the ThermoFinnigan AQA instrument, this voltage can be 
changed rapidly between scans, providing the ability to monitor a drug eluting from the 
column, at different voltages showing the pseudo molecular ion and a qualitative ion. 
Applying a voltage to the skimmer cone to induce fragmentation is also known as "cone 
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voltage" fragmentation. From the skimmer cone the ions are directed into the mass 
analyser. In the ThermoFinnigan AQA instrument this is a single quadrupole. 
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Figure 2-3 : Diagram of ion source in Finnigan AQA 
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The ion source in the LCQ instrument is very similar to the AQA. "In-source" 
fragmentation can be performed, but with the use of the ion trap to fragment ions further, it 
is not essentia1. As the charged analyte molecules leave the probe they enter the source 
through the skimmer cone and down a long transfer line to the ion trap. 
2.2.5 The Analyser 
There are many analysers available for LC-MS, the quadrupole, ion trap, time of flight and 
magnetic sector, not to mention hybrids of these. For this project two different instruments 
were used, the ThermoFinnigan AQA, a single quadrupole mass analyser, and the 
ThermoFinnigan LCQ Advantage, an ion trap analyser. 
2.2.5.1 Single Quadrupole, ThermoFinnigan AQA 
The quadrupole is the most common of analysers and can be used singularly as in the 
ThermoFinnigan AQA or in tandem (triple quadrupole) to give greater sensitivity and more 
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spectral infonnation. Its function is to filter the ions produced in the source into their 
mass/charge ratios. The quadrupole is made up of four rods parallel to each other making 
up four vertices of a cuboid. Figure 2-4 shows the view an ion would have travelling into 
the quadrupole. 
8 CB 
CB 8 
Figure 2-4 : End-on view of quadrupole 
The voltages applied consist of both RF and DC components l • Each voltage has a 
mass/charge ratio associated with it. If the mass/charge ratio does not match the voltage 
applied the ion spirals out of control and hits one of the rods, thus allowing only ions of a 
certain masS/charge ratio to pass through onto the detector. When using full scan analysis 
the quadrupoles scan through a range of mass/charge ratios. If Single Ion Monitoring 
(SIM) is used the quadrupoles identify specific ions detennined by the user. 
2.2.5.2 Ion Trap, TherrnoFinnigan LeQ Advantage 
The ion trap analyser is fonned out of three stainless steel electrodes. The ring electrode, 
which looks like a doughnut, and two endcaps which sit on either side fonning a cavity 
within. The endcaps have small holes in the centre of them to allow ions to enter and exit 
the trap. It is sometimes described as a three-dimensional quadrupole24• Instead of an ion 
having a stable trajectory following through the analyser and onto the detector, it is 
trapped. Figure 2-5 shows a cross section of the trap. 
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Figure 2·5 : Cross section of ion trap 
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Helium is present within the ion trap cavity at a partial pressure of -0.1 Pa. Heliwn is an 
important part of the trap as it greatly enhances sensitivity. When ions enter the cavity 
they collide with the helium atoms, thus reducing their kinetic energy and the amplitude of 
their oscillations. This results in the ions being focused into the centre of the cavity instead 
of being allowed to spread out. The helium atoms are also used in tandem mass 
spectrometry (MS-MS) to collide with the parent ion with sufficient energy to dissociate it 
into one or more daughter ions. 
When all the ions above a specified mass/charge ratio are trapped, a voltage is applied to 
the endcap electrodes and the voltage on the ring electrode is increased to eject all the ions 
sequentially as in Full MS mode. For MS-MS analyses an RF voltage is applied to the 
endcap electrodes to cause collision induced dissociation. The trap now contains the 
product ions of the pseudo-molecular ion. As before, these ions are scanned out by 
increasing the ring electrode voltage while simultaneously applying a voltage to the endcap 
electrode to facilitate ejection of the ions. Ions of increasing mass/charge ratio become 
unstable and are ejected from the trap to go on to the detectors. 
2.2.6 The Detector 
Once an ion has successfully made it through the analyser it reaches the detector. The 
main component in the detector is the photomultiplier tube. The ion strikes a conversion 
dynode that emits electrons. These electrons hit a phosphor screen that emits photons. 
The photons go on to the photocathode in front of the photomultiplier where an electron 
cascade is created. The cascade magnifies the original signal by -1,000,000 times and it is 
this signal that is then converted into a voltage that can be analysed and processed by the 
computer on board the instrumenf6. 
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An example of a mass spectra produced using an ion trap to obtain MS-MS data is shown 
in Figure 2-6. This shows the number of specific daughter ions produced which can all be 
used are further qualitative data. The chromatogram is produced by plotting each ion in 
the spectra over time. The area under the peak is related to the relative abundance of each 
ion in the spectra. 
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Figure 2-6 : Typical extracted chromatogram and MS-MS mass spectra obtained using an 
ion trap analyser. 
2.2.7 Matrix Effect 
26a 1 
Matrix effects from biological samples, e.g. blood, urine and oral fluid, play an important 
role in LC-MS. They can be described as a change in the ionisation process of an analyte, 
due to a co-eluting compound from the matrix. Ionisation of the analyte molecule occurs 
at the interface of the LC-MS. A complex series of charge-transfer and ion-transfer 
reactions occur to ionise the analyte molecule27 • It is clear that the matrix constituents 
present in the eluent will affect the efficiency of ionisation resulting in ion suppression or 
enhancement. ESI has been found to be more susceptible to matrix effects than APCI due 
to the different processes used to ionise analyte molecules2 • 
As ionisation of analytes is dependent on the matrix constituents present, problems arise 
when the matrix is not consistent between individuals, affecting reproducibility, precision 
and accuracy. Ways to reduce the impact ofthe matrix effects include extraction 
techniques, such as solid phase extraction to minimise the amount of matrix injected into 
300 
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the system, and the use of deuterated internal standards, as these elute at the same time as 
the analyte and are therefore affected in the same way by any matrix components present. 
Matrix effects highlight the importance of robust and suitably validated methods with the 
use of deuterated internal standards where possible. 
2.3 Conclusions 
Liquid Chromatography - Mass Spectrometry is a valuable technique for the analysis of 
drugs of abuse in biological matrices. It is a much softer option to Gas Chromatography-
Mass Spectrometry, so can be used for thermally labile molecules such as benzodiazepines 
and amphetamines. The use of soft ionisation allows the pseudo molecular ion to be 
monitored routinely with the option of further fragmentation for qualitative ions. Unlike 
GC-MS, derivatisation of polar functional groups is not required, therefore shortening 
sample preparation time. Although matrix effects are present with LC-MS these can be 
minimised with suitable extraction techniques and the use of deuterated internal standards. 
With the use of LC-MS-MS, more complex spectra can be produced, akin to GC-MS. 
Page 15 
3 Flunitrazepam in Whole Blood 
3.1 Introduction 
Flunitrazepam (Rohypnol is used for its sedative and 
~nol' l 
..... ~ anaesthetic properties. Its alleged use in connection with drug 
) 
facilitated sexual assault has gained wide pUblicity. 
Consequently the manufacturers, Roche Products Limited, altered 
the drug formulation making it harder to dissolve the drug in 
drinks and added a blue dye, making it more easily detectable29 • With the increased public 
awareness of the drug, there has been an increase in the number of requests for 
flunitrazepam analysis, however there are several problems to overcome. The drug 
belongs to a potent group of hypnotic benzodiazepines that are therapeutically effective at 
low doses. A 2 mg tablet can cause sedation after 20-30 minutes which can last several 
hours30. A further delay in sample collection can occur as victims of drug facilitated sexual 
assault can be reluctant to report a crime and are sometimes even unaware that a crime has 
taken place due to drug induced amnesia. This delay in sample collection results in a 
significant clearance in the amount of drug present in the blood or urine. One group found 
that 24 hours after the administration of a 2 mg dose ofRohypnol®, free 7-
aminoflunitrazepam levels in serum varied from 3.7-5.3 nglmVo. To be able to detect such 
low levels of the drug, the method of analysis must be specific (to minimise the 
signal/noise ratio) and have good recovery from the matrix to allow very low detection 
limits. 
3.2 Chemistry 
Flunitrazepam or 5-(2-Fluorophenyl)-1 ,3-dihydro-l-methyl-7-nitro-2H-l ,4-benzodiazepin-
2-one is a hypnotic benzodiazepine. When using liquid chromatography - mass 
spectrometry the pseudo-molecular ion is typically formed. Flunitrazepam forms a 
positive ion in the mass spectrometer. This is achieved by the addition of a proton to the 
structure thereby giving the analyte a positive charge and an increase in molecular weight 
of 1 amu. The most likely place for protonation to occur is at the cyclic ketone 
(highlighted in green in Figure 3-1). Flunitrazepam's metabolite 7-aminoflunitrazepam 
can also be protonated at this site. 7-Aminoflunitrazepam is similar in structure to 
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flunitrazepam except that it has a primary amine instead of a nitro group; this is shown in 
Figure 3-1 (highlighted in yellow). 
Flunitrazepam 7-Arninoflunitrazepam 
Figure 3-1 : Structure of flunitrazepam and 7-aminoflunitrazepam 
This amine group is the likely primary site of protonation, but as the ketone group is still 
available, there are two potential sites to produce the pseudo-molecular ion. In both the 
single quadrupole instrument and the ion trap, 7 -aminoflunitrazepam gives a higher 
response than flunitrazepam at the same concentration. Steric hindrance of the cyclic 
ketone may account for this. 
3.3 Metabolism and Excretion 
Flunitrazepam is metabolised to its major metabolite 7-aminoflunitrazepam by reduction of 
the nitro group to an amine. 7-aminoflunitrazepam is present in the plasma at 
concentrations of2-4 nglmL up to 24 hours after a single dose (2 mg) offlunitrazepam31 
3.4 Pharmacokinetics 
After a 2 mg dose of flunitrazepam, administered orally, peak blood concentrations of 6 
nglmL occur after 2 hours32 . Pharmacokinetic data for flunitrazepam is summarized in 
Table 3_1.31 
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Table 3-1 : Pharmacokinetic and physiochemical data for flunitrazepam 
Flunitrazepam 
Half Life (hours) 9-25 
Vd(LlKg) 3.4-5.5 
Protein Binding (%) 78 
pKa 1.8 
3.5 Toxicity 
A flunitrazepam overdose can result in ataxia, drowsiness, hypotension, respiratory 
depression and coma. 3 I 28 mg of flunitrazepam has resulted in death, with kidney levels of 
0.5 mglkg for both the parent drug and its metabolite. Flunitrazepam's potency at low 
concentrations and its rapid half-life make it a likely drug for drug facilitated sexual 
assault. 
3.6 Previous Work 
Analysis of Flunitrazepam has been largely done by GC_MS30,33.34,35,36.37.38,39 and 
HPLC40.41.42.43M.45.46.47,48.49. Owing to its rapid metabolism and the low doses of 
flunitrazepam administered, it is essential to have as low detection limits as possible. 
Using GC-MS, detection limits of between 10 ng/mL30 to 100 ng/mL in blood34 for 
flunitrazepam have been achieved. Using HPLC, detection limits for flunitrazepam range 
from 3.5 ng/mU7 to 20 ng/mL 48 in blood. As LC-MS is a relatively new technique there 
are fewer reports on the analysis offlunitrazepam in blood1s,so,s1. Using the technique, 
detection limits varying from 0.025 ng/mL so to 0.5 ng/mLls have been achieved. 
Most LC-MS instruments have the ability to change between an APCI and ESI probe with 
ease. Different groups have reported the use of both APCI and ESI probes with similar 
results. A variety of mobile phase buffers have also been employed from 0.03 % 
ammonium hydroxide to 50 mM ammonium formate producing comparable data. These 
reports would suggest that there are no set rules for the choice of probe and mobile phase 
in relation to the analyte. 
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LC-MS-MS has also been used for flunitrazepam analysis; one group52 used a 
ThermoFinnigan LCQ ion trap and achieved a detection limit of, 0.25nglmL, similar to that 
using a single quadrupole. 
3.7 Aim 
The aim of the following project was to develop a reliable and sensitive method for the 
detection of flunitrazepam and its major metabolite 7 -aminoflunitrazepam in blood, using 
Liquid Chromatography - Mass Spectrometry (LC-MS). 
3.8 Method Development 
The ThermoFinnigan AQA single quadrupole LC-MS was used for this project equipped 
with a P4000 quaternary pump, and AS3000 autosampler. For the development of this LC-
MS method a Phenomenex Luna ClS column, 150 x 2.0 mm, with 3 J.LIll packing material 
was used. A C 18 column was chosen as this is the most commonly used stationary phase 
for flunitrazepam analysis,s .. 40.5o.52. Initially the mobile phase comprised of 60 % methanol 
and 40 % deionised water, pumped isocratically, with a flow rate of 0.15 mUmin. These 
conditions were found to resolve the two analytes from each other and the solvent front. 
During the method development, the use of buffers in the mobile phase and the effect of 
changing the probe would be investigated. 
3.8.1 Chemicals 
Methanol, acetonitrile and hexane were HPLC grade obtained from VWR International 
(UK). Analytical grade potassium dihydrogen phosphate and ammonium acetate were 
supplied by BDH laboratory supplies (poole, England). Analytical grade concentrated 
ammonia, glacial acetic acid and concentrated formic acid were purchased from Sigma® 
Chemicals Co. (UK). 
3.8.2 Standards 
Stock standards of flunitrazepam, 7-aminoflunitrazepam, flunitrazepam-d7 and 7-
aminoflunitrazepam-d7 were purchased from Promochem as 100 J..lg/mL methanolic 
solutions. A working drug solution of 1 J..lglmL, for spiking blank blood, was prepared by 
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taking 50 J.1L of each standard (flunitrazepam and 7-aminoflunitrazepam) and adding 4900 
J.1L of methanol. A working internal standard solution was similarly prepared using the 
deuterated standards. 
3.8.3 Blank Blood 
Time expired packed red blood cells were provided from the blood bank for blank blood. 
These were suspended in a ratio of 1: 1 with isotonic saline solution which was made by 
dissolving 9.5 g of sodium chloride in 1 L of deionised water. 
3.8.4 Solutions 
3.8.4.1 Preparation of 5, 7.5 and 10mM Ammonium Acetate Solutions 
AIM solution of ammonium acetate was prepared first by adding 38.54 g of ammonium 
acetate to a 500 mL volumetric flask and making up to volume with deionised water. 5, 
7.5 and 10 mL of this solution was added to 3 x 1 L volumetric flasks and made up to 
volume with deionised water resulting in 5, 7.5 and 10 mM solutions. 
3.8.4.2 Preparation of 0.002, 0.004, 0.01, 0.05 and 0.1 % Formic Acid 
Solutions 
20, 40, 100, 500, and 1000 J.1L of concentrated fonnic acid was added to 5 x 1 L volumetric 
flasks, which were made up to volume with deionised water to produce 0.002,0.004,0.01, 
0.05 and 0.1 % solutions. 
3.8.4.3 Preparation of 0.1 M, pH 6.0 Phosphate Buffer 
6.81 g of potassium dihydrogen phosphate was weighed out into a 500 mL volumetric 
flask and 450 mL of deionised water was added. The pH was adjusted to 6.0 with 1 M 
potassium hydroxide solution, then made to 500 mL with deionised water. 
3.8.5 Optimisation of Skimmer Cone Voltage 
An unextracted standard was prepared by adding 100 J.1L of working drug solution and 100 
J.1L of working internal standard solution to a vial and blowing down under nitrogen at 
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35°C. This was reconstituted in 100 f.lL of mobile phase (60:40 methanol:deionised water) . 
20 f.lL of the standard was injected twice varying the skimmer cone voltage from 20-45 V 
for one injection and from 45-60 V for a second injection. The pseudo molecular ions 
were monitored in SIM mode. Table 3-2 shows the pseudo molecular ions monitored. 
Table 3-2 : Molecular weight and pseudo molecular ions for flunitrazepam and 7-
aminoflunitrazepam 
Molecular weight [M+Ht 
Analyte 
(amu) (m/z) 
Flunitrazepam 313 314 
Flunitrazepam-d7 320 321 
7 -Amino fluni trazepam 283 284 
7 -Aminoflunitrazepam-d7 290 291 
The areas produced for the pseudo molecular ion at each skimmer cone value were plotted 
and an optimum found. After 45 V the pseudo-molecular had fragmented and was no 
longer detectable. Figure 3-2 shows graphically how the peak areas changed for each ion 
as the skimmer cone voltage was varied. 
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Figure 3-2 : Optimisation of skimmer cone voltage for flunitrazepam and 7-
aminoflunitrazepam and their deuterated standards. 
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It is expected that the analyte and its deuterated standard produce the same curve on the 
graph as they have a common structure, and will therefore fragment similarly. 
A qualifier ion for both analytes was found by increasing the skimmer cone voltage and 
fragmenting the pseudo molecular ion. In a SIM experiment both the pseudo molecular 
ion and qualifier ion can be monitored by alternating between each voltage. Table 3-3 
shows the Skimmer cone values used for the rest of the method development. It was 
decided unnecessary to fragment the deuterated standards, as only the pseudo-molecular 
ion was needed for quantitation. 
Table 3-3 : Pseudo molecular ions, qualifier ions and skimmer cone voltages used for 
analysis 
Pseudo molecular ion Qualifier ion 
Analyte (Skimmer cone (Skimmer cone 
voltage) voltage) 
Flunitrazepam 314 (35 V) 268 (45 V) 
Flunitrazepam-d7 321 (35 V) N/A 
7 -Aminoflunitrazepam 284 (30 V) 226 (55 V) 
7 -Aminoflunitrazepam-d7 291 (30 V) N/A 
3.8.6 Investigation into Ammonium Acetate and Formic Acid as 
Additives in the Mobile Phase 
3.8.6.1 ESI Probe with Ammonium Acetate in the Mobile Phase 
An unextracted standard was prepared by adding 100 J.l.L of working drug solution and 100 
J.l.L of internal standard solution to a vial and blowing down under nitrogen at 35°C. This 
was reconstituted in 200 J.l.L of mobile phase and 10 J.l.L was injected 6 times. An average 
peak area was calculated for each ion under each condition. The mobile phase 
composition was kept at 40 % aqueous and 60 % methanol run isocratically at 0.15 
mLlmin. The first condition used deionised water as the aqueous part of the mobile phase. 
Ammonium acetate was then used instead of deionised water at concentrations of 5 mM, 
7.5 mM and 10 mM. The results of the experiment are shown in Figure 3-3. 
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Figure 3-3 : Effect of ammonium acetate concentration on response using an ESI probe 
3.8.6.2 APel Probe with Ammonium Acetate 
An unextracted standard was prepared as before in 3.8.6.1 and injected 6 times for each 
condition. An average peak: area was calculated for each ion under each condition. The 
same ammonium acetate concentrations were used as before, changing only the probe to 
APel. The graph in Figure 3-4 shows the result. 
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3.8.6.3 ESI Probe with Formic Acid 
The same procedure was carried out as in 3.8.6.1 although formic acid was used instead of 
ammonium formate with the ESI probe. Formic acid was used in concentrations of 0.002 
%,0.004 %, 0.01 % and 0.05 %. Figure 3-5 shows the result. 
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Figure 3·5 : Effect of formic acid concentrations on response using an ESI probe 
3.8.6.4 APel Probe with Formic Acid 
The same procedure was carried out as in 3.8.6.3 using the APel probe. The formic acid 
concentrations were slightly different than before, they were 0.004 %, 0.01 %,0.05 %, and 
0.1 %. The results are shown in Figure 3-6. 
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Figure 3-6 : Effect of formic acid concentration on response using an APel probe 
3.8.6.5 Conclusions 
The graphs show that at the higher concentrations of both additives the response of both 
analytes is either unchanged or decreased. By comparing the maximum responses 
achieved with each combination of probe and additive an optimum can be found. In Table 
3-4 the maximum responses are displayed. 
Table 3-4 : Maximum responses (7-aminoflunitrazepam-d7) found for each combination of 
additive and probe 
Electrospray Ionisation 
Atmospheric Pressure 
Chemical Ionisation 
Additive Formic Acid Ammonium Formic Acid Ammonium 
(amount) (0.004 %) Acetate (0) (0) Acetate (0) 
Maximum Response 
45,000,000 25,000,000 4,000,000 5,000,000 
(Arb. Units) 
From the above table it is clear that electro spray ionisation gives a higher response than 
atmospheric pressure chemical ionisation for flunitrazepam and its metabolite without any 
additives present. Also when any ammonium acetate was added to the mobile phase the 
response decreased with both probes. The optimum mobile phase and probe was found to 
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be 60 : 40, methanol: 0.004 % formic acid in deionised water, using electro spray 
ionisation. 
3.9 Development of Extraction Method 
To analyse flunitrazepam in blood, the analyte first needs to be extracted from the matrix 
and concentrated. The method needs to be able to wash enough interfering compounds 
away without diminishing the recovery of the analyte. It was decided to evaluate the use 
of three extraction methods found in the literature1S•S!.12. All three methods use solid phase 
extraction (SPE). It was necessary to first compare the analyte recovery of the three 
methods before optimising one of them for further use. 
3.9.1 Comparison of Three Extraction Methods 
The details of the three methods compared are found in Table 3-S below. 
Table 3-5 : Details of three extraction methods used for comparison 
Method SPE Column Wash Sequence Elution Solvent 
1 mL elution solvent 2.S mL 98 % ethyl 
3 mL Methanol acetate 2 % NH3 
3 mLDlwater 
2 mL phosphate buffer (0.1 M, pH 6) 
CleanScreen Add Sample 
A1s DAU 2mLDlwater (Octyl+benzyl 2 mL 20:80 Acetonitrile:phosphate buffer 
sulfonic acid) Dry 
2mLHexane 
Dry 
2 X2 mLDIWater 
Dry 
1 mL Methanol 2XO.SmL 
1 mLDIWater Methanol:O.S M 
2 mL Ammonium Carbonate Buffer (0.01 acetic acid, into 
BS1 Bond Elut CIS M,pH 9.3) tube with S J.1L 
Add Sample 0.001 MHCI 
2 mL Ammonium Carbonate Buffer 
Dry 
2 mL Methanol 1 mL Methanol 
2mLDIWater 
C2 Bond Elut CIS Add Sample 
2mLDIWater 
Dry 
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Initially the recoveries of flunitrazepam and 7-aminoflunitrazepam were calculated for the 
three extraction methods, without changing any factors. This was carried out by extracting 
in duplicate 50 ng of each analyte from 1 mL of blank blood with each extraction method. 
An unextracted standard of the same concentration, 50 ng, was also prepared at the same 
time in duplicate. 50 J.1L ofa 1 J.1g/mL solution offlunitrazepam-d7 and 7-
aminoflunitrazepam-d7 was added after the extraction to all extracted and unextracted 
samples. The ratios between the analyte and its respective deuterated standard were 
calculated. By dividing the extracted ratio by the unextracted ratio and mUltiplying by 100, 
a percentage recovery was calculated for each extraction. Table 3-6 shows the recoveries 
obtained experimentally and the recoveries reported in the literature. 
Table 3-6 : Recoveries of flunitrazepam and 7-aminoflunitrazepam using three different 
extraction methods 
Recovery (0/0) 
F1unitrazepam 7-Aminofiunitrazepam 
Experimental Literature Experimental Literature 
@50ng(n=2) @50ng(n=2) 
A IS 71 74@30ng 24 26@30ng 
BSI None Detected 93 31 92 
el2 40 102 (serum) 55 Not Analysed 
To establish which extraction gave the cleanest extract, the chromatograms were analysed 
visually. A comparison of the chromatograms is shown in Figure 3-7 below. 
3.9.2 Conclusions 
Using method B flunitrazepam was not detected and 7 -aminoflunitrazepam had a much 
lower recovery than that reported in the literature. This extraction method was used with 
an APCI probe in the report, the ESI probe was used in this investigation which is thought 
to suffer from the matrix effect more, this could be the cause of the dramatic loss in 
analytes in the extraction. 
By comparing an injection from each extract it was clear that using method A gave the 
cleanest extract with little interference. Method C was worse with an interefering peak co-
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eluting with 7-aminofiunitrazepam, followed by method B which gave the dirtiest 
chromatogram. 
3.9.3 Optimisation of Extraction Method 
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It was decided to continue using method A and try and improve the recovery of 7-
aminofiunitrazepam. The first step was to investigate if any analyte was being eluted from 
the solid phase with the washes. The hexane wash was explored first. 
3.9.3.1 Monitoring Hexane Wash 
An extraction of 50 ng of analyte in whole blood was carried out in duplicate. An 
unextracted 50 ng standard was also prepared in duplicate. After the first drying stage 2 
mL of hexane was added and collected. 50 ng of deuterated internal standards were added 
to the hexane wash and unextracted samples. These were then blown down under nitrogen 
with no heat and reconstituted in 100 J.1L of mobile phase, they were injected in duplicate. 
It was clear from the hexane wash chromatogram that there was no fiunitrazepam or 7-
aminofiunitrazepam present. This showed that the analytes were not being lost in the 
hexane wash, so this step was retained in the extraction method. 
3.9.3.2 Variation of the Number of Water Washes 
In the paper an unspecified number of water washes are performed after the hexane wash 
to ensure that all phosphate buffer has been washed off. If potassium ions from the buffer 
are left with the analytes, adducts can form and reduce the response of the molecular ion in 
the MS. It was postulated that some of the analytes were being washed away with these 
water washes. This was investigated by comparing the recoveries of the analytes with an 
increasing number of water washes used. 
In duplicate, the recovery of analytes was calculated using 1, 2, 3, 4 and 5 water washes 
before elution. The samples were injected in duplicate and the average recovery for each 
number of water washes found. The results are shown in Table 3-7. 
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The results show that there was no significant difference between the recovery of analytes 
with increasing number of water washes in the extraction. This would suggest that 
analytes were not being lost in this wash step. It was decided to use 3 water washes before 
elution to minimise the amount of buffer present. 
Table 3·7 : Recovery of analytes with increasing number of water washes 
Number of 0/0 Recovery (%RSD) (n=2) 
Water Washes F1unitrazepam 7-Aminoflunitrazepam 
1 100 (6) 46 (2) 
2 95 (6) 42 (1) 
3 120 (4) 48 (9) 
4 110 (8) 44 (3) 
5 102 (6) 45 (12) 
3.9.3.3 Comparison of Elution Solvents 
As the analytes were not being lost in the hexane wash or the water washes, it was thought 
that the analytes may still be adsorbed onto the solid phase even after the elution step. It 
was decided to investigate the elution solvent to try and increase the recovery of the 
analytes. There were 3 elution solvents compared. An extraction was performed in 
duplicate for each elution solvent, and injected in duplicate onto the LC-MS. The 
recoveries were calculated and averaged. The results are shown in Table 3-8 below. 
Table 3-8 : Recovery of analytes with varying elution solvents 
Elution solvent (3 mL) % Recovery (%RSD) (n=2) 
F1unitrazepam 7-Aminoflunitrazepam 
Ethyl Acetate with 2 % NH3 @ 5 ng 108 (6) 49 (12) 
Ethyl Acetate with 2 % NH3 @ 50 ng 121 (2) 40 (5) 
Dichloromethane with 4 % NH3 @ 5 ng 110 (7) 25 (12) 
Dichloromethane with 4 % NH3 @ 50 ng 124 (0) 33 (24) 
Methanol @ 5 ng 128 (14) 10 (37) 
Methanol @ 50 ng 109 (5) 47 (11) 
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Using dichloromethane with 4 % NH3 as the elution solvent decreased the recovery of7-
aminoflunitrazepam. Ethyl acetate with 2 % NH3 and methanol gave similar recoveries for 
both analytes. By looking at the chromatograms produce from each extract, Figure 3-8 it 
was clear that the methanol extract contained more interferents than the ethyl acetate 
extract. Therefore it was decided to continue using ethyl acetate with 2 % NH3 as the 
elution solvent. 
3.10 Method Validation 
The complete method used for validation and subsequent case samples was as follows. 
3.10.1 Sample Preparation 
Spiked blood samples were prepared by adding the appropriate amount of working drug 
solution (1,2,5, 10,25,50, 100 J.1L) and internal standard solution (100 J.1L) to test tubes, 
followed by 3.5 mL of 0.1 M, pH 6 phosphate buffer and 1 mL of blank blood. A blank 
was prepared without any standards present and another with internal standard only to 
assess any contamination of the deuterated standards. 
3.10.2 Extraction Method 
3.5 mL of 0.1 M, pH 6.0 phosphate buffer was added to 1 mL of whole blood. 100 J.1L of 1 
J.1g1mL solution offlunitrazepam-d7 and 7-aminoflunitrazepam-d7 was added as an internal 
standard. This was vortexed and centrifuged for 10 minutes at 3000 rpm. CleanScreen 
DAU® cartridges were conditioned with 1 mL ethyl acetate with 2 % NH3, 3 mL methanol, 
3 mL deionised water and 2 mL 0.1 M, pH 6.0 phosphate buffer prior to sample 
application. The cartridges were washed with 2 mL deionised water and 2 mL phosphate 
buffer (01 M, pH 6) : acetonitrile (80: 20), then dried under full vacuum for 1 minute. 2 
mL of hexane was applied and dried under full vacuum for a further minute. 3 x 2 mL 
aliquots of deionised water were applied to the cartridges drying under full vacuum for 1 
minute between each addition of water. After the third aliquot of water the cartridges were 
left at full vacuum for 10 minutes to dry thoroughly. The analytes were then eluted with 
2.5 mL ethyl acetate with 2 % NH3. This was blown down under nitrogen at 30°C until 
dry. Samples were reconstituted in 100 .u. of mobile phase (60 : 40 methanol: 0.004 % 
fonnic acid), with 20 .u. injected in duplicate. 
"T1 
cO' 
c: 
., 
(I) 
CN 
• co 
(') 
o 
3 
'lJ 
III 
~, 
en 
o 
::l 
o 
-cr 
Cii 
::l 
" o 
::l" 
., 
o 
3 
III 
.... 
o 
co 
iil 
3 
en 
c: 
en 
::l 
co 
a. 
3: (I) 
~ 
::l 
..... 
~ 
c: 
..... 
0' 
::l 
en 
o 
<" (I) 
::l 
..... 
en 
RT : 0 .00 - 1199 
., 
u 
c: 
III 
"0 
c: 
:> 
D 
<{ 
., 
.2 
m 
4i 
a:: 
o 
/~j~ L ~} ~J~ ~:.: "'II"Mli\t ~ 'I ~ 
,/1 ethyl acetate 'd' Wi 12% NH3 
dichloromethane with 4% NH3 
2 3 
interferent 
Expected 7-AF 
4 5 6 
T,me(min) 
7 8 
7-aminoflunitrazepam 
9 1) 11 
NL: 
157E4 
m/z= 
283.5-284.5 
MS 
DCMBlank 
02 
NL: 
743E4 
m/z= 
283.5-264.5 
MS 
MeOHBlan 
kOl 
RT: 0.00 - '12.00 
., 
u 
c: 
III 
-g 
:> 
D 
<{ 
o 
_ . 8 NL . 9 .~ 9 .92 99 
11.~55 2.0SE4 
9.70 m/z= 
''''-'''--<.' ""- '" ~~5-'" 
2.21 0.
38 ~ 
y acetate with 2°/ loNH3 249 eth 1 
methanol 
2 3 4 5 6 7 8 
T,me(m,n) 
flunitrazepam 
9.S8~80 
Expected 
/FLURT 
9 1) 11 
NL: 
t40E4 
m/z= 
313.5-314.5 
MS 
DCMBlank 
02 
NL: 
1.50E4 
12 
() 
-::r 
til 
'lJ 
<D 
-, 
W 
11 
C 
::l 
;::;: 
-, 
til 
N 
CD 
-0 
til 
3 
5' 
~ 
-::r 
o 
CD 
OJ 
o 
o 
a. 
-u 
til 
co 
CD 
w 
Chapter 3: Flunitrazepam in Whole Blood Page 32 
3.10.3 Instrumental Method 
Analysis of the extracts was performed on a Finnigan AQA mass spectrometer (San Jose, 
CA) equipped with a P4000 HPLC pump and an AS3000 autosampler. The mobile phase 
used was 60 : 40 methanol : 0.004 % formic acid. This was used isocratically for the 
separation of analytes. The organic content was increased to 90 % for 10 min at the end of 
the run, to elute any other substances, which could be present in the extract. Flow rate was 
set at 0.15 mLimin through a Phenomenex Luna C I8 column (150 x 2.0 rom, 3 /lm), fitted 
with a guard column. An electro spray interface was used in the source at 300 °C and a 
probe voltage of 4 kV. Single ion monitoring (SIM) was used to identify analytes and their 
deuterated standards. 
3.10.4 Linearity 
Flunitrazepam and 7-aminoflunitrazepam were found to have a linear response over the 
concentration range 1-100 nglmL in whole blood, refer to Figure 3-9. 
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~ 
'" c 
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Figure 3-9 : Linearity of flunitrazepam and 7-aminoflunitrazepam 
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3.10.5 Recovery 
Relative recoveries offlunitrazepam and 7-aminoflunitrazepam were calculated at three 
concentrations (5,50 and 100 nglmL). Each concentration was extracted five times 
without internal standard present. Two unextracted standards were also prepared at each 
concentration without internal standard and were kept in the fridge throughout the 
extraction. Before blowing down the samples under nitrogen to dryness, 100 ng of internal 
standard was added to each vial including the unextracted standards. Once the samples 
were dry, they were reconstituted in 100 J.LL of mobile phase and 20 J.LL was injected in 
duplicate. 
The recovery of each drug was calculated using the following equation. 
R ry(0/) Peak Area Ratio of Extracted Standard 100 ecove 10 = x 
Peak Area Ratio of Unextracted Standard 
Equation 1 
Recoveries for flunitrazepam and 7 -aminoflunitrazepam at each concentration are shown in 
Table 3-9 with an average recovery of 115 % and 43 % respectively. 
Table 3-9 : Recoveries of flunitrazepam and 7 -aminoflunitrazepam 
Concentration F1unitrazepam (n=5) 7-AminoOunitrazepam (n=5) 
(nglmL) Mean % Recovery (%RSD) Mean % Recovery (%RSD) 
5 104 (11) 42 (19) 
50 119 (7) 42 (5) 
100 122 (9) 44 (12) 
3.10.6 Limits of Detection 
Limits of detection were calculated using the intercept, Yo, and the standard error of the 
regression line, so. 53 The equations used are shown below, where m = the gradient. 
YLOD = YB + 3sB 
L.O.D.= (YLOD - YB) 
m 
Equation 2 
Equation 3 
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The limits of detection for flunitrazepam and 7-aminoflunitrazepam were found to be 0.2 
and 0.5 ng/mL respectively. 
3.10.7 Limits of Quantitation 
Limits of quantitation were calculated using the same method as in 3.10.6 except that 10 
times the standard error of the line was used. The equations were changed to equations 4 
and 5. 
YLOQ = YB + lOsB 
L.O.Q. = (YLOQ - YB) 
m 
Equation 4 
Equation 5 
Limits of quantitation for flunitrazepam and 7-aminoflunitrazepam were calculated as 0.8 
and 1.6 nglmL respectively. 
3.10.8 Inter-Day Precision 
Inter-day precision was calculated using five sets of linearity data acquired on five 
different days. The %RSD of the five values for two concentrations, 5 and 50 nglmL were 
calculated. The results are shown in Table 3-10. 
Table 3-10 : Inter-day precision data for flunitrazepam and 7 -aminoflunitrazepam 
Concentration F1unitrazepam 7-AminoOunitrazepam 
(nglmL) (%RSD) (n=5) (%RSD) (n=5) 
5 5.2 (9.0) 5.0 (8.5) 
50 48.9 (1.1) 50.4 (2.7) 
3.10.9 Intra-Day Precision between Injections 
Extracted standards were prepared at two concentrations, 5 and 50 nglmL. They were 
reconstituted in 150 J.1L of mobile phase and 20 J.1L was injected 5 times consecutively. 
The %RSD of the peak area ratios was calculated at each concentration for each drug. The 
results are shown in Table 3-11. 
Chapter 3: Flunitrazepam in Whole Blood Page 35 
Table 3·11 : Intra-day precision data for flunitrazepam and 7-aminoflunitrazepam 
Concentration Flunitrazepam 7-AminoOunitrazepam 
(nglmL) (%RSD) (n=5) (%RSD) (n=5) 
5 4.5 (2.8) 5.0 (3.3) 
50 49.3 (2.8) 50.8 (0.8) 
3.11 Discussion 
In the process of developing the final LC-MS method, the additives in the mobile phase 
were varied, and LC·MS conditions optimised for the target analytes. It was found that 
using very small amounts of additives, 0.004% formic acid, in the mobile phase gave the 
best response for the two analytes. This is in contrast to many published methods which 
use up to 0.1 % formic acid. The amount of additive will affect the chromatography of 
analytes. In the case of flunitrazepam analysis the most important factor was sensitivity 
and as only the parent drug and its major metabolite were analysed, resolution was found 
not to be a problem when varying buffers. The limits of quantitation achieved were very 
low, 0.8 ng/mL and 1.6 ng/mL for flunitrazepam and 7-aminoflunitrazepam respectively. 
Precision between five different days was found to be less than 10 % for both analytes at a 
concentration of 5 ng/mL. Precision between injections was found to be less than 4 % for 
both analytes at a concentration of 5 ng/mL. This precision at low concentrations and the 
low limits of detection enable this method to be applied to drug facilitated sexual assault 
case samples. 
3.12 Conclusions 
A liquid chromatography - mass spectrometry method was developed and validated for the 
extraction and quantitation of flunitrazepam and its major metabolite 7-
aminoflunitrazepam from whole blood. The method has been applied to case samples in 
the Forensic Medicine and Science Dept at the University of Glasgow, all have been found 
negative. 
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4 Diazepam and Metabolites in Whole Blood 
4.1 Introduction 
Diazepam is one of the most frequently prescribed drugs in the 
United States and is more commonly known by its 
pharmaceutical name, Valium®, It is prescribed as an anti-
anxiety agent, muscle relaxant or anticonvulsane I, 
In the UK, diazepam has been associated with an increased risk of road traffic accidents5\ 
and linked to fatalities from drugs of abuse55, In a French study of 900 injured drivers, 
benzodiazepines were the most frequently observed psychoactive therapeutic drug56, 
One ofthe concerns of diazepam is that the metabolites are all pharmacologically active to 
some degree, N-desmethyldiazepam is at least as active as diazepam, and temazepam and 
oxazepam are also active but are not accumulated in the blood significantly. 
Temazepam is a hypnotic benzodiazepine and causes sedation and 
drowsiness31, It was rescheduled in 1996 from schedule 4 to 
schedule 3 of the Misuse of Drugs Regulations 198557 • This resulted 
in a stricter control of prescribing and thus a decrease in availability, 
drug users looked to alternatives such as diazepam. In the 
Strathclyde region of Scotland there was a decrease in the number of 
post-mortem cases testing positive for temazepam in 1996 and 1997 and an increase in 
diazepam positive cases58 • 
Oxazepam is an anti anxiety agent similar to diazepam but 
less potent, used for mild anxiety. It has been used in the 
United States since 1965, and is also available in the UK, 
Owing to their continued use as anti anxiety and hypnotic agents, and their contribution to 
road traffic accidents and drug related deaths, it is essential to have a reliable and sensitive 
technique for the detection and quantitation of diazepam and its metabolites in forensic 
case samples, 
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4.2 Chemistry 
The metabolic pathway of diazepam and the structures of itself and its metabolites are 
shown in Figure 4-1 below. 
Diazepam Temazepam 
1 
conjugation 
/ 
N-desmethyldiazepam Oxazepam 
Figure 4-1 : Metabolic pathway of diazepam 
Diazepam and its metabolites all have a ketone group, which could be the site of ionisation 
for these molecules. The hydroxyl group next to the ketone in temazepam and oxazepams 
structure is also a potential ionisation site. All four molecules also have a chlorine atom in 
their structure. Chlorine atoms exist as stable isotopes, 37Cl has 2 more neutrons in the 
atom than 35Cl. This gives the potential for two pseudo-molecular ions, one with 35CI and 
one with 37 CI at a ratio of 3: 1. Monitoring both pseudo-molecular ions offers another piece 
of qualitative information. 
4.3 Metabolism and Excretion 
Diazepam metabolises by N-demethylation to form the active metabolite N-
desmethyldiazepaml1 • These compounds are then converted to their 3-hydroxy derivatives 
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temazepam and oxazepam. Temazepam and oxazepam are also active drugs but not to the 
same extent, as they do not accumulate in blood. 
4.4 Pharmacokinetics 
Peak blood concentrations of diazepam averaged 148 nglmL at 1 hour after a single 10 mg 
oral dose; this had fallen to 37 nglmL in 24 hours. Its metabolite N-desmethyldiazepam 
had reached its peak concentration of 29 nglmL after 24 hours. A single 30 mg oral dose 
oftemazepam administered to healthy volunteers resulted in an average peak plasma 
concentration of 870 nglmL, after 1.4 hours. Following a single 15 mg dose of oxazepam 
peak serum levels were reached after 1.5 hours with a concentration of 31 0 nglmL31. The 
pharmacokinetic properties of diazepam and its metabolites are summarized in the Table 
4-1. 
Table 4-1 : Pharmacokinetic and physiochemical properties of diazepam and Its metabolites 
Diazepam Temazepam N-desmethyldiazepam Oxazepam 
Half life (hr) 21-37 3-13 31-97 4-11 
Vd (L/kg) 0.7-2.6 0.8-1.0 - 0.7-1.6 
Protein 96 97 97 87-94 Binding (%) 
pI{. 3.4 1.3 3.5, 12.0 1.7, 11.6 
4.5 Toxicity 
Diazepam over dosage results in drowsiness, ataxia and muscular weakness. Serum 
concentrations of up to 20 mgIL have occurred in hospitalised patients exhibiting light 
coma31. Temazepam can cause sedation and drowsiness in normal doses, and a single oral 
dose of 20 mg at night has been shown to impair driving the next moming3l. Oxazepam 
has been found to impair driving with blood concentrations of between 0.2 and 8 mgIL.31 
Diazepam is rarely found alone in fatal cases, and it more likely to be in combination with 
other drugs e.g. alcohol and heroin. 
4.6 Previous Work 
Like flunitrazepam, diazepam and its metabolites have been primarily analysed by 
HPLC2.47.48. Benzodiazepines, in general, chromatograph well using liquid 
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chromatography. They also have a tendency to decompose in the injection ports of gas 
chromatographs, temazepam especially. Despite this gas chromatography has been used 
successfully in the analysis ofbenzodiazepinesS9,6(),61.37.34. Using liquid chromatography for 
its gentle separation and mass spectrometry for its specificity would be an ideal way to 
obtain reproducible, sensitive and qualitative information. Liquid chromatography - mass 
spectrometry has been used in benzodiazepine analysis in recent yearsI2•16,62063,64,6S. Of these 
papers, four analyse specifically for diazepam and its three metabolites temazepam, N-
desmethyldiazepam and oxazepam. Of these four, only two are extracted from whole 
blood the other two use hair in one and calliphora vicina larvae in the other. Using 
restricted-access solid-phase microextraction, one group has quoted limits of quantitation 
as 20, 20, 30 and 35 nglmL for diazepam, N-desmethyldiazepam, temazepam and 
oxazepam respectivelyM. Another group using liquid-liquid extraction obtained limits of 
quantitation of 13, 14,5 and 7 ngimUs. This was achieved using an ion trap mass 
spectrometer yielding MS-MS data. 
4.7 Aim 
The aim was to develop a method for the analysis of diazepam and its metabolites 
temazepam, N-desmethyldiazepam and oxazepam using liquid chromatography - single 
quadrupole mass spectrometry. Benzodiazepines are routinely analysed by HPLC with uv 
or diode array detection. If the extract is particularly dirty then there can be problems with 
interference, and the drug cannot be quantified. If the extract is very concentrated then the 
response can go off the scale of the detector and hence cannot be quantified without further 
dilution steps. At the other extreme, detection limits for HPLC-UV are higher than for LC-
MS. A more specific technique will generally give better detection limits because the 
noise will be less. If LC-MS were to be used, these problems could be overcome. 
4.8 Method Development 
4.8.1 Chemicals 
Methanol, acetonitrile and hexane were HPLC grade and obtained from VWR International 
(UK). Analytical grade potassium dihydrogen phosphate, ammonium acetate were 
supplied by BDH laboratory supplies (poole, England). Analytical grade concentrated 
• 
Chapter 4: Diazepam and Metabolites in Whole Blood Page 40 
ammonia, glacial acetic acid and concentrated formic acid were purchased from Sigrna® 
Chemicals Co. (UK). 
4.8.2 Standards 
Stock standards of diazepam, N-desmethyldiazepam, temazepam and oxazepam were 
purchased from Promochern as 100 )lglmL methanolic solutions. The ds deuterated 
standards of each drug were also purchased as 100 )lglmL methanolic solutions. A 
working drug solution of 1 )lglmL, for spiking blank blood, was prepared by taking 50 )lL 
of each standard and adding 4800 )lL of methanol. A working internal standard solution 
was prepared in the same way using the deuterated standards. 
4.8.3 Blank Blood 
Time expired packed red blood cells were provided from the blood bank for blank blood. 
These were suspended in a ratio of 1: 1 with isotonic saline solution which was made by 
dissolving 9.5 g of sodium chloride in 1 L of deionised water. 
4.8.4 Solutions 
4.8.4.1 Preparation of 5 and 10 mM Ammonium Acetate Solutions 
AIM solution of ammonium acetate was prepared first by adding 38.54 g of ammonium 
acetate to a 500 mL volumetric flask and making up to volume with deionised water. 5 
and 10 rnL of this solution was added to 2 x 1 L volumetric flasks and made up to volume 
with deionised water resulting in 5 and 10 mM solutions. 
4.8.4.2 Preparation of 0.002 %, 0.004 %, 0.008 %, 0.01 % and 0.05% Formic 
Acid Solutions 
20, 40, 80, 100, and 500 f.1L of concentrated formic acid was added to 5 x 1 L volumetric 
flasks, which were made up to volume with deionised water to produce 0.002, 0.004, 
0.008, 0.01 and 0.05 % solutions. 
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4.8.4.3 Preparation of 0.1 M, pH 6.0 Phosphate Buffer 
6.81 g of potassium dihydrogen phosphate was weighed out into a 500 mL volumetric 
flask and 450 mL of deionised water was added. The pH was adjusted to 6.0 with 1 M 
potassium hydroxide solution, then made up to 500 mL with deionised water. 
4.8.5 Liquid Chromatography - Mass Spectrometry 
The instrument used for this work was a ThermoFinnigan AQA LC-MS. It consisted of a 
TSP P4000 quaternary pump, a TSP AS3000 autosampler, a UV 4000 Diode Array 
Detector, and a single quadrupole mass spectrometer. The interface between the liquid 
chromatograph and the mass spectrometer could be interchanged between ESI, 
electro spray ionisation, and APC!, atmospheric pressure chemical ionisation. The probe 
temperature was set at 300°C. The mobile phase consisted of 50:50 acetonitrile:deionised 
water mixture, run isocratically at 0.15 mL/min. 
4.8.6 Optimisation of Skimmer Cone Voltage 
100J..lL of a 1 J..lglmL solution was blown down under nitrogen at 35°C and reconstituted in 
100J..lL of mobile phase, this was done for each drug individually. Two methods were set 
up using full scan analysis and scanning at 4 different skimmer cone voltages, duplicate 
injections were carried out on both. The first used 25, 30, 35, and 40 V and the second 
used 45,50,55 and 60 V. The UV detector was also used at 242nm. The UV response 
could be used as an internal standard, and account for inconsistent injection volumes. The 
ratio between the pseudo-molecular ion and the UV response was calculated at each 
skimmer cone voltage. The optimum was found for each analyte and this was the value 
used in SIM experiments. 
The following skimmer cone values shown in Table 4-2 were found to be optimum for 
diazepam and its metabolites. 
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Table 4-2 : Optimum skimmer cone values for diazepam and metabolites 
Analyte 
Optimum Skimmer 
Cone Value (V) 
Diazepam 40 
N-Desmethyldiazepam 35 
Temazepam 25 
Oxazepam 30 
These values were used to get the best sensitivity for the analytes; it is a compromise 
between separating the analyte from any adducts and not fragmenting the pseudo 
molecular ion too much. It was found that temazepam fragments readily to a daughter ion 
of mJz = 255, this could be seen starting to form at 35 V. Figure 4-2 shows the decrease in 
mlz = 301 ion and the increase in mlz = 255 ion with increasing skimmer cone voltages. 
mJz = 301 
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Figure 4-2 : Effect of increasing skimmer cone voltage from 25 V to 60 V on temazepam 
mass spectra 
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4.8.7 Methanol VS. Acetonitrile in the Mobile Phase 
To assess the effect of methanol compared to acetonitrile in the mobile phase, two 
chromatographic conditions were used. Two 100 ng unextracted standards were prepared 
for each analyte, with no deuterated standards present. The UV detector was used in 
tandem with the mass spectrometer at 242 nrn. The peak for the analyte observed with the 
UV detector was used as an internal standard. The two chromatographic conditions were 
(A) methanol: deionised water (70:30) and (B) acetonitrile: water (50:50), both 
isocratically for 10 minutes at a flow rate of 0.2 mLimin. Each analyte was injected 
individually on each system, and the ratios between the molecular ion and UV response 
calculated. The results are shown graphically in Figure 4-3. 
It s clear from these results that using acetonitrile: water (50:50) as the mobile phase gives 
a higher response for all four analytes than using methanol: water (70:30). Although the 
total organic solvent content in each condition is different, it is generally thought that a 
greater amount of organic solvent will increase desolvation and therefore response. These 
results show that even with a greater percentage of methanol, acetonitrile gives a higher 
response. Acetonitrile was used as the organic part of the mobile phase for all future 
analyses. 
diazepam 
n-
desmethyldiazepam 
temazepam 
oxazepam 
• Methanol 
• Acetonitrile I 
o 0.05 0.1 0.15 0.2 0.25 0.3 0.35 0.4 
Response 
Figure 4·3 : Difference in response of analytes using methanol and acetonitrile in the mobile 
phase 
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4.8.8 Investigation into Ammonium Acetate and Formic Acid as 
Additives in the Mobile Phase 
4.8.8.1 ESI Probe with Ammonium Acetate 
A standard was prepared by adding 100 ).lL of 1 IlglmL solution to a vial and blowing 
down under nitrogen to dryness. This was reconstituted in 200 ilL of mobile phase and 10 
ilL was injected 6 times onto the LC-MS. An average peak area was calculated for each 
ion under each mobile phase composition. The mobile phase composition was 50:50 
acetonitrile: aqueous buffer. Initially a mobile phase composition of 50:50 acetonitrile : 
deionised water was used. The deionised water was substituted for increasing amounts of 
ammonium acetate, specifically 5 and 10 mM. The results are shown in the Figure 4-4. 
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Figure 4-4 : Effect of ammonium acetate on response using an ESI probe 
4.8.8.2 APel Probe with Ammonium Acetate 
1 
10 
The same procedure was carried out as in 4.8.8.1, this time the APCI probe was used 
instead of ESI. Additives are routinely used in APeI to transfer charge between the probe 
and the analyte. The results are shown in Figure 4-5. 
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Figure 4-5 : Effect of ammonium acetate on response using an APCI probe 
4.8.8.3 APel Probe with Formic Acid 
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A standard was prepared as before in 4.8.8.1. The mobile phase conditions were initially 
at 50:50 acetonitrile: deionised water. The deionised water was substituted for 0.01 % and 
0.05 % formic acid. The results are shown below in Figure 4-6. 
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Figure 4-6 : Effect of formic acid on response using an APCI probe 
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4.8.8.4 ESI Probe with Formic Acid 
The same procedure was carried out as in 0, except the ESI probe was used instead of the 
APel probe. The results are shown in 
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Figure 4-7 : Effect of formic acid on response using an ESI probe 
From this result it was decided to investigate further into low concentrations of formic 
acid. A standard was prepared as before and formic acid was used in the mobile phase at 
concentrations of 0.002, 0.004 and 0.008 %. The results are shown in Figure 4-8 below. 
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Figure 4-8 : Effect of low concentrations of formic acid on response using an ESI probe 
4.8.8.5 Conclusions 
From the results it is clear that using both additives with the APel probe either produced a 
detrimental effect on the response of all analytes or no effect at all. There was no increase 
in response, as was expected, using a buffer with the APer probe. Ammonium acetate in 
the mobile phase had a negative effect on response when the ESr probe was used, but no 
significant effect when the APer probe was used. 
The only condition to give an increase in response was using formic acid with the ESr 
probe. But the highest concentration of 0.05 % formic acid started to give a decrease in 
response. Low concentrations were then investigated, and it was found that 0.004 % 
formic acid gave the optimum response for all four analytes and their d5 deuterated 
standards. It was decided to use 0.004 % formic acid: acetonitrile 50:50, for the mobile 
phase for future analyses. 
4.8.9 Sample Preparation 
Spiked blood samples were prepared by adding the appropriate amount of working drug 
solution (1,2,5, 10,25,50, 100 J..lL) and internal standard solution (100 J..lL) to test tubes, 
followed by 3.5 mL of 0.1 M, pH 6 phosphate buffer and 1 mL of blank blood. A blank 
was prepared without any standards present and another with internal standard only to 
assess any contamination of the deuterated standards. 
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4.8.10 Extraction Procedure 
The extraction method used for flunitrazepam analysis in Chapter 3 was employed for 
diazepam and its metabolites. 3.5 mL of 0.1 M, pH 6.0 phosphate buffer was added to I 
mL of whole blood. 100 J.lL of 1 J.lglmL solution of diazepam-ds, N-desmethyldiazepam-
ds, temazepam-ds and oxazepam-ds was added as an internal standard. This was vortexed 
and centrifuged for 10 minutes at 3000 rpm. CleanScreen® DAU cartridges were 
conditioned with 1 mL ethyl acetate with 2 % NH3, 3 mL methanol, 3 mL deionised water 
and 2 mL 0.1 M, pH 6.0 phosphate buffer prior to sample application. The cartridges were 
washed with 2 mL deionised water and 2 mL phosphate buffer (0.1 M, pH 6) : acetonitrile 
80 : 20, then dried under full vacuum for 1 minute. 2 mL of hexane was applied and dried 
under full vacuum for a further minute. 3 x 2 mL aliquots of deionised water were applied 
to the cartridges drying under full vacuum for 1 minute between each addition of water. 
After the third aliquot of water the cartridges were left at full vacuum for 10 minutes to dry 
thoroughly. The analytes were then eluted using 3 mL ethyl acetate with 2 % NH3. This 
was blown down under nitrogen at 30°C until dry. Samples were reconstituted in 100 ilL 
of mobile phase (50: 50 acetonitrile: 0.004 % formic acid), with 20 J.lL injected in 
duplicate. 
4.9 Method Validation 
For qualitative information about diazepam and its metabolites, the two pseudo-molecular 
ions were monitored 3sCI and 37 Cl. This combined with the relative retention time, with 
respect to the relevant deuterated standard, was used for positive identification of each 
analyte. 
4.9.1 Linearity 
Diazepam, N-desmethyldiazepam, temazepam and oxazepam were found to have a linear 
response over the concentration range 1-100 nglmL in whole blood. A 100 nglmL of whole 
blood, extracted standard is shown in Figure 4-9. 
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4.9.2 Recovery 
The recovery was assessed at three concentrations, 5, 50 and 100 nglmL and calculated as 
in Chapter 3.10.5. The results are displayed in Table 4-3. 
Table 4-3 : Recovery of diazepam and metabolites 
Mean % Recovery (%,RSD) (n=5) 
Analyte 5nglmL 50 nglmL 100 nglmL 
Diazepam 87 (3) 87 (2) 87 (3) 
N-desmethyldiazepam 81 (4) 86 (4) 79 (2) 
Temazepam 87 (6) 85 (5) 88 (2) 
Oxazepam 78 (7) 84 (3) 81 (4) 
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4.9.3 Limits of Detection 
Limits of detection were calculated as in Chapter 3.10.6. This was using three times the 
standard error of the line plus the intercept. The results are displayed in Table 4-4. 
Table 4-4 : Limits of detection for diazepam and metabolites 
Limit of Detection 
Analyte 
(nglmL) 
Diazepam 0.3 
N-desmethyldiazepam 0.4 
Temazepam 0.3 
Oxazepam 1.1 
4.9.4 Limits of Quantitation 
Limits of quantitation were calculated as in Chapter 3.10.7. This was using ten times the 
standard error of the line plus the intercept. The results are displayed in Table 4-5. 
Table 4-5 : limits of quantitation for diazepam and metabolites 
Analyte 
Limit of Quantitation 
(nglmL) 
Diazepam 0.9 
N-desmethyldiazepam 1.4 
Temazepam 1.2 
Oxazepam 3.8 
4.9.5 Inter-Day Precision 
Inter-day precision was calculated using five sets of linearity data acquired on five 
different days. The %RSD of the five values for three concentrations, 5, 50 and 100 
nglmL were calculated. The results are shown in Table 4-6. 
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Table 4-6 : Inter-day precision of diazepam and its metabolites 
Analyte 
Inter-Day Precision (%RSD) (n=5) 
5 nglmL 50 nglmL 100 nglmL 
Diazepam 5.1 (8.6) 49.1 (1.7) 100.2 (1.0) 
N-desmethyldiazepam 4.9 (7.6) 50.2 (2.2) 99.3 (0.9) 
Temazepam 4.9 (10.1) 49.4 (2.9) 99.9 (0.8) 
Oxazepam 4.8 (9.2) 49.3 (2.0) 100.3 (0.7) 
4.9.6 Intra-Day Precision between Injections 
Extracted standards were prepared at three concentrations, 5, 50 and 100 ngimL. They 
were reconstituted in 150 ~L of mobile phase and 20 ~L was injected 5 times. The %RSD 
of the peak area ratios was calculated at each concentration for each drug. The results are 
shown in Table 4-7. 
Table 4·7 : Intra-day precision of diazepam and its metabolite. 
Analyte 
Intra-Day Precision (%RSD) (n=5) 
5 nglmL SOnglmL 100 nglmL 
Diazepam 4.9 (4.0) 49.5 (1.7) 99.5 (1.9) 
N-desmethyldiazepam 4.7 (11.6) 51.3 (2.6) 99.4 (1.9) 
Temazepam 4.6 (7.0) 49.7 (1.5) 100.5 (1.4) 
Oxazepam 4.5 (5.8) 48.0 (5.7) 101.0 (1.0) 
4.10 Discussion 
The optimum response of diazepam and its metabolites was found using 0.004% formic 
acid in the mobile phase which is the same concentration that was found be the optimum 
for flunitrazepam analysis. As all analytes are from the same group of drugs, 
benzodiazepines, this is not wholly unexpected. The difference in response between 
methanol and acetonitrile in the mobile phase was significant, indicating that both the 
organic solvent and the aqueous buffer are capable of affecting the ionisation of an analyte. 
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The validated method shows good linearity throughout the range (1-100 nglmL) and 
detection limits are all less than 1.5 ngimL. Recoveries greater than 78 % were observed 
for all analytes at low, medium and high concentrations and intra and inter day precision 
was less than 2 % at 100 ngimL. As diazepam and its metabolites have chlorine in their 
molecules, two pseudo-molecular ions are produced in the mass spectrometer one with 
chlorine35 and one with chlorine37 at a ratio of 3: 1. The second molecular ion produced 
can be used as a qualifier ion, and the ratio between the two ions should be constant. This 
is further qualitative information ensuring reliable results. 
4.11 Conclusions 
A method has been developed and validated for the extraction of diazepam, N-
desmethyldiazepam, temazepam and oxazepam from whole blood, using solid phase 
extraction and liquid chromatography-mass spectrometry for analysis. 
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5 Sildenafil in Whole Blood 
5.1 Introduction 
Although originally marketed as an anti hypertensive agent, 
sildenafil citrate has been used for the treatment of erectile 
dysfunction, since its approval by the U.S . Food and Drug 
~ Administration (FDA) in March 1998. Since then the drug has 
been widely available and used recreationally. A study showed 
that 2% of dance music enthusiasts in the UK, with an average age of 28 years, had used 
sildenafil recreationally66. 
5.2 Chemistry 
The molecular structure of sildenafil is shown in Figure 5-1. Sildenafil is chemically 
known as 1-[[3-(6,7 -dihydro-1-methyl-7 -oxo-3-propyl-1H -pyrazolo[ 4,3-dJpyrimidin-5-yl)-
4-ethoxyphenylJsulfonyIJ -4-methylpiperazine citrate. It has a molecular weight of 474 
amu, producing a pseudo-molecular ion ofrnlz = 475 in the LC-MS source. 
Figure 5-1 : Molecular structure of sildenafil 
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5.3 Metabolism and Excretion 
Metabolism of sildenafil is mainly through biotransformation; with 80 % of these products 
excreted in the faeces. N-desmethylsildenafil is a major plasma metabolite and has half the 
pharmacological activity of its parent dru~l. 
5.4 Pharmacokinetics 
One study found peak plasma concentrations of sildenafil occur between 0.5 and 2.5 hours 
after oral administration. Peak plasma concentrations of 159 nglmL were found with 
sildenafil barely detected at 24 hours (0.8 ng/mL).67 Pharmacokinetic data for sildenafil is 
summarised in Table 5_131. 
Table 5·1 : Pharmacokinetic and physiochemical data for slldenafil 
Sildenafl) 
Half Life (hours) 1.3-3.4 
Vd(LlKg) 1.0-1.5 
Protein Binding (%) 96 
pKa 8.7 
5.5 Toxicity 
Adverse effects associated with sildenafil tend to be transient and moderate; they include 
flushing, nasal congestion and headaches. When taken in overdose amounts sildenafil may 
produce hypotension, tachycardia and cardiac arresfl. 
5.6 Previous Work 
Several LC-MS methods have been published, most using tandem mass spectrometry, 
which is not always available68.69,70. One groUp'l reported the use ofa single quadrupole 
LC-MS instrument using liquid-liquid extraction. Presented here is a simple, fast, specific 
method using solid phase extraction and a single quadrupole mass spectrometer for the 
determination of sildenafil in whole blood. 
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5.7 Aim 
A post-mortem blood sample was submitted to the laboratory for sildenafil analysis. The 
aim was to develop a method for the detection and quantitation of sildenafil citrate, the 
active drug in Viagra®, in whole blood. 
5.8 Method Development 
After some initial experiments with mobile phase composition and flow rates the following 
conditions were found sufficient for analysis. Separation was performed on a Phenomenex 
Luna CI8(2) 150 x 2.0 mm Ld. with 3 J.UIl packing, kept at 35°C. A guard column with 
identical packing material was used to prolong the column life. Mobile phase comprised 
(A) 10 mM ammonium bicarbonate and (B) acetonitrile, with the gradient shown in Table 
5-2 
Table 5·2 : Mobile phase gradient for sildenafil analysis 
Time (min) Flow (mL/min) A(%) B(%) 
0.0 0.3 50 50 
5.0 0.3 90 10 
5.1 0.5 90 10 
7.0 0.5 90 10 
7.1 0.3 50 50 
12.0 0.3 50 50 
5.8.1 Chemicals 
Methanol, acetonitrile and hexane were HPLC grade and obtained from VWR International 
(UK). Analytical grade potassium dihydrogen phosphate, ammonium acetate and 
ammonium bicarbonate were supplied by BDH laboratory supplies (poole, England). 
Analytical grade concentrated ammonia, glacial acetic acid and concentrated formic acid 
were purchased from Sigma® Chemicals Co. (UK). 
5.8.2 Standards 
A stock standard of sildenafil was prepared by weighing 2.43 mg of sildenafil citrate and 
dissolving this in 1.729 mL of methanol, this gave a solution of 1 mglmL free sildenafil. A 
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second solution of I 00 ~glmL sildenafil was prepared by taking 500 ~L of 1 mglmL stock 
solution and adding 4500 ~L of methanol. This was then diluted down further taking 50 
~L of 1 00 ~glmL solution and adding 4950 ~L of methanol producing a 1 ~glmL working 
solution. Cocaine-d3 was purchased from Radian International as a 1 00 ~glmL methanolic 
solution. A working internal standard solution was prepared by taking 50 ~L of 100 
J.1g1mL solution and adding 4950 J.1L of methanol. 
5.8.3 Blank Blood 
Time expired packed red blood cells were provided from the blood bank for blank blood. 
These were suspended in a ratio of 1: 1 with isotonic saline solution which was made by 
dissolving 9.5 g of sodium chloride in 1 L of deionised water. 
5.8.4 Solutions 
5.8.4.1 Preparation of 10 mM Ammonium Bicarbonate Buffer 
0.7906 g of ammonium bicarbonate was weighed into alL volumetric flask and made up 
to volume with deionised water, resulting in a 10 mM solution. 
5.8.4.2 Preparation of 0.1 M, pH 6.0 Phosphate buffer 
6.81 g of potassium dihydrogen phosphate was weighed out into a 500 mL volumetric 
flask and 450 mL of deionised water was added. The pH was adjusted to 6.0 with 1 M 
potassium hydroxide solution, then made up to 500 mL with deionised water. 
5.8.4.3 Preparation of 0.01 M Acetic Acid 
57 ~L of glacial acetic acid was placed in a 100 mL volumetric flask this was made up to 
volume with deionised water, resulting in a 0.01 M solution. 
5.8.5 Optimisation of Skimmer Cone Voltage 
In-source collision or cone voltage fragmentation can be used in the LC-MS source to 
provide more structural information without the aid of tandem MS. The major difference 
with in-source fragmentation is that it is indiscriminate and any substance present in the 
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source will have the voltage applied. This can give complicated spectra, but it can also 
give a daughter ion for qualitative purposes. The optimum skimmer cone voltage was 
found for the parent and daughter ions. A standard was prepared for injection by adding 
100 J.lL of 1 J.lglmL sildenafil solution to a vial, this was blown down under nitrogen at 
35°C and reconstituted in 200 J.lL of mobile phase. 20 J.lL was injected onto the LC-MS in 
duplicate for each condition. In an injection the skimmer cone voltage can be set at 4 
different levels for each ion monitored. Table 5-3 displays the voltages set for each 
injection. 
Table 5-3 : Skimmer cone voltages used to optimise sildenafil response 
Injection Skimmer cone voltages (V) 
1,2 5, 10, 15,20. 
3,4 25,30.35,40 
5,6 45,50,55,60 
7,8 65,70,75,80 
As the skimmer cone voltage is increased the molecular ion response increases until it 
starts to fragments. At this point the response of the molecular ion is at its optimum. By 
increasing the voltage further the daughter ion increases in response until it starts to 
fragment further. This second voltage is used for optimum response of the daughter ion. 
Figure 5-3 shows the difference in peak area and spectra produced with increasing the 
skimmer cone voltage. 
The final results showed that 30 V was optimum for the pseudo molecular ion mJz = 475 
and 60 V was optimum for the daughter ion mJz = 283. The proposed fragmentation is 
shown in Figure 5-2. 
Figure 5·2 : Proposed fragmentation of slldenatll In the source 
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5.9 Method Validation 
5.9. 1 Sample Preparation 
Spiked blood samples were prepared by adding the appropriate amount of working drug 
solution (1,2,5, 10,25,50, 100,200, 500 ~L) and internal standard solution (200 ~L) to 
test tubes, followed by 3.5 mL of 0.1 M, pH 6 phosphate buffer and 1 mL of blank blood. 
A blank was prepared without any standards present and another with internal standard 
only to assess any contamination of the deuterated standards. 
5.9.2 Extraction Procedure 
The extraction method employed was based on a solid phase extraction method used for 
extracting acidic and basic drugs simultaneously72. To 1 mL of whole blood, 3.5 mL of 0.1 
M, pH 6.0 phosphate buffer and 200 ~L of internal standard was added, vortexed and 
centrifuged at 3000 rpm for 10 minutes. Bond Elut Certify® LRC cartridges were 
condition with 2 mL of methanol followed by 2 mL of phosphate buffer (0.1 M, pH 6). 
The sample was applied and allowed to drip through with no vacuum applied. To wash the 
cartridges 1 mL of deionised water followed by 0.5 mL of 0.01 M acetic acid was used. 
The cartridges were dried for 10 minutes with full vacuum applied, before adding 50 .... L of 
methanol and drying for a further 2 minutes. 4 mL of acetone : chloroform, 1:1, was 
applied; this was used as a clean-up step and was not collected. Elution was achieved 
using 2 mL of ethyl acetate with 2 % ammonia. The sample was blown down to dryness 
under nitrogen at 30 °e. 60 .... L of mobile phase, acetonitrile and 10 mM ammonium 
bicarbonate (50:50), was used to reconstitute the sample, before injecting 20 .... L onto the 
LC-MS system. Duplicate injections of each extract were made. 
5.9.3 Linearity 
Linearity of response for sildenafil was demonstrated over a wide dynamic range 1-500 
nglmL. This is shown graphically in Figure 5-4. Although plotting the daughter ions 
response with concentration only gives an R2 value of 0.9864, this ion would not be used 
for quantitation but rather qualitative purposes. Its linearity shows that the fragmentation 
is consistent and that the ratio between the pseudo molecular ion and the daughter ion 
should be stable. 
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Figure 5-4 : Linearity of sildenafil 
5.9.4 Recovery 
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The Bond Elut Certify® extraction method gave a mean recovery of 60 % for sildenafil. 
Recovery was calculated at 3 different concentrations 5, 50 and 500 nglmL extracted 5 
times refer to Chapter 3.10.5 for calculation. The mean recovery found at each 
concentration is shown in Table 5-4. 
Table 5-4 : Recovery of sildenafil 
Concentration Sildenafil (n=5) 
(ng/mL) Mean % Recovery (%RSD) 
5 61 (13) 
50 57 (17) 
500 63 (11) 
5.9.5 Limit of Detection 
Limits of detection were calculated as in Chapter 3.10.6. This was using three times the 
standard error of the line plus the intercept. The limit of detection for sildenafil was found 
to be 0.3 ngimL. 
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5.9.6 Limit of Quantitation 
The same procedure was used as in Chapter 3.10.7 using ten times the standard error. The 
limit of quantitation was found to be 1.0 nglmL. 
5.9.7 Inter-Day Precision 
Inter-day precision was found to be 9.9 % (5.2 nglmL) at 5 nglmL and 2.6 % (49.2 nglmL) 
at 50 nglmL standards. This was determined using linearity data from 5 different days. 
The %RSD of these five values was found. 
5.9.8 Intra-Day Precision between Injections 
Intra-day precision was found by injecting spiked standards 5 times into the system and 
calculating the %RSD, which was found to be 7.2 % (6.9 nglmL) at 5 nglmL and 4.0 % 
(47.5 nglmL) at 50 nglmL standards. 
5.10 Discussion 
Most LC-MS methods using single quadrupole instruments suffer from limited mass 
spectral data. This is due to the type of ionisation used in LC-MS. Atmospheric pressure 
ionisation techniques are termed soft ionisation, as they gently ionise the molecule with 
little fragmentation. This is very different to the ionisation used in GC-MS, where electron 
impact is used, termed hard ionisation. More energy is applied which breaks the molecule 
down into several fragments, and a complex spectrum is produced, with various ions to 
choose from to identify and quantify with. A specific daughter ion for sildenafil was found 
by alternating between a low and high skimmer cone voltage to produce the parent and 
daughter ion respectively. The fragmentation was also found to be consistent between 
concentrations resulting in a ratio between the parent and daughter ion that could be used 
as another qualitative piece of data. 
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5.11 Conclusions 
This method demonstrates that the use of a single quadrupole LC-MS is sufficient to 
identify and quantify sildenafil in whole blood. The method was applied to a post-mortem 
whole blood sample, refer to Chapter 10.1. 
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6 Oral Fluid 
6.1 Introduction 
Oral fluid was first used almost 30 years ago for therapeutic drug monitoringl. It has since 
been evaluated for use in the forensic field, recognising its advantages over other 
matrices73• It is a non-invasive sampling technique that does not require a medical 
practitioner to perform. Thus, a police officer or researcher is able to obtain a sample for 
analysis. Unlike urine sampling there is little chance of adulteration, and it is thought to be 
more acceptable to donate oral fluid than blood or urine. In recent years there has been 
great interest in the use of saliva testing at the roadside to identify potentially impaired 
drivers. 
Oral fluid is the name given to the mixture of fluids collected in the oral cavity and is made 
up of several components, including saliva, oral mucosal transudate, epithelial cells, food 
debris and oral micro-organisms. Saliva is defined as the fluid produced by the salivary 
glands in the mouth. Oral mucosal transudate can be defined as a serum derived fluid that 
enters saliva from the gingival crevice and across oral mucosal surfaces74 or fluid that 
comes from the area between the teeth and gums 75. 
In the course of this study two types of oral fluid collection devices were used, the 
modified Omni-Sal® device and the Intercept® device. Each device has a different 
approach to the collection of oral fluid. The modified Omni-Sal® device collects -1 mL of 
oral fluid using a pad without stimulation, shown in Figure 6-1. This pad is placed in the 
mouth until an indicator turns blue at the end of the stick. This infonns the user that 1 mL 
of oral fluid has been collected. The pad is then placed in a collection tube, which has 2 
mL of buffer. Once the sample has been transported to the lab, the pad is separated from 
the stick, and the resultant mixture filtered. A mixture ofbuffer:oral fluid 2: 1 is then 
available for analysis. A correction factor (multiply by 3) is applied when quoting a result 
in nglmL of oral fluid. 
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Figure 6-1 : The modified Omni-Sal® oral fluid collection device 
The Intercept@ device collects oral mucosal transudate using a pad with stimulation, shown 
in Figure 6-2. The pad is impregnated with common salts and gelatin, which stimulates 
saliva flow. The pad is placed between the lower gum and cheek and left for 2-5 minutes. 
Once the pad is removed from the mouth it is placed in a collection tube with 0.8 mL of 
buffer. A group of authors showed that the average volume obtained with the InterceptR, 
device is 0.38 ± 0.19 (SD) with a range of 0.05 to 0.8 mU6. Taking this into account the 
same correction factor as before is required. The stick is snapped off as the pad is inserted 
into the tube, and a lid secures the sample for transport. In the laboratory the bottom bit of 
plastic is snapped off to reveal a hole. The collection tube is placed in a second tube and 
then placed in the centrifuge at 3000 rpm for 10 minutes. The oral fluid and buffer are 
separated from the pad into the second tube ready for analysis. All of these matrices 
include saliva in their composition and therefore the knowledge of the chemistry of saliva 
is vitally important. 
Figure 6-2 : The Intercept® oral fluid collection device 
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Drugs are found in saliva by transportation over a thin layer of epithelial cells separating 
the blood circulation and saliva duct. This means that the drug concentration in saliva is 
related to the unbound fraction of drug circulating in the blood. This allows the use of 
saliva instead of blood to predict current drug use. A study assessed the use of 
expectorated oral fluid as a means of determining impairment in drivers and found it to be 
a valuable new matrix for the detection of drugs77 • 
6.2 Saliva Composition 
In the mouth three major paired glands produce saliva. The parotid gland, at the roof of 
the mouth, produces a watery serous fluid, the sublingual glands, at the sides of the mouth 
produce a mixture of serous fluid and mucin that makes the saliva sticky, and the 
submandibular gland produces a mixture like the sublingual gland and is positioned at the 
base of the tongue. 
Accessory 
parotid g la nd 
Parotid gland -ri-!m;r~~~SiQI~-~~~-r Parotid duct 
Subma ndibular gland 
Sublingual 
gl';lOd 
Figure 6-3: Diagram of saliva glands in the mouth78 
Whole saliva is made up from 71 % submandibular, 25 % parotid and 4 % sublingular and 
other minor glands. Saliva consists mostly of water, 99 %, some proteins, 0.3 %, and 
mucin, 0.3 %. Unstimulated saliva has a pH range of 5.6-7.0, but this can increase to 8.0 
when stimulated79• 
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6.3 Drug Transport 
Drugs are transported into saliva across a thin layer of epithelial cells that separate the 
saliva duct from the systemic circulation. The external carotid artery provides the arterial 
blood, which flows in the opposite direction to the salivary flow within the duct80• Drugs 
can be transported by three ways active transport, diffusion and passive di ffusion. Active 
transport (secretion) involves the movement of very small molecules such as Li+, this can 
cause a higher concentration in saliva than in plasma. Diffusion occurs through water-
filled pores and involves molecules with a molecular weight less than 100 amu e.g. 
ethanol. Most drugs of interest have molecular weights above 100 amu and are transported 
via passive diffusion across a concentration gradient. Passive diffusion of drugs occurs in 
both directions until equilibrium is reached. As the concentration of drugs in plasma is 
changing with metabolism, passive diffusion is occurring constantly in both directions. 
Lipoidal biological membranes are not permeable to ionised molecules. Therefore transfer 
rates of drugs into saliva are determined by their lipid solubilityl. Drugs need to have 
some lipophilicity to be able to cross the membrane, but also water solubility to be retained 
in the saliva. Ionisation provides water solubility and prevents back diffusion. Once 
equilibrium is reached the ratio between the drug concentration in saliva and in plasma 
depends on the pH of the saliva. Figure 6_479 shows the transfer of drugs from saliva into 
plasma through the cell membrane. 
Cellular 
Plama membrane allvn 
Acidic Drugs: G A - +H· .... HA. ~HA I->HA .... W+A-~ 
Trapped in plas!l1ll Trapped in aliv3 
~ ""'"~ or '''''''''''" ""''" ,or 'o"""io, ~ 
Basic Drugs: BH+ BH+ +B~ ~ B ~ ~B+H+ BHB+ 
Figure 6-4 : Drug transport between plasma and saliva 
Saliva/plasma ratios are derived from two equations, the Henderson-Hasselbalch equation, 
Equation 6, and the equation for mass balance, Equation 779 • 
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pH = pKa + log [A -] 
[HA] 
[A] = [A -] + [HA] 
where pKa is the pH at which the drug is 50% ionised 
[A-] is the concentration of the ionised fonn of the drug 
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Equation 6 
Equation 7 
[HA] is the concentration of the non-ionised fonn of the drug 
[A] is the total concentration of drug in both fonns 
By solving both equations: 
[A -] = [ A] - [HA] therefore pH = pKa + log [A] - [HA] 
[HA] 
log [A]-[HA] =pH-pKa 
[HA] 
[A]-[HA] = 1 o (pH-pKa) 
[HA] 
[A] = 1 + 10(PH-pKa) 
[HA] 
Equation 8 
Equation 9 
Equation 10 
Equation 11 
As the above equation can be applied to both saliva and plasma, the saliva/plasma ratio can 
be calculated by: 
[A'aJiva ] 
saliva _ [HA,aliva] 
plasma - [Ap1aslllll ] 
[HApllulllll ] 
= [Asaliva ] [HApllulllll ] 
[ A pllulllll ] [HA,aJiva ] = 
Equation 12 
1 + 10(PHIIIM-pKa) 
1 + 10 (PH.-.. -pKa) 
Equation 13 
Plasma contains both free and bound drug, if protein binding is taken into account and 
[HA] is assumed to be equal in plasma and saliva, the following equations can be derived: 
saliva 1 + lO(PHIIIM-pKa) free Iasma 
---= X p 
plasma 1 + lO(PH.-..-PKa) free saliva 
Equation 14 Acidic Drugs ~ 
Basic Drugs ~ 
saliva 1 + lO(pKa-pHIIIM) free 
___ = X plasma 
plasma 1 + 10(pKa-PH.-..) free
saliva 
Equation 15 
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These equations predict that it is the amount of unbound drug in plasma that will affect the 
amount of drug in saliva. As it is only the unbound drug that is pharmacologically active, 
and this is reflected in the saliva concentration, saliva analysis has great potential for 
detennining recent drug use. 
6.4 Drugs of Abuse in Saliva 
Drugs that are not ionisable or are un-ionised within the salivary pH range are most 
suitable for analysis in saliva. This means a change in saliva pH or flow rate does not 
effect the saliva drug concentration. If a drug is ionised in the saliva, it will not be able to 
diffuse back into the plasma reSUlting in the drug concentrations in the two matrices is not 
being in equilibrium and therefore the saliva drug concentration can not predict the plasma 
concentration. For drugs that have a pKa less than 5.5 and greater than 8.5, saliva pH has 
little effect on drug concentrations82. Unfortunately some drugs of abuse have pKa values 
close to 8.5 and can be affected by saliva pH. As saliva flow increases, as does the 
bicarbonate content which makes the saliva more alkalineso• High saliva flow rates can 
result in a pH of 7.4 - 7.6, much higher than the normal range of 5.6-7.0. Stress, anxiety 
and medication can all depress the flow of saliva and lower its pH. Saliva flow and pH are 
at their lowest in the early morning and peak at about 4 pm. Unstimulated saliva flow rates 
range from 0.3 to 0.5 mLimin, with 2% citric acid stimulated saliva, the flow rate ranges 
from 1.0 to 3.0 mUmin83. Stimulated saliva can be collected by citric acid under the 
tongue, chewing parafilm wax or Teflon, or sucking on pebbles. Not only do these 
methods increase flow rate therefore increasing alkalinity and decreasing saliva/plasma 
ratios, there is the possibility of adsorption of drugs onto the parafilm wax or Teflon'3. As 
well as drugs of abuse having pKa values close to the pH of saliva, there is also the 
problem of contamination. Sources of contamination include orally ingested, smoked or 
internasally administered drugs. Contamination produces elevated drug concentrations in 
the saliva, thus making prediction of the plasma drug concentration difficult. Drugs of 
abuse found in saliva can infer recent drug use, but concentrations showed be looked at 
with caution, taking saliva collection and contamination issues into account. 
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6.4. 1 Amphetamines 
Amphetamines as a class include the classical amphetamines, amphetamine 
and methamphetamine and the methylenedioxy derivatives, 
methylenedioxymethamphetamine (MDMA), 
methylenedioxyethylamphetamine (MDEA), and methylenedioxyamphetamine 
(MDA) as shown in Figure 6-5. Amphetamine and methamphetamine are 
commonly abused by oral administration. They have been used both 
intranasally and by intravenous injection. Methamphetamine hydrochloride 
also known as "ice" is usually smoked. Users experience a "rush" which is not attained 
when taken orally or intranasallY4. The methylenedioxy derivatives seem to produce 
different effects to the classical amphetamines such as feelings of euphoria happiness, 
increased energy and feeling close to others. Some authors described these effects as 
"entactogenic,,85. Young people at "raves" increasingly use these drugs because of the 
unique feeling they produce86. MDMA, MDEA and MDA are usually taken orally as pills. 
Amphetamine 
('YYCH3 V NH2 
MDEA 
'-': 
MDMA 
Methamphetamine 
V):CH3 I ~ NH 
/ 
H3C 
Figure 6-5 : Molecular structures of amphetamine, methamphetamine, MDMA, MDEA and 
MDA 
6.4.1.1 Metabolism and Pharmacokinetics 
Amphetamine is metabolised by hydroxylation of the aromatic ring to p-hydroxy-
amphetamine and by deamination to benzylmethylketone, followed by oxidation to 
benzoic acid87. Methamphetamine is partially metabolised to amphetamine, which is then 
metabolised further88• MDMA and MDEA both metabolise to MDA. Although not 
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extensively researched it is thought that a substantial portion ofMDA is excreted 
unchanged31. 
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Pharmacokinetic data for amphetamine, methamphetamine and MDMA is shown in Table 
6_131. There has been little research done on the pharmacokinetics ofMDEA and MDA. 
We can assume they will have similar protein binding and pKa values to amphetamine and 
methamphetamine. 
Table 6·1 : Pharmacokinetic and physiochemical data for the amphetamine, 
methamphetamine and MDMA 
Amphetamine Methamphetamine MDMA 
Half life (hr) 7-34 (urine pH 6-15 (urine pH 6-9 
dependent) dependent) 
Vd (L1k2) 3.2-5.6 3.0-7.0 5.0-8.0 
Protein 16 10-20 -
Binding (0/0) 
PI<. 9.9 9.9 -
6.4.1.2 Saliva Concentrations 
A study found MDMA concentrations in saliva an order of magnitude greater than 
concentrations in plasma89• Another group found that amphetamine saliva concentrations 
were three times that of plasma concentrations90• A further study into methamphetamine 
saliva concentrations found that these were five times greater than plasma concentrations91 • 
These high concentrations in saliva can be explained by a number of reasons. 
Amphetamines have low protein binding in plasma (-20 %) leaving more molecules 
available for diffusion into the salivary glands. The cell membrane favours low molecular 
weights, with amphetamines ranging from 135 amu for amphetamine, to 207 amu for 
MDEA. Saliva is slightly more acidic than plasma therefore ampbetamines are ionised in 
saliva and cannot diffuse back into plasma. Thus they accumulate in the saliva elevating 
saliva concentrations; this is sometimes referred to as "ion trapping"91. MDMA is known 
to act on serotonergic neurotransmission leading to vasoconstriction and a reduction in 
saliva production concentrating drugs in this matrix92• Individuals often experience dry 
mouth93• Peak oral fluid MDMA concentrations have been reported as 1215 nglmL94 (75 
mg dose) and 3375 nglmL (100 mg dose). The high concentrations ofampbetam.ines in 
saliva make them particularly suited for oral fluid analysis, to show recent drug use. One 
still has to be aware of the potential of contamination through oral and intranasal ingestion. 
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6.4.2 Benzodiazepines 
Benzodiazepines as a class include the most frequently 
prescribed and abused drugs diazepam and temazepam. 
Diazepam is prescribed as an antianxiety agent, muscle 
relaxant or anticonvulsant. Temazepam is a metabolite of 
diazepam and a prescribed drug in its own right. It is used for 
insomnia and is short acting. Both of these drugs have been 
associated with abuse in the west of Scotland. Between 1995 and 1998 a study into drug 
related deaths in the Strathc1yde region of Scotland showed that 45 % of cases were 
positive for diazepam and 33 % positive for temazepam58 • A further study into the 
prevalence of drugs in impaired drivers during 1995 and 1998 found benzodiazepines in 82 
% of cases. With temazepam the most frequently encountered then diazepam95 • 
6.4.2.1 Metabolism and Pharmacokinetics 
The metabolism of diazepam is shown in Figure 4-1. The pharmacokinetic properties of 
the diazepam and its metabolites are shown in Table 6-2 below. 
Table 6-2 : Pharmacokinetic and phYSiochemical data for 1,4-benzodiazepines 
Diazepam Temazepam N-desmethyldiazepam Oxazepam 
Half life (hr) 21-37 3-13 31-97 4-11 
Vd (L/kg) 0.7-2 .6 0.8-1.0 0.7-1.6 
Protein 96 97 97 87-94 
Binding (%) 
pKa 3.4 1.3 3.5, 12.0 1.7, 11.6 
6.4.2.2 Saliva Concentrations 
Diazepam (Valium®) is a long-acting lipophilic benzodiazepine, which exhibits extensive 
protein binding (96-99 %) allowing only a small percentage to diffuse through into saliva. 
Concentrations in saliva are found in the 0 - 20 nglmL range and are observed up to 8 
hours after dosing88. A metabolite of diazepam, N-desmethyldiazepam has also been 
found in saliva. After chronic dosing saliva concentrations were approximately equivalent 
to diazepam, 1.2 - 23 nglmV8. There seems to be little research on the analysis of 
benzodiazepines in oral fluid. This may be due to the high protein binding of the 1,4-
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benzodiazepines in blood. One group attempted to analyse diazepam in saliva after a 
single oral dose but found their chromatographic method lacked enough sensitivity96. 
6.4.3 Cocaine 
Cocaine is extracted from the leaves of Erythroxylum coca, which 
contain up to 2 % in weighe'. Illicit cocaine is sold as cocaine 
hydrochloride usually administered intranasally or intravenously. 
Cocaine base "crack cocaine" is used for smoking. Cocaine is 
absorbed into the blood stream from all sites of application including 
mucous membranes, the gastrointestinal tract and lung aveoli88 • Lung 
alveoli are especially efficient at cocaine absorption, and some users 
prefer a low cocaine dose smoked than a high dose injected. Intranasal and oral routes of 
administration produce lower plasma concentrations over a prolonged time, due to slower 
absorption97. Cocaine is a CNS stimulant and produces feelings of well-being and 
euphoria88 • 
6.4.3.1 Metabolism and Pharmacokinetics 
Once in the blood stream, cocaine is hydrolysed to its two major metabolites, 
benzoyl ecgonine (BZE) and ecgonine methyl ester (EME) and a number of minor 
metabolites3 ' . Cocaine's pharmacokinetic data is presented in Table 6-3 and the structures 
of cocaine and its metabolites are shown in Figure 6-6. 
Table 6-3 : Pharmacokinetic and physiochemical data for cocaine 
Cocaine 
Half life (hr) 0.7-1.5 
Vd (L/kg) 1.6-2.7 
Protein Binding 92 
(%) 
pKa 8.6 
Peak concentrations of cocaine occur in plasma within 2 hours after oral administration98• 
The half life of cocaine in plasma was determined as 1.5 hours after acute administration98 
and 3.8 hours after frequent use99• As a result of cocaine's lipophilicity it is thought that 
cocaine is accumulated in the fatty tissues and CNS during chronic use and excreted over a 
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period of2-3 weeks1oo• Plasma half lives for BZE and EME have been reported as 6.4 
hours and 3.7 hours respectivelY8. 
Cocaine H3C, Benzoylecgonine 
N 0 
Ecgonine methyl ester 
o 
~ o ~ ~ Cocaethylene 
o 
Figure 6-6 : Molecular structures of cocaine and Its metabolites 
6.4.3.2 Saliva Concentrations 
Cocaine concentrations in plasma correlate significantly with saliva concentrations and 
subjective efIectslol. The individual saliva cocaine concentrations were frequently found to 
be higher than respective plasma concentrations. Another study found that detection times 
for cocaine in saliva were longer than in plasma102• These findings are consistent with 
cocaine having a saliva/plasma ratio of>l. BZE and EME are less lipid-soluble than 
cocaine and are found in lower concentrations in saliva than plasma samples collected at 
the same time103• In one study however, EME was found in higher concentrations in saliva 
compared to plasma98• In the same study a mean peak EME saliva concentration of 11,566 
nglmL was found whereas the mean peak BZE saliva concentration was 2,980 nglmL and 
the mean peak cocaine saliva concentration was 1,978 ngimL. These atypical results may 
be due to the chronic administration of cocaine, subsequent accumulation and prolonged 
elimination. Cocaine could be found in the saliva of these chronic users for 5-10 days after 
abstinence. Another group found that cocaine saliva concentrations were -2.4 fold higher 
than plasma concentrations, BZE saliva concentrations were a 1I5th of plasma 
concentrations and EME saliva concentrations were equivalent to plasma concentrations99• 
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This group studied the levels of cocaine and its metabolites during abstinence, which may 
account for the differences in results. 
If cocaine is administered intranasally or smoked, contamination of the oral cavity can 
occur. This will artificially elevate the saliva concentrations. The extent of contamination 
by the intranasal route of administration was found to be highly variable and lasted longer 
(2 hours) than contamination by the smoked route (0.25 hoursy02. The difference in extent 
of contamination by the different routes is thought to be due to ion trapping of the drug in 
saliva and successive swallowing resulting in rapid clearance ofthe drug while smoking. 
All routes of administration reach the limit of detection (1 nglmL) within 12 hours l02. 
Another factor effecting cocaine levels in saliva is the method of collection, whether saliva 
flow is stimulated or unstimulated. A study found that there was a 5 fold reduction in 
cocaine, BZE and EME saliva concentrations after stimulationlO4. 
Cocaine was first detected in the saliva of an impaired driver in 198477• Since then various 
studies have been performed on the deposition of cocaine and its metabolites in saliva. It 
is thought that plasma cocaine concentrations are significantly correlated with saliva 
concentrations 101, if cocaine is administered intravenously or there has been time for 
contamination to clear from the oral cavity, ~2 hours l02. There is a longer window of 
detection in saliva than plasma, due to the high saliva/plasma ratio and possible 
accumulation of cocaine in the fatty tissues of chronic users 100. Saliva analysis of cocaine 
can be indicative of recent use and if contamination is known not be a factor then plasma 
concentrations can be predicted. 
6.4.4 Opiates: Morphine, Codeine and 6-monoacetylmorphine 
Opium is the dried exudate of the poppy Papaver 
Somniferum, it contains morphine and codeine amongst other 
natural alkaloids88 • Clandestine laboratories acetyl ate 
morphine to diamorphine to be sold on the black market. 
This procedure results in the conversion of codeine to 
acetylcodeine. In the USA heroin and diamorphine are interchangeable names. In the UK 
heroin is commonly defmed as the mixture of the impurities reaction intermediates, 
breakdown products manufactured during the synthesis of diamorphine, and excipients and 
adulterants used to dilute or cut the drug105. 
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6.4.4.1 Metabolism and Pharmacokinetics 
Diamorphine is metabolised rapidly in plasma with a half-life of2-6 minutes31 . For this 
reason it is rarely the primary target for opiate detection in body fluids. Diamorphine 
metabolises to morphine via 6-monoacetylmorphine (6-MAM), this allows the detection of 
6-MAM to be conclusive of diamorphine use. As codeine is extracted from the poppy at 
the same time as morphine, it is also present in heroin, and hence can be detected in body 
fluids after heroin administration. The metabolism of diamorphine is shown in Figure 6-7. 
Codeine found in body fluids from heroin overdose victims is due to the impure heroin, 
and not metabolism31. 
Codeine metabolises to morphine, by O-demethylation, and norcodeine via N-
demethylation. Both are excreted in their free form or their glucuronide conjugates in 
urine. Norcodeine is found in trace amount in serum, and therefore it is unlikely to find 
any appreciable amounts in saliva. Morphine can be found in serum up to 10% of the 
codeine concentration within 6-8 hours31. 
Diamorphine 
HO 
CH3COO 
6-acetylmorpbine 
Figure 6·7: Metabolism of dlamorphlne 
Morphine 
Codeine is a commonly prescribed opiate used for pain relief and cough suppression, its 
structure is shown in Figure 6-8. It can also be abused for both its euphoric and depressant 
effects, and to prevent opiate withdrawal. Owing to its availability there have been several 
studies on codeine in oral fluid96.106.107.108.109. 
Table 6-4 : Pharmacoklnetic and physiochemical data for dlamorphlne, morphine and 
codeine 
Diamorphine Morphine Codeine 
Half life (br) 2-6 minutes 1.3-6.7 1.9-3.9 
Vd (Llka) 25 2-5 3.5 
Protein Binding 40 35 7-25 
(%) 
pI{. 7.6 8.1, 10 8.2 
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Figure 6-8 : Chemical structure of codeine 
6.4.4.2 Saliva Concentrations 
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Morphine plasma concentrations have been shown to peak at 0.25 - 0.5 hours, while saliva 
concentrations tend to be slightly delayed reaching maximum at 0.5 hours. Morphine 
concentrations found in saliva tend to be lower than the equivalent plasma samples. One 
study found a peak morphine plasma concentration of 150 nglmL following a 20mg dose. 
The equivalent peak morphine saliva concentration was 38 ngimL. Both matrices gave 
positive morphine results up to 24 hours106. 
The same study found that in contrast to morphine, codeine saliva concentrations were 
higher than plasma concentrations. After a 120 mg dose of codeine, peak plasma 
concentrations of272 nglmL were observed compared to 308 nglmL in saliva. A different 
study found that codeine saliva concentrations remained 3 - 4 times greater than plasma 
concentrations throughout 24 hours107• Codeine was even found to be present for a longer 
period oftime in saliva (36 hr) than in plasma (24 hr)l06. This is supported by another 
group of authors who found that codeine was detected 5 - 9 hours longer in oral fluid than 
in plasma109 and another group who found codeine was detected in saliva 12 hours longer 
than in plasma107• 
One group studied the effect of collection method on saliva concentrations of codeine and 
found that "spitting" gave consistently higher results than any of the collection devices, 
even a cotton roll without any stimulating salts impregnated. This could be due to 
adsorption of drugs onto the device or the stimulation effect of the device. They found 
spitting to give 3.5 times higher results than acidic stimulation and 1.3 - 2.0 times higher 
results than any other device108• They also concluded that there was considerable 
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interindividual variability in peak codeine concentrations between collection methods and 
within each collection group. 
One point to note is that even after brushing teeth, oral contamination is sti 11 present, 
supporting a theory of small depots of drug in the oral cavity releasing over a period of 
timelo7. 
6.4.5 Morphine Substitutes: Methadone, Buprenorphine and 
Dihydrocodeine 
Methadone, buprenorphine and dihydrocodeine are all used in the 
treatment of heroin addiction. 
Methadone is a morphine substitute, and possesses many of the 
pharmacologic properties of morphine. However it can accumulate 
in the body with repeated administration and cause sedative effects. 
Since 1965 it has been used for opioid maintence patients, with daily 
doses as high as 180 mg. It is known that doses of 50 mg or less can be fatal in nontolerant 
adults3l. 
Buprenorphine is a synthetic thebaine derivative with both analgesic and opioid antagonist 
properties3l. It is used as a morphine substitute like methadone. Buprenorphine has not 
been found to be a contributor in drug related deaths or impaired driving58.95 . A study into 
drug related deaths in Edinburgh and Glasgow found 1 death positive for buprenorphine 
and concluded that the lack of positive samples implied that the drug is very unlikely to 
lead to deathllo. 
Dihydrocodeine is a semisynthetic narcotic analgesic, prepared by the reduction of codeine 
and can be prescribed as an alternative to methadonelll . Its structure is shown in Figure 
6-9 . 
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Figure 6-9 : Chemical structure of dihydrocodeine 
6.4.5.1 Metabolism and Pharmacokinetics 
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Table 6-5 : Pharmacokinetic and physiochemical data for methadone. buprenorphine and 
dihydrocodeine 
Methadone Bup_renoJ'Phine Dihydrocodeine 
Half life (hr) 15-55 2-4 3.4-4.5 
VdJL/kg) 4-5 2.5 1.0-1.3 
Protein Binding 87 96 -
(%) 
pI{. 8.6 8.5, 10.0 8.8 
Methadone it metabolised to 2-ethylidene-l,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) 
by mono-N-demethylation with spontaneous cyclization as shown in Figure 6-10. EDDP 
is not found to any significant extent in plasma during therapeutic usage of methadone. 
Methadone plasma concentrations peak at 4 hours with an average value of 0.83 mgIL with 
chronic administration of 100-200 mg daily oral dosel l • 
Methadone 
Figure 6-10 : Metabolism of methadone to EDDP 
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Blood concentrations ofbuprenorphine tend to be very low. 2 mg of sublingual 
administered buprenorphine in 6 patients gave an average peak plasma concentration of 1.6 
nglmL at 1.3 hours. Buprenorphine is metabolised to norbuprenorphine which is also 
pharmacologically active their structures are shown in Figure 6-11. In the urine free 
buprenorphine and norbuprenorphine levels may be up to 20 nglmL in abuse cases.31 
HO 
HC-O 3 
HO CH3 
C(CH~)~ 
Buprenorphine 
Figure 6·11 : Metabolism of buprenorphine 
HO 
HC-O 3 
HO CH3 
C(CH~)~ 
Norbuprenorphine 
Dihydrocodeine is thought to undergo the same biotransformation steps as codeine31 • Peak 
plasma concentrations of dihydrocodeine of 70 nglmL have been found at 1.6 hours after a 
30mg oral dose. 
6.4.5.2 Saliva Concentrations 
There are conflicting views on the use of oral fluid for methadone analysis. The theoretical 
saliva/plasma ratio is calculated by using the pH of oral fluid and plasma. As the pH of 
oral fluid is not constant the theoretical saliva/plasma ratio can vary also. A value of 1.3 
was calculated by one group, who concluded that methadone was an ideal candidate for 
oral fluid analysis, as there would be a good linear relationship between the two 
matrices1t2. However a more recent study found no correlation between methadone saliva 
and serum concentrations 113. 
Saliva concentrations ofbuprenorphine are substantially less than plasma with a 
saliva/plasma ratio of 0.05-0.41, following intramuscular administration88• It would be 
unlikely to find buprenorphine or its metabolite norbuprenorphine in oral fluid due to the 
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very low levels found in plasma. Oral contamination could indicate its recent ingestion but 
no information on plasma levels could be deduced. 
After oral administration of 60 mg dihydrocodeine to six subjects dihydrocodeine was 
found in saliva for up to 12-24 hours and the half-life in saliva was twice that of blood. 
After chronic administration of dihydrocodeine, the parent drug was the main analyte in 
saliva with only a few samples positive for N-nordihydrocodeine. 114 
6.5 Conclusions 
It is known that some drugs can collect in oral fluid through passive diffusion over lipid 
membranes in the salivary glands. It is also understood that blood and urine are not 
preferred body fluids to give or obtain. A medical practitioner needs to take blood, and 
urine gives us information on what drugs have been taken in the past and not what is in the 
circulatory system at present. Oral fluid analysis provides information on drugs which are 
in the blood stream at the time of collection, or in the case of contamination, drugs which 
have been ingested within the past few hours. Owing to the advantages of oral fluid 
analysis, it has the potential to find a place in roadside testing and heroin rehabilitation 
centres. 
Page 82 
7 Drugs of Abuse in Oral Fluid Using LC-MS 
7.1 Introduction 
As part of a departmental project, 60 oral fluid samples were to be analysed for a wide 
spectrum oflicit and illicit drugs. Samples were collected using the modified Omni-Sal® 
device, supplied by Cozart Bioscience Ltd. This device collects I mL of oral fluid through 
a pad placed at the side of the mouth. This was then diluted with 2 mL of buffer to 
preserve the sample until analysis. As sample volume was limited it was decided to use 
both the GC-MS and LC-MS to screen the samples for as many analytes as possible. A 
single extraction procedure was needed and the extract would be split for injection onto 
both instruments. 
7.2 Aim 
Most of the common drugs of abuse have been analysed by LC-MS in the past. These 
include morphinellS,116,117,118, methadone119,120,121, buprenorphinel22, amphetamines 123, 124 and 
combinations of these, opioids and cocainel2S, and opiates, amphetamine and cocainel26• 
The aim of this project was to develop and validate a method for the extraction of twenty 
drugs of abuse and their metabolites from 1 mL of oral fluid and identify them using liquid 
chromatography - mass spectrometry. 
7.3 Method Development 
Initially the pseudo molecular ions for the analytes must be identified and the voltage 
applied to the skimmer cone (AQA max voltage) optimised. Once the ions are identified 
the chromatography can be improved by changing the mobile phase to try and resolve the 
analytes. The initial mobile phase conditions were 50:50 acetonitrile :0.004 % formic acid 
at 0.15 mUmin using a Phenomenex Luna CI8(2) 150 x 2.0 mm, 3).Ull packing. These 
conditions were chosen as they had worked well in benzodiazepine analysis, refer to 
Chapter 4. 
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7.3. 1 Chemicals 
Methanol, acetonitrile and hexane were HPLC grade and obtained from VWR International 
(UK). Analytical grade potassium dihydrogen phosphate, ammonium acetate and 
ammonium bicarbonate were supplied by BDH laboratory supplies (poole, England). 
Analytical grade concentrated ammonia, glacial acetic acid and concentrated formic acid 
were purchased from Sigma® Chemicals Co. (UK). 
7.3.2 Standards 
Stock standards of analytes were purchased from Promochem as 100 J.1g/mL methanolic 
solutions. The deuterated standards of each drug were also purchased as 100 J.1g/mL 
methanolic solutions. The analyte and deuterated standards used are shown in Table 7-1. 
In the first instance 1 J.1g/mL solutions of each analyte were prepared so they could be 
injected singularly. This was done by taking 10 J.1L of 100 J.1g/mL solution and adding 990 
J.1L of methanol. A working drug solution of 1 J.1g/mL for each drug, was prepared by 
taking 250 J.1L of each standard into a 25 mL volumetric flask and making up to volume 
with methanol. A working internal standard solution was prepared in the same way using 
the deuterated standards. 
Table 7-1 : Purchased standards and deuterated standards 
Analyte Deuterated Standard 
Amphetamine Amphetamine-ds 
Methamphetamine Methamphetamine-ds 
MDA MDA-ds 
MDMA MDMA-ds 
MDEA MDEA-ds 
Diazepam Diazepam-ds 
N-desmethyldiazepam N-desmethyldiazepam-ds 
Temazepam Temazepam-ds 
Oxazepam Oxazepam-ds 
Cocaine Cocaine-d3 
Benzoylecgonine Benzoylecgonine-d3 
Cocaethylene Cocaethylene-d3 
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Analyte Deuterated Standard 
Morphine Morphine-d3 
Codeine Codeine-d3 
6-MAM 6-MAM-d3 
Dihydrocodeine Dihydrocodeine-dt; 
Methadone Methadone-d9 
EDDP EDDP-d3 
Buprenorphine Buprenorphine-<4 
Norbuprenorphine Norbuprenorphine-d3 
7.3.3 Spiked Oral Fluid Samples 
Drug free oral fluid was collected from healthy volunteers using Omni-Sal® devices with 
proprietary modifications as supplied by Cozart Biosciences Ltd., Abingdon, UK. Oral 
fluid, ImL, was collected with each device as indicated by a colour change at the end of 
the stick. This was then placed into 2 mL of buffer and the stick was twisted to detach the 
pad. This mixture of oral fluid and buffer (1:2 v/v) was then expressed through a filter to 
separate it from the pad and was used as the matrix for preparation of oral fluid standards. 
7.3.4 Solutions 
7.3.4.1 Preparation of 0.1 M, pH 6.0 Phosphate Buffer 
6.81 g of potassium dihydrogen phosphate was weighed out into a 500 mL volumetric 
flask and 450 mL of deionised water was added. The pH was adjusted to 6.0 with 1 M 
potassium hydroxide solution, then made to 500 mL with deionised water. 
7.3.4.2 Preparation of 0.004% Formic Acid Solution 
40 J.1L of concentrated formic acid was placed in aiL volumetric flask and made up to 
volume with deionised water. 
7.3.4.3 Preparation of Ammonium Formate and Formic Acid Buffers 
Table 7-2 show the amounts of ammonium fonnate and concentrated fonnic acid that were 
added to aiL volumetric flask and made up to volume with deionised water. 
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Table 7·2: Amounts of ammonium formate and concentrated formic acid used to make 
mobile phase buffers 
Ammonium Formic 
Final Concentration in 1 litre 
Formate (g) Acid (JAL) 
20 mM Ammonium Fonnate + 0.001 % Formic Acid 1.261 10 
10 mM Ammonium Fonnate + 0.001 % Formic Acid 0.631 10 
5 mM Ammonium Fonnate + 0.001 % Formic Acid 0.315 10 
3 mM Ammonium Fonnate + 0.001 % Fonnic Acid 0.189 10 
2 mM Ammonium Fonnate + 0.001 % Formic Acid 0.126 10 
3 mM Ammonium Fonnate + 0.002 % Fonnic Acid 0.189 20 
3 mM Ammonium Formate + 0.004 % Formic Acid 0.189 40 
7.3.5 Optimisation of Skimmer Cone Voltage 
Single standards were prepared by taking 100 J.1L of a 1 J.1g1mL solution into a vial and 
blowing down under nitrogen. This was reconstituted in 200 J.1L of mobile phase and 10 
iJ.L injections were made. Full scan mode was used, setting the skimmer cone voltage to 5, 
10, 20 and 30 V for the first injection and 40, 50, 60 and 70 V for the second injection. 
The skimmer cone values for diazepam and its metabolites were taken from previous work, 
refer to Chapter 4. The results are shown in Table 7-3 below. 
Table 7-3 : Pseudo molecular ions and skimmer cone values for 20 analyt •• 
Molecular Pseudo molecular Skimmer cone 
Analyte 
weight (amu) ion [M+Ht (m/z) voltage (V) 
Amphetamine 135 136 5 
~ethampheUunine 149 150 10 
MDA 179 180 10 
MD~ 193 194 10 
MDEA 207 208 10 
Diazepam 284 285 40 
N-desmethyldiazepam 270 271 3S 
Temazepam 300 301 2S 
Oxazepam 286 287 30 
Cocaine 303 304 10 
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Molecular Pseudo molecular Skimmer cone 
Analyte 
weight (amu) ion [M+H]+ (m/z) voltage (V) 
Benzoylecgonine 289 290 20 
Cocaethylene 317 318 20 
Morphine 285 286 20 
Codeine 299 300 30 
6-MAM 327 328 30 
Dihydrocodeine 301 302 5 
Methadone 309 310 10 
EDDP 277 278 20 
Buprenorphine 467 468 30 
Norbuprenorphine 413 414 40 
All of the analytes eluted within a couple of minutes of the solvent front, so it was clear 
that a gradient would have to be used to resolve the analytes and a higher buffer content in 
the initial conditions to separate the analytes from the solvent front. 
7.3.6 Optimisation of Mobile Phase Conditions 
Although it is widely believed that basic drugs ionise more efficiently with an acidic buffer 
in the mobile phase, it has been shown that a high pH buffer such as ammonium 
bicarbonate can give satisfactory results127. A mixture of ammonium fonnate and formic 
acid has also been used in the mobile phase for the analysis of a complex mixture of 
opioids and cocainel2S• It was decided to investigate the effect of using both ammonium 
fonnate and fonnic acid at different concentrations in the mobile phase. A fonnic acid 
concentration of 0.00 1 % was used and the amount of ammonium fonnate added was 
changed to 20, 10, 5, 3, and 2 mM. Each mobile phase conditions were equilibrated on the 
LC system before 5 injections of drug mixture were run. The average peak area was 
calculated for each drug, a selection of analytes is shown in Figure 7-1. 
Chapter 7: Detection of Drugs of Abuse Using LC-MS 
,..... 
II") 
9.E+07 
8.E+07 
~ 7.E+07 
'-' 
~ 6.E+07 
... 
~ 5.E+07 
~ 
~ 4.E+07 
~ 3.E+07 ~ 
... 
~ 2.E+07 
< 
1.E+07 
O.E+OD 
. 20mM 
. 10mM 
. 5mM 
I . 3mMJ ~M 
Page 87 
Figure 7-1 : Variation of response with decreasing ammonium formate concentration 
As before in Chapter 4, response of analytes increased with lower amounts of buffer 
present. It was decided to use 3mM ammonium formate and change the concentration of 
formic acid to see what effect it had on analyte response. Three concentrations of formic 
acid were investigated, 0.001,0.002 and 0.004 %, with 3 mM ammonium formate. The 
results are shown in Figure 7-2. From the results it was shown that 3 mM ammonium 
formate with 0.001 % formic acid gave the optimum response for the analytes. 
A group of authors who used 10 mM ammonium formate and 0.001 % formic acid in the 
mobile phase used a Synergi Polar RP column for separation l2S • During this project a C18 
column was used. It was decided to investigate the use of a basic buffer compared to an 
acidic buffer and the use of a Synergi Polar RP column compared to a CI8 column. The 
systems used for comparison are detailed in Table 7-4. 
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Figure 7-2 : Variation of response with increasing formic acid concentration 
Table 7-4 : Different columns and buffers investigated 
y tern Column Buffer 
I---
Ph nom nex C18 Luna 150 
l 
2 nun, 3 mM ammonium formate + 
1 
3 flm packing 0,001 % formic acid 
Ph nomene C 18 Luna 150 x 2 mm, 
2 10 mM ammonium bicarbonate 
3 ~lffi packing 
Phenom ne S)TI rgi Polar RP 150 x 2 mm, 3 mM ammonium formate + 
3 
..:> ~tm packing 0.001 % formic acid 
Unfortunatel) the ba ie buffer was too high in pH to run through the Polar RP column 
without damagmg it. The gradient u ed i hown in Table 7-5. Analysis was done in SIM 
mode in two injections. The fir t inje tIOn included the opioids, benzodiazepines and 
cocain and it m labolite~. The cond injection included the five amphetamines. Two 
inj cLions \\' r ne d d b c the instrument could not monitor all of the ions at the same 
time. Five inje rion for e h ondition \",ere performed consecutively, and the mean area 
calculat d for h an I 
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Table 7·5 : Mobile phase gradient used with different buffers and columns 
Time Flow Buffer Acetonitrile 
(min) (mL/min) (0/0) (%) 
0.00 0.3 90 10 
2.00 0.3 90 10 
15.00 0.3 10 90 
15.01 0.6 10 90 
30.00 0.6 10 90 
30.01 0.6 90 10 
40.00 0.6 90 10 
40.10 0.3 90 10 
7.3.6.1 Results 
Figure 7-3 shows the difference in response of analytes between each column and mobile 
phase. It was clear that using the CI8 column (systems 1 & 2) gave a greater response for 
every analyte except methadone and EDDP. As methadone and EDDPs response was so 
much greater than the other analytes it was thought a compromise would be to pick the best 
conditions for the smaller response analytes. The difference in response between an acidic 
and basic buffer on a CI8 column was not consistent for every analyte. It was decided to 
use the basic buffer with the CI8 column (system 2), as this gave the greatest response for 
most of the analytes of interest. This is in contrast to the hypothesis that when analysing 
basic drugs, acidic buffers should be used in the mobile phase to promote ionisation. 
7.3.7 Sample Preparation 
Spiked oral fluid samples were prepared by adding the appropriate amount of working 
drug solution (5, 10,25,50, 100,200 J.LL) and internal standard solution (200 J.LL) to test 
tubes, followed by 3.5 mL of 0.1 M, pH 6 phosphate buffer and I mL of blank oral fluid. 
A blank was prepared without any standards present and another with internal standard 
only to assess any contamination of the deuterated standards. 
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Figure 7-3 : Difference in mean peak area for 20 analytes using different mobile and 
stationary phases 
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7.3.8 Extraction Procedure 
A single extraction method was used for the analysis of 60 oral fluid samples. Prior to 
extraction oral fluid samples were frozen when they arrived in the department until 
analysis. Once defrosted the pad was removed by twisting the top, until the pad came free 
from the stick. The stick was removed and the filter was used to obtain the sample, 
consisting of a mixture of oral fluid: buffer 1 :2. The solid phase extraction method used, 
was developed for extracting acidic and basic drugs simultaneously72. To -1 mL of oral 
fluid:buffer mixture (accurately measured), 3.5 mL of 0.1 M, pH 6.0 phosphate buffer was 
added, vortexed and centrifuged at 3000 rpm for 10 min. Bond Elut Certify® LRC 
cartridges were conditioned with 2 mL of methanol followed by 2 mL of phosphate buffer 
(0.1 M, pH 6). The sample was applied and allowed to drip through with no vacuum. To 
wash the cartridges 1 mL of water followed by 0.5 mL of 0.01 M acetic acid was used. 
The cartridges were dried for 10 minutes with full vacuum applied, before adding 50 J.LL of 
methanol and drying for a further 2 minutes. The acidic/neutral fraction was collected 
using 4 mL of acetone: chloroform, 1: 1, this fraction contained diazepam and its 
metabolites. Elution of basic drugs was achieved using 2 x 1.5 mL of ethyl acetate with 2 
% ammonia. After elution the eluents were split in two (one for the GC-MS and one for 
the LC-MS) before being blown down under nitrogen with no heat. Both fractions were 
reconstituted in 80 J.LL of mobile phase (acetonitrile: 10mM ammonium bicarbonate 10 : 
90). 20 J.LL injections of both fractions were made on the LC-MS. Diazepam and its 
metabolites were monitored in the acidic/neutral fraction, and the other 16 analytes were 
monitored in the basic fraction. 
7.4 Method Validation 
7.4. 1 Linearity 
Linearity was demonstrated over the concentration range 5-200ng. This is shown in Figure 
7-4 to Figure 7-8. 
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Figure 7--8 : Linearity data for buprenorphine, methadone, EDDP and norbuprenorphine 
7.4.2 Recovery 
Mean recoverie of each analyte were calculated over five extractions at a concentration of 
200 nglmL, without internal standard present. Two unextracted standards were also 
prepared at the arne cone ntration and kept in the fridge. Before blowing the samples 
down und r nitrog n, 100 nJ ofintemal standard was added to each vial including the 
unextracted standards. Once the amples \\ ere dry, they were reconstituted in 100 ).LL of 
mobile phase and 20 ~L mj cted. 
The reco cry of each drug \\ a calculated using the following equation. 
R (01) Peak Area Ratio of E tracted Standard 100 eco\ ery 1 0 = -- X 
P uk AI a Ratio of nextracted Standard 
Equation 16 
The rccoverie calculat d for ach analyte is shown in Table 7-6. Recovery for each 
analyte varied from - % for bcnzoylccgonine to 105 % for cocaethylene. 
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7.4.3 Limits of Detection 
Limits of detection were calculated as in Chapter 3.10.6. The results are displayed in 
Table 7-6. Limits of detection ranged from 0.1 nglmL for buprenorphine to 1.5 nglmL for 
cocaethylene. 
7.4.4 Limits of Quantitation 
Limits of quantitation were calculated as in Chapter 3.10.7. The results are displayed in 
Table 7-6. Limits of quantitation ranged from 0.4 nglmL for buprenorphine to 5.0 nglmL 
for cocaethylene. 
Table 7-6 : Recovery and limits of detection and quantitatlon data 
Mean % Recovery Limit of Detection Limit of Quantitation 
Analyte 
(%RSD) (n=5) (nglmL) (nglmL) 
Amphetamine 59 (11.1) 1.1 3.8 
~ethamphetamine 85 (10.7) 1.3 4.5 
MDA 88 (9.0) 1.1 3.6 
MDMA 90 (3.9) 1.3 4.4 
MDEA 94 (5.0) 1.2 4.1 
Diazepam 80 (1.6) 0.5 1.5 
N-desmethyldiazepam 64 (1.2) 0.7 2.5 
Temazepam 93 (2.0) 1.3 4.3 
Oxazepam 89 (0.9) 0.7 2.3 
Cocaine 60 (1.7) 0.8 2.5 
Benzoylecgonine 58 (13.6) 1.4 4.7 
Cocaethylene 105 (11.0) 1.5 5.0 
Morphine 97 (9.4) 1.5 4.9 
Codeine 90 (8.8) 0.8 2.5 
6-~ 79 (7.5) 1.5 4.8 
Dihydrocodeine 85 (5.3) 1.3 4.4 
~ethadone 96 (4.3) 1.4 4.6 
EDDP 92 (3.7) 1.2 3.9 
Buprenorphine 98 (0.8) 0.1 0.4 
Norbuprenorphine 89 (7.7) 0.4 1.2 
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7.4.5 Inter-Day Precision 
Inter-day precision was calculated using five sets of linearity data acquired on five 
different days. The %RSD of the five values for two concentrations, 50 and 200 nglmL 
were calculated. The results are shown in Table 7-7. 
Table 7-7: Inter-ciay precision for 20 analytes 
Inter-day precision 
Aoalyte (%RSD) (n=5) 
SOng 200ng 
Amphetamine 53 (4.2) 199 (5.6) 
Methamphetamine 47 (6.2) 199 (2.2) 
MDA 49 (13.4) 200 (1.3) 
MDMA 48 (7.4) 199 (1.5) 
MDEA 49 (2.5) 200 (1.5) 
Diazepam 52 (4.5) 197 (1.1) 
N-desmethyldiazepam 52 (4.0) 198 (1.4) 
Temazepam 51 (2.9) 200 (1.8) 
Oxazepam 52 (3.9) 200 (0.8) 
Cocaine 48 (10.6) 198 (1.7) 
Benzoylecgonine 53 (7.2) 201 (0.8) 
Cocaethylene 47 (4.0) 195 (8.0) 
Morphine 45 (9.6) 200 (2.2) 
Codeine 51 (11.7) 201 (1.5) 
6-MAM 52 (10.9) 199 (1.8) 
Dihydrocodeine 51 (10.1) 199 (0.9) 
Methadone 51 (3.3) 201 (1.3) 
EDDP 49 (4.7) 201 (0.8) 
Buprenorphine 51 (4.4) 199 (1.3) 
Norbuprenorphine 50 (5.2) 200 (0.8) 
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7.4.6 Intra-Day Precision between Injections 
Extracted standards were prepared at two concentrations 50 and 200 ng/mL. They were 
injected 5 times consecutively. The %RSD of the peak area ratios was calculated at each 
concentration for each drug. The results are shown in Table 7-8. 
Table 7-8 : Intra-day precision of 5 consecutive injections 
Intra-day precision 5 injections 
Analyte (%RSD) (n=5) 
50ng 200ng 
Amphetamine 45 (4.3) 212 (9.5) 
Methamphetamine 50 (4.6) 203 (6.8) 
MDA 51 (8.1) 205 (9.8) 
MDMA 50 (1.7) 201 (3.0) 
MDEA 51 (3.9) 200 (1.4) 
Diazepam 49 (1.4) 199 (5.2) 
N-desmethyldiazepam 52 (1.4) 198 (2.1) 
Temazepam 50 (3.8) 197 (2.1) 
Oxazepam 51 (0.5) 202 (2.2) 
Cocaine 51 (3.6) 202 (2.8) 
Benzoylecgonine 49 (8.7) 203(7.4) 
Cocaethylene 49 (7.6) 202 (4.1) 
Morphine 44 (2.5) 201 (7.7) 
Codeine 56 (5.1) 200 (4.4) 
6-MAM 56 (8.0) 200 (8.2) 
Dihydrocodeine 46 (7.1) 200 (8.6) 
Methadone 45 (2.4) 201 (1.3) 
EDDP 49 (1.7) 200 (1.0) 
Buprenorphine 51 (2.6) 203 (3.0) 
Norbuprenorphine 54 (6.5) 194 (5.9) 
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7.4.7 Intra-Day Precision between Extracts 
Five extracted standards at two concentrations, 50 and 200 nglmL, were prepared 
simultaneously. The %RSD of the peak area ratios were calculated for each extraction, at 
each concentration, for each drug. The results are shown in Table 7-9. 
Table 7-9: Intra-day precision of 5 extractions 
Intra-day precision 5 extractions 
Analyte (%RSD) (n=S) 
SOng 200ng 
Amphetamine 43 (9.2) 194 (10.8) 
~ethamphetamine 48 (9.7) 197 (5.6) 
MDA 49 (9.3) 195 (7.2) 
~MA 51 (7.5) 200 (3.8) 
MDEA 48 (4.2) 200 (3.3) 
Diazepam 51 (3.2) 197 (2.2) 
N-desmethyldiazepam 52 (3.4) 197 (1.2) 
Temazepam 51 (2.8) 203 (1.6) 
Oxazepam 51 (2.7) 200 (2.0) 
Cocaine 46 (7.3) 197 (2.9) 
Benzoylecgonine 51 (8.0) 200 (8.0) 
Cocaethylene S2 (3.7) 199 (2.9) 
Morphine 49 (7.0) 202 (8.9) 
Codeine 49 (8.1) 201 (S.2) 
6-MAM S9 (8.1) 200 (S.9) 
Dihydrocodeine Sl (6.4) 196 (S.2) 
Methadone SO (2.4) 198 (1.8) 
EDDP SO (1.9) 201 (1.6) 
Buprenorphine Sl (2.7) 200 (3.0) 
Notbuprenorphine SI (S.4) 198 (4.1) 
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7.5 Discussion 
While investigating the buffers used in the mobile phase, it was noted that low 
concentrations of acidic buffers, 3 mM ammonium fonnate, enhance response greater than 
higher concentrations, 10 mM ammonium fonnate. This is concurrent with earlier findings 
for diazepam and its metabolites in Chapter 4. The use of a basic buffer in the mobile 
phase, ammonium bicarbonate, was evaluated and found to improve sensitivity compared 
to using ammonium fonnate and fonnic acid. These findings suggest that it is not always 
necessary to use an acidic buffer when analysing basic drugs, and the use of a high pH 
buffer could be an alternative. 
All linear correlation coefficients were greater than 0.99, ranging from 0.9906 for 
methamphetamine to 0.9999 for cocaine and norbuprenorphine. For most analytes 
recoveries were between 80 and 100 %. Benzoylecgonine had the lowest recovery of 58 
%, and cocaethylene had the highest recovery of 105 %. Limits of detection for all 
analytes were less than or equal to 1.5 nglmL, and limits of quantitation were all less than 
5 nglmL. Intra and Inter - day precision was less than 11 % at 200 ng/mL for all analytes. 
7.6 Conclusions 
A liquid chromatography - mass spectrometry method was developed and validated for the 
extraction and quantitation of 20 drugs of abuse and their metabolites from oral fluid. 
Analytes were identified by their retention time with respect to the deuterated standard, and 
using the pseudo-molecular ion. Further qualitative data was acquired using the GC-MS in 
full scan mode. 
This method was applied to 60 oral fluid samples collected by the modified Omni-Sal® 
device, refer to Chapter 10.2. 
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8 The Detection of Drugs of Abuse in Oral Fluid 
Using LC-MS-MS 
8.1 Introduction 
As part ofthe European project, Impaired Motorists, Methods of Roadside Testing and 
Assessment for Licensing, otherwise known as IMMORTAL (Deliverable R4.2), the 
University of Glasgow was required to analyse 1396 oral fluid samples, collected from 
drivers, for a wide range of drugs. Samples were collected in and around the city of 
Glasgow from drivers stopped at random. Drivers were asked to give an oral fluid 
specimen by use of the modified Omni-Sal® device, supplied by Cozart Biosciences. 
8.2 Aim 
The aim of this project was to develop and validate an LC-MS-MS method for the 
identification and quantitation of 21 drugs of abuse and their metabolites extracted from 
oral fluid specimens. 
8.2.1 Chemicals 
Methanol and acetonitrile were HPLC grade obtained from VWR International (UK). 
Analytical grade potassium dihydrogen phosphate, ammonium formate were supplied by 
BDH laboratory supplies (poole, England). Analytical grade concentrated ammonia, 
glacial acetic acid and concentrated formic acid were purchased from Sigma ® Chemicals 
Co. (UK). 
8.2.2 Standards 
Stock standards of analytes were purchased from Promochem. as 100 J.1g1mL methanolic 
solutions. The deuterated standards of each drug were also purchased as 100 J.1g1mL 
methanolic solutions. The analyte and deuterated standards used are shown in Table 8-1. 
In the first instance 1 J.1g1mL solutions of each analyte were prepared so they could be 
infused singularly. This was done by taking 10 J.1L of 100 J.1g1mL solution and adding 990 
J.1L of methanol. A working drug mixture with a concentration of 1 J.1g/mL for each drug, 
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was prepared by taking 250 J.lL of each standard into a 25 mL volumetric flask and making 
up to volume with methanol. A working internal standard solution was prepared in the 
same way using the deuterated standards. 
Table 8-1 : Purchased standards and deuterated standards 
Analyte Deuterated Standard 
Amphetamine Amphetamine-ds 
Methamphetamine Methamphetamine-ds 
MDA MDA-ds 
MDMA MDMA-ds 
MDEA MDEA-ds 
Diazepam Diazepam-ds 
N-desmethyldiazepam N-desmethyldiazepam-ds 
Temazepam Temazepam-ds 
Oxazepam Oxazepam-ds 
Cocaine Cocaine-d3 
Benzoylecgonine Benzoylecgonine-d3 
Ecgonine Methyl Ester Ecgonine Methyl Ester-d3 
Cocaethylene Cocaethylene-d3 
Morphine Morphine-d3 
Codeine Codeine-d3 
6-MAM 6-MAM-d3 
Dihydrocodeine Dihydrocodeine-<4 
Methadone Methadone-d9 
EDDP EDDP-d3 
Buprenorphine Buprenorphine-dt 
Norbuprenorphine Norbuprenorphine-d3 
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8.2.3 Solutions 
8.2.3.1 Preparation of 0.1 M, pH 6.0 Phosphate Buffer 
6.81 g of potassium dihydrogen phosphate was weighed out into a 500 mL volumetric 
flask and 450 mL of deionised water was added. The pH was adjusted to 6.0 with 1 M 
potassium hydroxide solution, then made to 500 mL with deionised water. 
8.2.3.2 Preparation of 3 mM ammonium formate with 0.001 % formic acid 
0.189 g of ammonium formate was placed into alL volumetric flask with 10 JlL 
concentrated formic acid. This was made up to volume with deionised water. 
8.3 Method Development 
This project involved the use of an LC-MS with an ion trap analyser which allowed MS-
MS data to be collected for each analyte. Previously only 8IM mode could be carried out 
on the single quadrupole instrument. As a result of the soft ionisation process in LC-MS, 
full scan MS data regularly consists of the pseudo-molecular ion only. Using tandem MS 
allows the pseudo-molecular ion to be fragmented to obtain specific daughter ions. This 
gives another element of specificity, and therefore greater accuracy in quantitation. 
Each analyte was infused into the source, by-passing the chromatographic column. This 
allows a constant signal of analyte ions. Mobile phase was also allowed to flow into the 
source at the same time, trying to reconstruct a real chromatographic run environment. 
The pseudo-molecular ions were known from previous work (Chapter 7). Each analytes 
pseudo-molecular ion was "tuned" automatically by the instrument. This optimises 
settings within the optics of the mass spectrometer for each analyte. 
Whilst infusing the analyte, the daughter ions were determined, by increasing the collision 
energy applied and recording what ions were produced at different collision energies. In 
this way the collision energy and daughter ions specific to that analyte are determined. 
The collision energy and daughter ions determined are found in Table 8-2. 
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Table 8-2 : Analyte precursor and daughter ions and collision energies 
Precursor ion Collision energy Product ion(s) 
Analyte 
(mlz) (0/0) (mlz) 
Amphetamine 136 22 119 
Methamphetamine 150 27 119,91 
MDA 180 20 163 
MDMA 194 25 163 
MDEA 208 25 163 
Diazepam 285 42 257,222 
N-desmethyldiazepam 271 40 243,208 
Temazepam 301 25 283,255 
Oxazepam 287 40 269,241 
Cocaine 304 35 182 
Benzoylecgonine 290 28 168 
Ecgonine methyl ester 200 28 182 
Cocaethylene 318 28 196 
Morphine 286 35 201,229,268 
6-MAM 328 35 211,268 
Codeine 300 35 215,243,282 
Dihydrocodeine 302 35 245,201,227 
Methadone 310 25 265 
EDDP 278 38 249 
Buprenorphine 468 36 414,396 
Norbuprenorphine 414 32 396,340 
8.3.1 Fragmentation Patterns in the Ion Trap 
Amphetamine and MDA both lose a fragment equal to 17 amu. This can be attributed to a 
-NH3 + group being knocked off the main structure. Amphetamines fragmentation is 
shown in Figure 8-1. Methamphetamine and MDMA both lose a fragment equal to 31 
amu, suggesting the loss of a -NH2 + - CH3 group. Methamphetamine seems to fragment 
further to an ion rnIz = 91. This can be explained by the loss ofa part of the carbon branch 
as shown in Figure 8-2. MDEA is similar in structure to MDMA, except its alkyl chain is 
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one carbon longer, giving it its higher molecular weight. The daughter ion is the same as 
shown in Figure 8-3. 
amphetamine 
119 
MDA 
[M+H]+ = 136 [M+H]+ = 180 
Figure 8-1 : Proposed fragmentation of amphetamine and MDA In the ion trap 
By looking at the fragmentation patterns of these amphetamines the common mJz 119 ion 
for amphetamine and methamphetamine is apparent as is the common mJz 163 ion for 
MDA, MDMA and MDEA. 
methamphetamine MDMA 
91 
+ 
h- /NH2 
H3C 
[M+H]+ = 150 [M+H]+ = 194 
Figure 8-2 : Proposed fragmentation of methamphetamine and MDMA In the Ion trap 
As a result of the amphetamines being so similar in structure, it is difficult to resolve them 
all on the liquid chromatography column. Therefore there is some overlapping of 
chromatographic peaks. When using the single quadrupole analyser in Chapter 7, it was 
impossible to tell which daughter ion came from which drug. By using MS-MS data, 
although the amphetamines have common daughter ions, the analyser can differentiate 
between them by knowing which parent ion they came from. This is one of the major 
advantages of using MS-MS data, and what gives it its specificity. 
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MDEA 
163 
[M+H]+ = 208 
Figure 8-3 : Proposed fragmentation of MDEA in the Ion trap 
Diazepam metabolises to N-desmethyldiazepam and are therefore very similar in structure, 
differing only in a methyl group. In the ion trap, they fragment in a similar manner by first 
losing a -CO group, and then a chlorine atom. A proposed scheme for diazepam is shown 
in Figure 8-4. Diazepam and N-desmethyldiazepam metabolise to temazepam and 
oxazepam respectively, with the addition of a hydroxyl group to the 7-membered ring. It is 
thought that temazepam and oxazepam undergo the loss of a -H20+ fragment before the 
loss of a -CO group as with diazepam and N-desmethyldiazepam. One would expect the 
loss of the chlorine atom next, but this is not observed in the MS-MS spectra. This may be 
observed in MS3 data. Unfortunately the instrument did not have the relevant computer 
software to do this. 
Cocaine, benzoylecgonine and cocaethylene all have a common loss of 122 amu from their 
pseudo-molecular ion. This can be attributed to the loss of a benzene ring, carbonyl and 
oxygen group from the structure. Their proposed fragmentations are shown in Figure 8-5. 
The same fragmentation of cocaine has been shown by GC-MS with chemical ionisation 
which is a soft ionisation like ESp28. Ecgonine methyl ester fragments to the same 
daughter ion as cocaine mJz 182, but this is with the loss of a -H20+. 
The opiates including dihydrocodeine have very complex ring systems in their structures, 
making it very difficult to propose a fragmentation pattern. The ring system must be 
broken somewhere to give the mJz 201 ion for morphine. The loss of a -HzO+ fragment 
from morphine would explain the mJz 268 ion, but this ion is very small compared to mJz 
201. 
Methadone and EDDP tend to fragment to just one daughter ion, by the loss of a branch 
from the structure. This is shown graphically in Figure 8-6. 
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[M+H]+ = 285 
1 ~o 
[M-27]+ = 257 
j ~I 
[M-62]+ = 222 
Figure 8-4 : Proposed fragmentation of diazepam in the Ion trap 
Buprenorphine fragments with the loss of a methylcyclopropane group to 
norbuprenorphines pseudo-molecular ion. This in turn fragments with the loss of a -H20+ 
group, producing a mJz 396 daughter ion observed in both buprenorpbine and 
norbuprenorpbines MS2 spectra. This is shown in Figure 8-7. 
Chapter 8: The Detection of Drugs of Abuse Using LC-MS-MS 
[M+H]+ = 304 
H3C, cocaethylene 
N 0 
O...--CH3 
196 
[M+H]+ = 318 
168 
benzoylecgonine 
o 
OH 
[M+H]+ = 290 
ecgonine methyl ester 
H3C, 
N 
182 
[M+H]+ = 200 
Page 107 
Figure 8·5 : Proposed fragmentation of cocaine, benzoylecgonlne, ecgonine methyl ester 
and cocaethylene 
methadone EDDP 
[M+H]+ = 310 [M+H]+ = 278 
Figure 8-6 : Proposed fragmentation of methadone and EDDP 
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[M+H]+ = 468 
Figure 8·7 : Proposed fragmentation of buprenorphine 
8.3.2 Chromatography Conditions 
It was decided to use mobile phase conditions previously investigated (Chapter 7). This 
was 3 mM ammonium formate + 0.001 % formic acid, and acetonitrile on a Phenomenex 
C18 Luna column. Although 10 mM ammonium bicarbonate gave greater response on the 
signal quadrupole instrument, the analytes peak shape was found to deteriorate quicker 
than the acidic buffer. 
Using the gradient shown in Table 8-3 and a Phenomenex Luna C18 150 x 2.0 mm, 3 J.1Ill 
packing, the retention times for the analytes were determined. 
Table 8-3 : Mobile phase gradient conditions 
Time Flow 3 mM ammonium formate + Acetonitrile 
(min) (mL/min) 0.001 «Yo formic acid (<<Yo) (%) 
0 0.3 95 5 
13 0.3 74 26 
22 0.3 20 80 
26 0.3 5 95 
29 0.3 5 95 
30 0.3 95 5 
36 0.3 95 5 
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Once retention times were found, analytes could be split up into segments or retention 
windows. Each segment has different scan events thereby looking for different analytes 
and their deuterated standards in each segment. It is important to try and minimise the 
number of scan events in each segment, to maximise the number of data points across the 
chromatographic peak. It was noted that looking for many ions at the same time, reduced 
the number of data points across the peak and thereby reducing reproducibility of peak 
areas. Unfortunately many analytes eluted very close to one another. which resulted in 
poor reproducibility between injections. To overcome this problem it was decided to inject 
the sample twice and monitor different analytes each time. Although this increased the 
total run time on the instrument. reproducibility between injections was much better. 
The extraction used was the same as the one used previously in Chapter 7. This produced 
two fractions. The first fraction was analysed for diazepam and its metabolites in one 
injection. The second fraction was analysed for the amphetamines, cocaine and its 
metabolites in one injection and the opioids and metabolites in a second injection. The 
mobile phase conditions were kept the same for every injection, with only the scan events 
changed for relevant analytes. The different segments and scan events are detailed in 
Table 8-4. Full MS-MS data:was acquired for analytes and SIM data was acquired for the 
deuterated standards as further qualitative data was not required for them. 
Table 8-4 : Segments and scan events for each analyte 
Internal 
Injection Analyte Segment Scan Events 
Standard 
Full MS-MS mJz 287 
1 Oxazepam ds 1 
SIMmJz292 
1 Temazepam ds Full MS-MS mJz 301 & 271 
2 
1 Nordiazepam ds SIM mJz 306 & 276 
Full MS-MS mJz 285 
1 Diazepam ds 3 
SIMmJz290 
Ecgonine methyl Full MS-MS mJz 200 
2 d3 1 
ester SIMmJz203 
Full MS-MS mJz 136 
2 Amphetamine ds 2 
SIMmJz 141 
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Internal 
Injection Analyte Segment Scan Events 
Standard 
2 MDA ds Full MS-MS m1z 180, 150 & 194 
2 Methamphetamine ds 3 SIM m1z 185, 155 & 199 
2 MDMA ds 
2 MDEA ds Full MS-MS m1z 208 & 290 
4 
2 Benzoylecgonine d3 SIM m1z 213 & 293 
Full MS-MS m1z 304 
2 Cocaine d3 5 
SIMmlz 307 
Full MS-MS m1z 318 
2 Cocaethylene d3 6 
SIMmlz 321 
Full MS-MS m1z 286 
3 Morphine d3 1 
SIMmlz289 
3 Codeine d3 Full MS-MS m1z 300 & 302 
2 
3 Dihydrocodeine ~ SIM m1z 303 & 308 
Full MS-MS m1z 328 
3 6-MAM d3 3 
SIMmlz 321 
Full MS-MS m1z 414 
3 Norbuprenorphine d3 4 
SIMmlz417 
Full MS-MS m1z 278 
3 EDDP d3 5 
SIMmlz281 
3 Methadone d9 Full MS-MS m1z 310 & 468 
6 
3 Buprenorphine <4 SIM m1z 319 & 472 
Using the same mobile phase gradient for each injection allowed the queuing up of 
samples, and therefore the instrument could be run almost continuously. 
8.4 Method Validation 
The sample preparation and extraction method used in conjUnction with the LC-MS-MS 
was the same as in the previous chapter, 7.3.7 and 7.3.8. This extraction method had been 
used successfully for the analysis of20 drugs of abuse and their metabolites, and was used 
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to validate the LC-MS-MS method for 21 drugs of abuse and metabolites extracted from 1 
mL oral fluid . 
8.4. 1 Linearity 
Linearity was demonstrated over the range 1 - 200 ngimL. All analytes gave a correlation 
coefficient > 0.99. Figure 8-8 shows examples of linearity data obtained for 5 drugs and 
Table 8-5 shows linearity equations and correlation coefficient data for all analytes. 
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Figure 8-8 : Linearity graphs for MDMA, diazepam, cocaine, morphine and EDDP 
Table 8·5 : Linearity data for all 21 drugs of abuse and their metabolites 
Analyte Linearity Equation RZ value 
Amphetamine y = 0.0068x - 0.014 0.9956 
Methamphetamine y= 0.0066x + 0.0136 0.9947 
MDMA y = 0.0071x + 0.0032 0.9997 
MDEA Y = 0.0063x + 0.0039 0.9934 
MDA y = 0.0057x - 0.02 0.9978 
Diazepam y = 0.0052x + 0.0007 0.9998 
N -desmeth yldiazepam y = O.OOSlx + 0.006 0.9994 
Temazepam y = 0.0044x + 0.0029 0.9986 
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Analyte Linearity Equation Rlvalue 
Oxazepam y = 0.0056x - 0.0138 0.9982 
Cocaine y = 0.0095x - 0.0268 0.9988 
Benzoylecgonine y = 0.0085x - 0.0094 0.9989 
Cocaethylene y = 0.0067x - 0.0342 0.9974 
Ecgonine methyl ester y = 0.0054x - 0.0119 0.9953 
Morphine y = 0.0073x - 0.0057 0.998 
Codeine y = 0.0079x - 0.0151 0.9986 
6-monoacetylmorphine y = 0.0062x + 0.0009 0.9969 
Dihydrocodeine y = 0.0078x + 0.0524 0.9906 
Methadone y = 0.0007x - 0.0024 0.9993 
EDDP Y = 0.0087x - 0.0241 0.9992 
Buprenorphine y = 0.009lx + 0.0569 0.9923 
Norbuprenorphine y = 0.0082x - 0.0142 0.9996 
8.4.2 Recovery 
Recovery was calculated as the mean recovery of 5 extractions at 200 nglmL, refer to 
Chapter 3.10.5 for calculation. The results are shown in Table 8-6. 
8.4.3 Limits of Detection 
Limits of detection were calculated as before in Chapter 3.10.6. This was using 3 times the 
standard error of the line plus the intercept. The results are shown in Table 8-6. 
8.4.4 Limits of Quantitation 
Limits of quanti tat ion were calculated as before in Chapter 3.10.7. This was using 10 
times the standard error of the line plus the intercept. The results are shown in Table 8-6. 
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Table 8-6 : Recovery, LOD and LOQ data 
Mean % Recovery LOD LOQ 
Analyte 
(% RSD) (n=5) (nglmL) (nglmL) 
Amphetamine 75 (8.8) 0.4 1.2 
Methamphetamine 100 (6.4) 0.4 1.3 
MDA 74 (8.3) 1.0 3.3 
MDMA 98 (14.8) 0.8 2.5 
MDEA 80 (12.4) 1.2 4.0 
Diazepam 65 (5.8) 0.3 0.9 
N-desmethyldiazepam 57 (4.0) 0.4 1.2 
Temazepam 109 (11.0) 0.5 1.6 
Oxazepam 77 (3.3) 0.8 2.5 
Cocaine 89 (2.1) 0.9 3.1 
Benzoylecgonine 63 (12.4) 3.4 11.4 
Ecgonine methyl ester 30 (6.3) 0.3 0.9 
Cocaethylene 95 (7.0) 1.0 3.4 
Morphine 52 (7.3) 0.5 1.7 
6-MAM 93 (2.6) 0.3 1.0 
Codeine 98 (7.4) 0.5 1.8 
Dihydrocodeine 92 (5.3) 0.5 1.7 
Methadone 96 (9.0) 0.7 2.2 
EDDP 95 (2.7) 0.2 0.8 
Buprenorphine 109 (10.7) 0.5 1.8 
Norbuprenorphine 91 (1.8) 0.5 1.6 
8.4.5 Inter-Day Precision 
Inter-day precision was calculated using five sets of linearity data acquired on five 
different days. The %RSD of the five values for two concentrations 25 and 200 nglmL 
were calculated. These results are shown in Table 8-7. 
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Table 8-7 : Inter-day precision 
Inter-day precision 
Analyte (% RSD) (n=5) 
25ng 200ng 
Amphetamine 25 (5.8) 201 (0.9) 
~etllamphetamine 26 (12.0) 200 (0.8) 
MDA 26 (6.9) 202 (1.2) 
MD~ 26 (9.0) 201 (1.9) 
MDEA 24 (3.0) 199 (2.8) 
Diazepam 25 (2.7) 198 (0.7) 
N-desmetllyldiazepam 26 (10.0) 200 (1.2) 
Temazepam 23 (8.2) 196 (2.4) 
Oxazepam 24 (6.3) 202 (1.6) 
Cocaine 22 (2.9) 202 (0.4) 
Benzoylecgonine 24 (13.8) 198 (1.7) 
Ecgonine methyl ester 24 (11.3) 200 (1.4) 
Cocaetllylene 23 (2.6) 204 (1.2) 
~orphine 25 (5.0) 202 (1.5) 
6-~ 23 (3.5) 200 (0.6) 
Codeine 25 (2.6) 202 (0.7) 
Dihydrocodeine 27 (5.7) 199 (1.9) 
~ethadone 23 (12.2) 208 (2.2) 
EDDP 25 (3.5) 201 (1.5) 
Buprenorphine 25 (8.3) 201 (1.5) 
Norbuprenorphine 24 (3.3) 201 (0.6) 
8.4.6 Intra-Day Precision between Injections 
Extracted standards were prepared at two concentrations 2S and 200 ng/mL. They were 
injected 5 times consecutively. The o/oRSD of the peak area ratios were calculated at each 
concentration for each drug. These results are shown in Table 8-8. 
Chapter 8: The Detection of Drugs of Abuse Using LC-MS-MS Page 115 
Table 8-8 : Intra-clay precision between 5 consecutive injections 
Intra-day precision between 5 injections 
Analyte (% RSD) (n=5) 
2Sng 200ng 
Amphetamine 27 (6.0) 208 (3.4) 
Methamphetamine 24 (12.4) 199 (4.7) 
MDA 25 (8.9) 198 (8.6) 
MDMA 25 (8.0) 202 (1.8) 
MDEA 27 (2.6) 202 (1.2) 
Diazepam 26 (4.0) 203 (2.1) 
N-desmethyldiazepam 29 (6.6) 197 (9.8) 
Temazepam 23 (7.6) 196 (6.9) 
Oxazepam 28 (3.8) 204 (3.1) 
Cocaine 25 (3.0) 207 (3.0) 
Benzoylecgonine 23 (5.4) 200 (6.0) 
Ecgonine methyl ester 25 (2.8) 200 (0.9) 
Cocaethylene 25 (1.0) 201 (2.1) 
Morphine 22 (6.0) 199 (5.7) 
6-MAM 24 (6.4) 209 (3.8) 
Codeine 22 (10.5) 209 (2.0) 
Dihydrocodeine 24 (5.8) 199 (2.8) 
Methadone 22 (12.7) 193 (4.3) 
EDDP 24 (6.0) 198 (1.4) 
Buprenorphine 28 (7.9) 202 (5.0) 
Norbuprenorphine 21 (5.1) 206 (2.2) 
8.4.7 Intra-Day Precision between Extracts 
Five extracted standards at two concentrations 25 and 200 nglmL were prepared 
simultaneously. The %RSD of the peak area ratios were calculated for each extraction, at 
each concentration, for each drug. These results are shown in Table 8-9. 
Chapter 8: The Detection of Drugs of Abuse Using LC-MS-MS Page 116 
Table 8-9 : Intra-day precision between 5 extracts 
Intra-day precision between 5 extracts 
Analyte (% RSD) (n=5) 
25ng 200ng 
Amphetamine 24 (8.9) 201 (9.5) 
Methamphetamine 19 (10.4) 199 (3.6) 
MDA 18 (10.2) 206 (7.7) 
MDMA 19 (12.4) 200 (8.4) 
MDEA 28 (5.7) 203 (5.2) 
Diazepam 29 (4.3) 203 (2.7) 
N-desmethyldiazepam 24 (5.9) 201 (10.3) 
Temazepam 23 (6.4) 201 (1.8) 
Oxazepam 26 (6.4) 201 (4.2) 
Cocaine 24 (2.8) 201 (4.2) 
Benzoylecgonine 19 (19.7) 209 (9.1) 
Ecgonine methyl ester 24 (7.2) 200 (3.7) 
Cocaethylene 24 (6.2) 201 (5.6) 
Morphine 27 (5.1) 200 (2.0) 
6-MAM 26 (3.4) 203 (3.1) 
Codeine 27 (9.4) 202 (5.8) 
Dihydrocodeine 23 (5.5) 199 (3.7) 
Methadone 33 (11.4) 203 (8.0) 
EDDP 28 (2.9) 202 (1.9) 
Buprenorphine 25 (10.4) 199 (8.2) 
Norbuprenorphine 27 (8.5) 203 (6.3) 
8.5 Discussion 
Linearity was demonstrated over 1 - 200 nglmL for all analytes. Although some 
recoveries were not as high as expected, all limits of detection were below 3.4 nglmL. 
Limits of detection were similar to those found using a single quadrupole, showing there is 
little difference in the sensitivity of the two analysers. 
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To obtain a %RSD ofless than 10% at 200nglmL for repeat injections, three injections of 
each sample were needed. Although this increased the total run time, 21 drugs of abuse 
and their metabolites were analysed from one extract of ImL of sample. A variation of 
20% is generally considered acceptable129• Effectively it is instrument time, not analysts 
time that is the rate determining step. 
8.6 Conclusions 
The developed method successfully extracted and analysed 21 drugs of abuse and their 
metabolites. The ion trap analyser proved invaluable in producing greater specificity than 
a single quadrupole. This greater specificity allowed the Use of this technique alone, 
without confirmation from a GC-MS. 
This method was successfully applied to 1396 oral fluid samples donated from a random 
selection of drivers in and around the city of Glasgow. Refer to Chapter 10.3. 
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9 Comparison of Oral Fluid Collection Devices for 
the Detection of Drugs of Abuse and Their 
Metabolites 
9.1 Introduction 
The advantages of oral fluid analysis have been discussed in Chapter 6. This project 
involved the collection of various biological matrices from opiate dependent subjects while 
attending a residential crisis centre. Presently, urine analysis is used to detennine opiate 
use when the patients are first admitted. Urine concentrations are accumulated over a 
period of time and are not a true reflection of what is circulating in the body at the time of 
collection. Another problem of urine analysis is the potential for adulteration ifnot passed 
under supervision. Blood would give circulating concentrations of drugs, but poses the 
problem of a medical practitioner taking the sample, risk of infection and with respect to 
opiate addicts, difficulty in obtaining a sample. 
Oral fluid analysis could solve some of these problems. It can be taken by a non-medically 
trained care worker, it would give infonnation on the drugs circulating in the body at the 
time of collection and it is a much more acceptable body fluid to donate. 
9.2 Aim 
The aim of this project was to analyse a variety of sample matrices, namely urine, blood 
and oral fluid. Two oral fluid samples were collected, one using the modified Omni-Sal® 
device and another using the Intercept® collection device. The modified Omni-Sal® device 
was used first followed by the Intercept device to prevent the salts present in the Interceptl> 
device affecting the modified Omni-Sall> device. The samples to be collected were taken 
back to the laboratory for opiate and benzodiazepine analysis using LC-MS-MS, there was 
no initial screening test carried out. An extraction method used previously was employed. 
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9.3 Chemicals 
Methanol and acetonitrile were HPLC grade obtained from VWR International (UK). 
Analytical grade potassium dihydrogen phosphate, ammonium formate were supplied by 
BDH laboratory supplies (Poole, England). Analytical grade concentrated ammonia, 
glacial acetic acid and concentrated formic acid were purchased from Sigma® Chemicals 
Co. (UK). 
9.4 Standards 
Stock standards of analytes were purchased from Promochem as 100 J.LglmL methanolic 
solutions. The deuterated standards of each drug were also purchased as 100 J.LglmL 
methanolic solutions. The analyte and deuterated standards used are shown in Table 9-1. 
A working drug mixture with a concentration of 1 J.LglmL for each drug, was prepared by 
taking 250 J.LL of each standard into a 25 mL volumetric flask and making up to volume 
with methanol. A working internal standard solution was prepared in the same way using 
the deuterated standards. 
Table 9-1 : Purchased standards and deuterated standards 
Analyte Deuterated Standard 
Diazepam Diazepam-ds 
N-desmethyldiazepam N-desmethyldiazepam-ds 
Temazepam Temazepam-ds 
Oxazepam Oxazepam-ds 
Morphine Morphine-d3 
Codeine Codeine-d3 
6-MAM 6-MAM-d3 
Dihydrocodeine Dihydrocodeine-<4 
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9.5 Spiked urine, blood and oral fluid samples 
Time expired packed red blood cells were provided from the blood bank for blank blood. 
These were suspended in a ratio of 1 : 1 with isotonic saline solution which was made by 
dissolving 9.5 g of sodium chloride in 1 L of deionised water. 
Drug free urine and oral fluid, collected using the two different devices, was obtained from 
healthy volunteers. 
9.6 Solutions 
9.6.1 Preparation of 0.1 M, pH 6.0 Phosphate Buffer 
6.81 g of potassium dihydrogen phosphate was weighed out into a 500 mL volumetric 
flask and 450 mL of deionised water was added. The pH was adjusted to 6.0 with 1 M 
potassium hydroxide solution, then made to 500 mL with deionised water. 
9.6.2 Preparation of 3 mM Ammonium Formate with 0.001 % 
Formic Acid 
0.189 g of ammonium fonnate was placed into aiL volumetric flask with 10 JJL 
concentrated formic acid. This was made up to volume with deionised water. 
9.7 LC-MS-MS Conditions 
9.7.1 LC Conditions 
The column used for analysis was a Phenomenex Luna C18, 150 x 2.0 mm, 3 J.lffi packing. 
A guard column packed with identical stationary phase was used prior to the column to 
extend column lifetime. Mobile phase consisted of3 mM ammonium formate + 0.001 % 
formic acid and acetonitrile. The gradient conditions are shown in Table 9-2. The column 
oven was maintained at 35°C throughout the analysis. 
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Table 9·2 : Mobile phase conditions 
Time Flow 3 mM ammonium formate + Acetonitrile 
(min) (mL/min) 0.001 % formic acid (%) (0/0) 
0 0.3 9S S 
13 0.3 74 26 
22 0.3 20 80 
26 0.3 5 9S 
29 0.3 5 95 
30 0.3 9S 5 
36 0.3 9S S 
9.7.2 MS Conditions 
Full MS-MS data was collected for each analyte, while deuterated internal standards were 
monitored using SIM analysis. All mass spectral data was collected in electro spray 
positive ion mode. The following settings were applied throughout the analysis: transfer 
capillary temperature, 280°C; probe voltage, 4.5 kV; sheath and auxiliary gases were set to 
20 and 15 units on the data system arbitrary scale. 
9.8 Method Validation for Urine Specimens 
Spiked urine samples were prepared by adding the appropriate amount of working drug 
solution (5, 10,25,50, 100,200 J.LL) and internal standard solution (100 ~L) to test tubes, 
followed by 3.5 mL of 0.1 M, pH 6 phosphate buffer and 1 mL of blank urine. A blank 
was prepared without any standards present and another with internal standard only to 
assess any contamination of the deuterated standards. 
The extraction method was the same as that used in Chapter 7.3.6. 1 mL of urine was 
added to 3.5 mL of phosphate buffer (0.1 M, pH 6.0) and 100 ng ofintemal standard 
mixture, before vortex mixing and centrifuging. The solid phase extraction procedure 
involved conditioning Bond Elut Certify® columns with 2 mL methanol and 2 mL 
phosphate buffer (0.1 M, pH 6) before the sample was applied. 2 mL of deionised water, 
followed by 0.5 mL of 0.01 M acetic acid was applied before drying under full vacuum for 
10 minutes. 50 JlL of methanol was then applied before drying once more for 2 minutes. 
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Diazepam and its metabolites were eluted using 4 mL of acetone: chloroform 1: 1. Opiates 
were eluted using 2 x 1.5 mL ethyl acetate with 2 % ammonia. Each fraction was blown 
down under nitrogen at 35°C until dryness. Samples were reconstituted in 80 llL of 
mobile phase, before 20 ilL was injected onto the LC-MS-MS. 
There were two fractions for each sample, and these were injected separately onto the LC-
MS-MS. The first fraction contained diazepam, N-desmethyldiazepam, temazepam and 
oxazepam. The second frac60n contained morphine, 6-MAM, codeine and 
dihydrocodeine. 
9.8.1 Linearity 
Linearity was demonstrated over 5 - 200 ng/rnL for each analyte. 
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Figure 9-1 : Linearity of diazepam and metabolites in urine 
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Figure 9-2 : Linearity of morphine, codeine, 6-MAM and dihydrocodeine in urine 
9.8.2 Recovery 
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Recovery was calculated as the mean of 5 extractions at 200 nglmL, refer to Chapter 3.10.5 
for calculation. The results are shown in Table 9-3. 
9.8.3 Limits of Detection 
Limits of detection were calculated as in Chapter 3.10.6. The results are shown in Table 
9-3 
9.8.4 Limits of Quantitation 
Limits of quantitation were calculated as in Chapter 3.10.7. The results are shown in Table 
9-3. 
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Table 9-3: Recovery, LOD and LOQ for urine specimens 
Mean % Recovery LOD LOQ 
Analyte (%RSD) (n=S) (nglmL) (nglmL) 
Diazepam 92 (6.5) 0.6 1.9 
~-desDle~yldiazepam 92 (5.6) 1.1 3.7 
TeDlazepam 66 (7.3) 0.7 2.3 
Oxazepam 94 (4.7) 0.5 1.7 
Morphine 66 (3.6) 1.0 3.5 
Codeine 96 (4.8) 0.9 3.1 
6-MAM 95 (3.7) 0.9 3.0 
Dihydrocodeine 81 (3.5) 0.4 1.5 
9.8.5 Inter-Day Precision 
Inter-day precision was calculated using five sets of linearity data acquired on five 
different days. The %RSD of~e five values for two concentrations, 50 and 200 ng/DlL 
were calculated. The results are shown in Table 9-4. 
Table 9-4 : Inter-day precision for urine specimens 
Inter-day precision 
Analyte (%RSD) (n=5) 
SOng 200ng 
Diazepam 50 (5.8) 198 (1.2) 
~-desDle~yldiazepam 46 (12.8) 201 (1.4) 
TeD1azepam 50 (11.5) 200 (0.1) 
Oxazepam 51 (3.4) 200 (0.8) 
Morphine 55 (3.9) 199 (0.3) 
Codeine 56 (2.3) 197 (0.9) 
6-MAM 57 (7.1) 199 (0.4) 
Dihydrocodeine 57 (1.4) 199 (1.4) 
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9.8.6 Intra-Day Precision between Injections 
Extracted standards were prepared at two concentrations, 50 and 200 ng/mL. They were 
injected 5 times consecutively. The %RSD of the peak area ratios were calculated at each 
concentration for each drug. The results are shown in Table 9-5. 
Table 9-5 : Intra-day preCision between injections for urine specimens 
Intra-day precision 5 injections 
Analyte (%RSD) (n=5) 
50ng 200ng 
Diazepam 49 (2.9) 199 (1.5) 
N-desmethyldiazepam 56 (6.4) 203 (1.4) 
Temazepam 55 (2.3) 202 (3.4) 
Oxazepam 51 (4.0) 200 (3.2) 
Morphine 54 (3.0) 199 (3.2) 
Codeine 45 (3.3) 200 (3.7) 
6-MAM 56 (3.2) 200 (1.6) 
Dihydrocodeine 49 (1.9) 199 (2.5) 
9.8.7 Intra-Day Precision between Extracts 
Five extracted standards at two concentrations, 50 and 200 ng/roL, were prepared 
simultaneously. The %RSD of the peak area ratios were calculated for each extraction, at 
each concentration, for each drug. The results are shown in Table 9-6. 
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Table 9-6 : Intra-day precision between extracts for urine specimens 
Intra-day precision 5 extracts 
Analyte (%RSD) (n=5) 
50 ng 200 ng 
Diazepam 51 (4.1) 199 (4.9) 
N-desmethyldiazepam 50 (7.1) 198 (8.5) 
Temazepam 47 (6.0) 199 (9.8) 
Oxazepam 50 (2.7) 201 (3.9) 
Morphine 51 (4.5) 194 (2.6) 
Codeine 49 (6.3) 199 (7.7) 
6-MAM 49 (4.1) 196 (2.9) 
Dih ydrocodeine 50 (2.3) 199 (1.6) 
9.9 Method Validation for Whole Blood Specimens 
The same solid phase extraction method described in 9.8 was used with 1 mL of whole 
blood. 
9.9.1 Linearity 
Linearity was demonstrated over 5 - 200 ng/mL for each analyte. 
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Figure 9-4 : Linearity of morphine, codeine, 6-MAM and dihydrocodeine in whole blood 
9.9.2 Recovery 
Recovery was calculated as the mean of 5 extractions at 200 ng/mL, refer to Chapter 3.10.5 
for calculation. The results are shown in Table 9-7. 
9.9.3 Limits of Detection 
Limits of detection were calculated as in Chapter 3.10.6. The results are shown in Table 
9-7. 
9.9.4 Limits of Quantitation 
Limits of quantitation were calculated as in Chapter 3.10.7. The results are shown in Table 
9-7. 
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Table 9-7 : Recovery, LOD and LOQ for whole blood specimens 
Mean % Recovery Limit of Detection Limit of Quantitation 
Analyte 
(%RSD) (n=5) (nglmL) (nglmL) 
Diazepam 40 (4.4) 0.6 2.0 
N-desmethyldiazepam 32 (7.7) 4.4 14.7 
Temazepam 99 (9.9) 1.0 3.4 
Oxazepam 56 (7.1) 0.8 2.7 
Morphine 63 (6.6) 0.9 3.1 
Codeine 97 (3.9) 0.8 2.6 
6-MAM 102 (3.6) 0.5 1.8 
Dihydrocodeine 83 (2.8) 0.5 1.5 
9.9.5 Inter-Day Precision 
Inter-day precision was calculated using five sets of linearity data acquired on five 
different days. The %RSD of the five values for two concentrations, 50 and 200 nglmL 
were calculated. The results are shown in Table 9-8. 
Table 9-8 : Inter-day precision for whole blood specimens 
Inter-day precision 
Aaalyte (%RSD) (n=5) 
SOng 200ng 
Diazepam 53 (1.9) 199 (1.1) 
N-desmethyldiazepam 55 (28.1) 203 (2.8) 
Temazepam 46 (7.2) 201 (1.3) 
Oxazepam 50 (5.1) 201 (0.7) 
Morphine 52 (8.1) 201 (1.5) 
Codeine 52 (7.7) 197 (1.4) 
6-MAM 54 (9.0) 199 (0.6) 
Dihydrocodeine 57 (6.7) 195 (0.6) 
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9.9.6 Intra-Day Precision between Injections 
Extracted standards were prepared at two concentrations, SO and 200 ng/mL. They were 
injected 5 times consecutively. The %RSD of the peak area ratios was calculated at each 
concentration for each drug. The results are shown in Table 9-9. 
Table 9-9 : Intra-day precision between injections for whole blood specimens 
Intra-day precision 5 injections 
Analyte (%RSD) (n=S) 
SOng 200ng 
Diazepam 51 (6.7) 201 (4.0) 
N-desmethyldiazepam SO (12.2) 199 (8.8) 
Temazepam 49 (5.8) 197 (3.7) 
Oxazepam 47 (4.6) 201 (3.7) 
Morphine 55 (2.6) 200 (1.3) 
Codeine 53 (2.0) 199 (2.9) 
6-MAM 53 (3.5) 198 (1.9) 
Dihydrocodeine 54 (1.0) 201 (2.4) 
9.9.7 Intra-Day Precision between Extracts 
Five extracted standards at two concentrations, SO and 200 ng/mL, were prepared 
simultaneously. The %RSD of the peak area ratios were calculated for each extraction, at 
each concentration, for each drug. The results are shown in Table 9-10. 
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Table 9-10: Intra-day precision between extracts for whole blood specimens 
Intra-day precision 5 extracts 
Analyte (%RSD) (n=5) 
50 ng 200 ng 
Diazepam 53 (3.3) 201 (1.0) 
N-desmethyldiazepam 50 (8.4) 201 (6.8) 
Temazepam 50 (7.8) 199 (5.1) 
Oxazepam 49 (3.5) 201 (1.5) 
Morphine 52 (2.9) 198 (3.7) 
Codeine 50 (3.5) 201 (2.7) 
6-MAM 50 (2.8) 199 (2.5) 
Dih ydrocodei ne 50 (2.5) 200 (2.9) 
9.10 Method Validation for the Intercept® Device 
The same solid phase extraction method described in 9.8 was used with 0.5 mL of the oral 
fluid:buffer mixture obtained from the device. 
9.10.1 Linearity 
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Figure 9-5 : Linearity for diazepam and metabolites for the Intercept® collection device 
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Figure 9-6 : Linearity for morphine, codeine, 6-MAM and dihydrocodeine for the Intercept® 
collection device 
9.10.2 Recovery 
Recovery was calculated as the mean of 5 extractions at 200 ng/rnL. The results are shown 
in Table 9-11. 
9.10.3 Limits of Detection 
Limits of detection were calculated as in Chapter 3.10.6. The results are shown in Table 
9-11. 
9.10.4 Limits of Quantitation 
Limits of quantitation were calculated as in Chapter 3.10.7. The results are shown in Table 
9-11. 
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Table 9-11 : Recovery, LOD and LOQ for the Intercepte collection device 
Mean % Recovery Limit of Detection Limit of Quantitation 
Analyte 
(%RSD) (n=5) (nglmL) (nglmL) 
Diazepam 46 (7.1) 1.9 6.2 
N-desmethyldiazepam 22 (8.7) 8.6 28.6 
Temazepam 103 (5.3) 0.7 2.5 
Oxazepam 67 (5.5) 0.6 2.0 
Morphine 47 (8.6) 0.4 1.4 
Codeine 92 (2.9) 0.5 1.7 
6-MAM 86 (2.9) 0.7 2.5 
Dihydrocodeine 84 (5.6) 0.3 1.1 
9.10.5 Inter-Day Precision 
Inter-day precision was calculated using five sets of linearity data acquired on five 
different days. The %RSD of the five values for two concentrations, 50 and 200 nglmL 
were calculated. The results are shown in Table 9-12. 
Table 9-12 : Inter-day precision for the Intarcapte collection davlce 
Inter-day precision 
Analyte (%RSD) (n=5) 
50ng 200ng 
Diazepam 51 (0.5) 200 (1.2) 
N-desmethyldiazepam 47 (5.5) 202 (0.8) 
Temazepam 50 (9.3) 202 (1.2) 
Oxazepam 50 (0.2) 201 (2.4) 
Morphine 53 (3.2) 199 (0.3) 
Codeine 49 (12.4) 198 (0.2) 
6-MAM 52 (6.1) 201 (0.3) 
Dihydrocodeine 53 (9.6) 198 (0.3) 
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9.10.6 Intra-Day Precision between Injections 
Extracted standards were prepared at two concentrations, 50 and 200 nglmL. They were 
injected 5 times consecutively. The %RSD of the peak area ratios was calculated at each 
concentration for each drug. The results are shown in Table 9-13. 
Table 9-13: Intra~ay precision between injections for Intercept" collection device 
Intra-day precision 5 injections 
Analyte (%RSD) (n=5) 
50ng 200ng 
Diazepam 50 (4.6) 199 (1.2) 
N-desmethyldiazepam 54 (10.7) 203 (3.7) 
Temazepam 55 (12.9) 204 (3.3) 
Oxazepam 51 (3.6) 200 (2.8) 
Morphine 52 (1.4) 200 (5.3) 
Codeine 52 (3.7) 200 (4.6) 
6-MAM 50 (9.2) 201 (9.8) 
Dihydrocodeine 50 (9.5) 199 (5.2) 
9.10.7 Intra-Day Precision between Extracts 
Five extracted standards at two concentrations, 50 and 200 nglmL, were prepared 
simultaneously. The %RSD of the peak area ratios were calculated for each extraction, at 
each concentration, for each drug. The results are shown in Table 9-14. 
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Table 9-14 : Intra-day precision between extracts for InterceptS collection device 
Intra-day precision 5 extracts 
Analyte (%RSD) (n=S) 
SOng 200ng 
Diazepam 49 (7.0) 200 (3.6) 
N-desmethyldiazepam 48 (7.0) 201 (7.1) 
Temazepam 53 (9.7) 198 (5.0) 
Oxazepam 49 (3.3) 200 (2.9) 
Morphine 45 (9.7) 199 (5.6) 
Codeine 54 (3.8) 200 (3.5) 
6-MAM 50 (2.7) 198 (3.7) 
Dihydrocodeine 53 (8.7) 199 (1.6) 
9.11 Discussion 
During the course of this project the same extraction and LC-MS method was validated for 
each matrix analysed. When using LC-MS the matrix has an important role to play in the 
ionisation of analytes, it can enhance or suppress ionisation, recognized as the "matrix 
effect". By using an extensive extraction technique such as solid phase extraction, the 
analyte is retained while much of the matrix is lost in the clean up steps. However, some 
constituents of the matrix will always be retained and go on to effect the recovery of 
analytes and hence limits of detection. It has been shown by one group that solid phase 
extraction offers cleaner extracts and was preferred for plasma analysis of morphine, while 
protein precipitation was sufficient for oral fluid analysis, and sample dilution was suitable 
for the high concentrations found in urine 130. Another group have reported the presence of 
endogenous phospholipids found in plasma which are not washed away during solid phase 
extraction using mixed-mode columns, and elute late on in the chromatographic run'3'. 
Diazepam and its metabolites elute late on in the chromatographic run and the difference in 
their recoveries over the different matrices could be accounted for by interference from 
matrix constituents. All analytes have recoveries greater than 66 % for urine analysis. 
Diazepam has a recovery of 92 % from urine but only 46 % from the Intercept~ device and 
40 % from blood. The same drop in recovery is true for N-desmethyldiazepam and 
oxazepam. In general recoveries are best for urine then blood and lastly the Intercept~ 
collection device. In line with the low recovery ofN-desmethyldiazepam from blood and 
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the Intercept@ device, limits of detection change from 1.1 nglmL in urine, to 4.4 nglmL in 
blood and 8.6 nglmL in the Intercept@ device. Intra and inter- day precision was similar 
for each matrix, less than 10 % at 200 nglmL. 
9.12 Conclusions 
The method used for analysis was taken from previous work (Chapter 8) and validated 
successfully for the additional matrices blood, urine and the Intercept@ device. 
The method was applied to 48 whole blood samples, 87 urine samples, 91 oral fluid 
samples collected by the Intercept@ device and 95 oral fluid samples collected by the 
modified Omni-Sal® device. These samples were collected from 20 opiate addicts in a 
rehabilitation centre, refer to Chapter 10. 
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10 Case Samples 
10.1 Sildenafil in Whole Blood 
10.1.1 Post-Mortem Case Sample 
A male, 29 years old, was found dead in his bed with sildenafil tablets missing from a 
packet beside his bed. It was suspected that the deceased could have taken an overdose of 
sildenafil. At the post-mortem, femoral whole blood was collected and this was 
subsequently analysed for sildenafil using the method in Chapter 5. The concentration in 
the blood was found to be within the expected therapeutic range of concentrations for this 
drug, and not the cause of death. A single 50 mg dose of sildenafil citrate has produced 
peak plasma concentrations of 0.260 mg/VI. Using the pseudo-molecular ion as the 
quantitation ion gave a level of 0.093 mg/L of blood. If the daughter ion was used instead, 
the level was found to be 0.088 mg/L. These results demonstrate the consistency of 
fragmentation that takes place within the source. Figure 10-1 shows the chromatogram 
produced for the blood sample. 
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10.1.2 Conclusions 
The method developed and validated in Chapter 5 was successfully applied to a post-
mortem case sample. The result was within the therapeutic range and therefore not the 
cause of death. 
10.2 Detection of Drugs of Abuse in Oral Fluid by LC-MS 
The method developed in Chapter 7 was used to analyse 60 oral fluid samples collected by 
the modified Omni-Sal® device, supplied by Cozart Biosciences Ltd. This was part ofa 
UK project, British Roadside Impairment Test Evaluation (BRITE), which involved the 
evaluation of the Field Impairment Test (FIT) for use at the roadside in the UK. 
FIT is a battery of tests to help the police officer decide if the driver is under the influence 
of drugs. FIT includes four attention tests, "walk and tum", "one legged stand", "finger to 
nose" and the Romberg test. Pupillary examination is also included giving a total of five 
tests to evaluate the driver. The police officer makes a judgement on whether the subject is 
impaired or not on the totality of the results of the tests. For the purposes of this project, if 
the subject was found not to be impaired they were asked to provide an oral fluid sample 
voluntarily. By analysing these oral fluid samples, a picture of the types and 
concentrations of drugs in drivers found not to be impaired could be established. These 
oral fluid samples were analysed for licit and illicit drugs using the LC-MS and GC-MS. 
10.2.1 Results 
60 oral fluid samples were analysed for 20 drugs of abuse and their metabolites. The 
samples were collected from drivers who had been stopped by police officers for a reason. 
97 % (n=58) were positive for at least one analyte. The number of cases positive for each 
analyte is shown in Figure 10-2. The concentration ranges and median for each analyte are 
shown in Table 10-1. Concentrations above the linearity range should be viewed with 
caution, unfortunately there was insufficient sample volume for repeat analysis. Morphine 
was the most frequently detected analyte (n=50), followed by 6-MAM (n=21), indicating 
recent heroin use. Morphine concentrations ranged from therapeutic concentrations up to 
concentrations associated with contamination levels. When a drug is taken orally, a 
residue of the drug has the potential to remain in the mouth for a period of time. If oral 
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fluid is collected immediately after oral administration the resulting concentration will be a 
combination of that in the saliva and drug residue in the mouth. A past study has shown 
that with controlled intravenous administration of 5, 10 and 20 mg heroin hydrochloride, a 
peak saliva concentration of20 nglmL of morphine was reached. In the same study, 2.6 
mg smoked heroin base was administered in a controlled manner, and peak saliva levels 
reached 3531 nglmL of morphine 132 . A median morphine concentration of25 nglmL 
would suggest intravenous use, or heroin smoked several hours before sample collection. 
However the very high concentrations are indicative of recently smoked heroin. 
Morphine was found without 6-MAM or codeine in 27 cases. These concentrations ranged 
from 2- 175 nglmL with a median of 11 ng/mL. Morphine, 6-MAM and codeine were 
found together in 19 cases, the morphine result ranging from 8-5361 nglmL with a median 
of 156 nglmL. Morphine and codeine were found together in 2 cases, and morphine and 6-
MAM in another two cases. There were no instances when codeine was found alone, 
indicating that codeine was not present from prescribed or over the counter medications 
but from impure "street heroin" use. 
6-MAM was found with morphine in 42 % (n=21) of morphine positive cases. A 
workplace study found 6-MAM to be present in 67 % of the morphine positive case 
samples133. This study employed a different collection device, which could account for the 
increased presence of 6-MAM compared to this study or it may be due to the variations in 
the time between administration and collection and/or the purity of the heroin. 
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Methadone was present in 28% (n=17) of all cases, with its metabolite EDDP present in 
only 5% (n=3). EDDP was not found without methadone. EDDP is not found at any 
significant level in plasma, during therapeutic usage of methadone, therefore it is not 
unexpected to see very few cases positive for EDDP. Methadone concentrations ranged 
from 4 - 597 nglmL with a mean of 82 nglmL and a median of 11 nglmL. Methadone oral 
fluid concentrations have been found to show great inter-individual variability134. 
Methamphetamine was found in 27% (n=16) of all case samples. The levels found were 
very low, apart from one sample at 5OnglmL. This sample was also positive for MDMA, 
MDA and amphetamine. A previous study analysing oral fluid collected by the modified 
Omni-Sal® device from heroin addicts, found II % positive for amphetamines, mainly 
methamphetamine, and at very low concentrations, around LOD of 1 - 10 nglmL 135. 
N-desmethyldiazepam, diazepam and temazepam were found in 18 % (n=II), 15 % (n=9) 
and 2 % (n=l) of all cases respectively. All analytes were found alone, except in one case 
where N-desmethyldiazepam and temazepam were found together. The concentrations of 
the benzodiazepines were quite low ranging from 5 - 51 nglmL. Benzodiazepines have a 
high protein binding capacity, allowing only a small percentage to diffuse into saliva. A 
past study has shown similar concentrations to those presented here87• 
Amphetamine was found positive in 13 % (n=8) of all case samples. Amphetamine was 
only found present with MDMA in one case, which was also positive for MDA and 
methamphetamine. In this case 6525 nglmL of amphetamine was found with 50 nglmL of 
methamphetamine, 245 nglmL ofMDMA and 27 nglmL ofMDA. This case could be 
explained by impure amphetamine, and/or the combination of drugs administered. Three 
case samples had amphetamine levels over 3000 nglmL indicating intranasal 
contamination, through "snorting". 
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Table 10-1 : Drug concentrations detected in oral fluid case samples 
Mean Median Concentration 
Analyte n (nglmL) (nglmL) Range (nglmL) 
Morphine 50 224 25 2 - 5361 
6-MAM 21 637 29 2 - 5400 
Codeine 21 74 15 2-468 
Methadone 17 82 11 4-597 
Methamphetamine 16 6 2 2-50 
N-desmethyldiazepam 11 13 5 1- 51 
Diazepam 9 5 5 2-15 
Amphetamine 8 1662 178 43 -6525 
Cocaine 7 275 172 36-863 
Benzoylecgonine 7 201 124 18 -746 
MDA 6 11 7 1-27 
Norbuprenorphine 4 19 17 1 -43 
MDMA 3 313 245 225 -468 
EDDP 3 5 4 4-8 
Dihydrocodeine 2 2 2 2,2 
Temazepam 1 - - 32 
Cocaine and its metabolite benzoylecgonine were found in 12 % (n=7) of all case samples. 
In every sample both cocaine and benzoylecgonine were present. Cocaine values ranged 
from 36 - 863 nglmL, while benzoylecgonine had similar values ranging from 18 - 746 
ngimL. Previous studies, using stimulated saliva collection, have shown that smoking and 
intranasally administered cocaine, results in saliva concentrations in the thousands initially, 
decreasing to limits of detection within 12 hours. Intravenous administration of cocaine 
hydrochloride results in peak concentrations of cocaine in the hundreds, decreasing to trace 
amount after 12 hours 104.132. The difference in magnitude can be accounted for by oral 
contamination from the route of administration. The results presented here suggest that the 
oral contamination has cleared, and cocaine has been taken within the last few hours. 
The results for cocaine and benzoylecgonine were plotted against each other to assess if 
there was any correlation. The graph in Figure 10-3 shows the results. 
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This showed significant correlation between cocaine and benzoylecgonine oral fluid 
concentrations. The concentrations of cocaine and benzoylecgonine in the same sample 
were in the same range unlike the studies previously mentioned, where benzoylecgonine 
levels were a magnitude lower than cocaine concentrations. This could be due to the 
stimulated condition u ed to collect the saliva in these previous studies. Stimulation of 
saliva production results in an increase in saliva pH which would drive benzoylecgonine to 
its unionised form leaving it free to cross the lipid membrane back into the blood. At a 
lower pH benzoylecgonine would exist in its ionised form which would be trapped in the 
saliva. 
MDMA was found in 5 % (n=3) of all case samples. Its metabolite MDA was also found 
in the same three case samples and in an additional two at very low levels. MDMA was 
found at concentrations ranging from 225 - 468 ng/mL, with a median of 245 ng/mL. 
These levels are below what would be expected for oral contamination and suggest recent 
use. 
Of the 58 samples found positive, 42 % (n=25) had one drug group, 31 % (n=18) 2 drug 
groups, 16 % (n=9) 3 drug groups, 2 % (n=l) 4 drug groups and 9 % (n= 5) 5 drug groups. 
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Figure 10-4 shows the extent of polydrug use in this population of samples. Less than half, 
42%, of the samples had one drug group present. Polydrug use has been reported 
previously amongst drivers in blood and urine samples95,136,137. The most common drug 
group taken in combination with other drug group was the opiates, namely morphine 
attributed to heroin use in combination with benzodiazepines and methadone. 
10.2.2 Comparison of LC-MS and GC-MS Results 
Some analytes were quantified using both the GC-MS and the LC-MS. Correlation 
between the instruments for these analytes are shown below in Figure 10-5. The higher 
sensitivity of the LC-MS resulted in some discrepancies between the two instruments 
results. 
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10.2.3 Discussion 
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The samples analysed were obtained from drivers who were stopped for a reason by the 
police officer, but were later found to be unimpaired using FIT. The results show that 97% 
of these samples were posi.tive for at least one drug group, indicating that although drugs 
were found in the dri ers' system they may not have exerted an impairing effect at the time 
FIT was carried out. It could also indicate tolerance to drugs in the individual or that more 
training is required for the police officers. Morphine, indicating heroin use, was the most 
commonly detected drug, which is in line with previous studies on drivers and drug deaths 
in the West of Scotland area58.95.138. 
Cannabinoids were analysed in the acidic/neutral fraction of the extraction on the GC-MS. 
There have been papers published which describe the analysis of cannabinoids using Le-
MS, but using the present chromatographic conditions /),9_ THC did not elute from the 
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column. This meant that !::t.9 - THC analysis was not possible on the LC-MS for this project 
and the GC-MS was used. 
There was good correlation between GC-MS and LC-MS quantitative results. This 
showed that LC-MS was a viable alternative to GC-MS for the drugs analysed. For some 
of the benzodiazepines and buprenorphine, no GC-MS data was obtained because of 
difficulties with analysing these drugs by this method. The LC-MS also required less 
maintenance and was in general more reliable than the GC-MS. 
10.3 Drugs of Abuse in Oral Fluid by LC-MS-MS 
The method validated in Chapter 8 was applied to 1396 oral fluid samples collected by the 
modified Omni-Sal® device. This was part of a European project, Impaired Motorists, 
Method of Roadside Testing and Assessment for Licensing, IMMORTAL. 
Samples were collected at the roadside in and around the city of Glasgow. Drivers were 
stopped at random and were asked to participate voluntarily. Oral fluid samples was taken 
and transported to the Forensic Medicine and Science Department, where they were frozen 
on arrival until the analysis was carried out. 
The samples were analysed for 21 drugs of abuse and their metabolites by LC-MS-MS. 
Prescription drugs and cannabinoids were analysed by GC-MS, refer to Appendix 1 for 
GC-MS methodology139. 
10.3.1 Results 
1396 oral fluid samples were analysed for 21 drugs of abuse and their metabolites. 12.8 % 
(n=178) were positive for at least one drug. The number of cases positive for each analyte 
is shown in Figure 10-6. The concentration ranges and median for each analyte are shown 
in Table 10-2. 
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MDMA, was the most frequently detected drug (n=70) followed by its metabolite MDA, 
(n=51). The concentrations detected for MDMA, range from trace amounts to 
contamination level, 1 - 3144 ngimL. Only 4 cases out of70 indicated contamination 
with MDMA Ie eis greater than 1000 ngimL. The median was 93 nglmL indicating drug 
use within 24 hours '9. 
MDA was found without MDMA in 3 cases, at very low levels, 1,9 and 9 nglmL. This 
would suggest that the MDA positive cases are from the metabolism ofMDMA and not 
from the ingestion ofMDA alone. 
There are 48 cases where both MDMA and MDA are found in the sample. By plotting the 
MDMA and MDA concentrations, it is shown that there is little correlation between the 
two, Figure 10-7. This is in contrast to cocaine and benzoylecgonine in the previous set of 
case samples (Figure 10-3). 
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Table 10-2 : Drug concentrations detected in oral fluid case samples 
Mean Median Concentration 
Analyte n (nglmL) (nglmL) Range (nglmL) 
MDMA 70 224 93 1- 3144 
MDA 51 44 24 1-275 
Codeine 31 139 50 4-1504 
Cocaine 22 1001 80 4-11110 
Benzoylecgonine 22 1134 82 2 -11471 
Dihydrocodeine 18 332 91 2 -1315 
Temazepam 16 33 13 3-189 
Ecgonine methyl ester 12 337 76 4 -1520 
Amphetamine 12 2231 433 12 -16414 
Diazepam 12 11 8 1-28 
Morphine 10 784 12 2-7442 
N-desmethyldiazepam 9 46 16 4-221 
Methadone 6 1578 667 8-6949 
EDDP 6 16 12 8-38 
Oxazepam 5 14 10 4-33 
6-MAM 4 1906 11 3 -7600 
Cocaethylene 4 46 32 2-119 
Methamphetamine 3 34 2 1-98 
MDEA 3 10 13 4-14 
After MDMA and MDA the next most frequently detected drug was codeine with 17.4 % 
(n= 31) of case samples found positive. Codeine was found without any other drug in 23 
case samples. A sample positive for codeine only suggests codeine use through over the 
counter medication. Of the other eight case samples positive for codeine, two were 
positive for dihydrocodeine, also indicating over the counter medication. Four were 
positive for morphine, and one of those also positive for 6-MAM. Finding codeine and 
morphine in oral fluid could be the result of codeine use alone (as codeine metabolises to 
morphine) or heroin use. 6-MAM present in a sample is conclusive of heroin use, as 6-
MAM is the metabolite of diamorphine, found in heroin. The other two cases had a small 
amount ofEDDP in one and MDMA in the other. 
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Figure 10·7 : Correlation between MDMA and MDA concentration in oral fluid 
Cocaine and its metabolite benzoylecgonine were the next most frequently detected drugs, 
both in 12.4 % (n = 22) of positi e case samples. Ecgonine methyl ester, another cocaine 
metabolite, was found in 6.7 % (n = 12) of positive case samples. Benzoylecgonine and 
ecgonine methyl ester" ere found without cocaine in only four cases. Cocaine and 
benzoylecgonine were found together in nineteen cases, and cocaine and both its 
metabolites were found together in ten cases. In the previous set of oral fluid data, there 
was significant correlation between cocaine and benzoylecgonine. When the current data 
was plotted the correlation is not as significant as before, with an R2 value of 0.8957, 
Figure 10-8. This may be because of the widespread range in levels found in this project 
compared with the previous study. 
Temazepam was found in 19 % (n = 16) of positive samples. It was found without 
diazepam, -desmethyldiazepam and oxazepam in seven samples. This finding indicates 
either the use of temazepam or diazepam. An additional five samples had only one 
benzodiazepine present. Diazepam as next most frequently detected (6.7 %) 
benzodiazepine after temazepam, followed by N-desmethyldiazepam, 5.1 %, and 
oxazepam, 2.8 %. 
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10.3.2 Discussion 
12.8 % of sample collected from drivers at random were found positive for at least one 
drug. The most frequently found drug was MDMA and its metabolite MDA, with median 
concentration repre enting u e within the last 24 hours. In one study it was shown that 
although vehicle control i not greatly affected after MDMA ingestion, the decreased sense 
of risk taking ha a major part to play in accident involvement14o• This is confmned by a 
further study showing that MDMA use is not consistent with safe driving and that 
impairment can last for a con iderable time after last use 141 . Codeine was the next most 
frequently detected drug with 25 out of 31 cases representing over the counter medications. 
Cocaine use was observed in 22 cases, with a median concentration of 80 nglmL, this 
would indicate u e within the la t 2-8 hours depending on the route of administration 1 02 . 
Only five out of the 22 cas howed concentrations of 1000 nglmL indicating oral 
contamination and use within the last couple of hours prior to sampling. 
The majority of ample po itive can be explained by over the counter medications or 
concentration indicating u e \\ ithin the last 24 hours, and not necessarily exerting an 
impairing effect on the driver. 
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Figure 10-9 show the numb r of drugs detected in drivers involved in road traffic 
accidents v. ithin the same \ ieinity as oral fluid samples taken from random drivers. This 
data has been taken from routine blood samples analysed within the department. 
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Figure 10·9 : Number of posit ive samples from drivers involved in road traffic accidents in 
the same v icinity as random ora l f luid samples collected 
In drivers invohed in road traffic accidents, diazepam is the most frequently detected drug. 
Cannabinoids, morphine, methadone and temazepam are the next most frequently detected 
drugs. The five most frequently detected drugs all have sedative properties 142, 143 . This is in 
contrast to oral fluid amples collected from non-impaired drivers where MDMA was the 
most frequently det eted drug, followed by codeine and cocaine. MDMA and cocaine 
both produce stimulating effectsI42.143. As discussed earlier there have been studies on the 
effect ofMDMA on driving, which suggest that it does have some impairment effectsI4o,141. 
MDMA found in dti\efS \\ho are non-impaired can be explained by either contamination 
of the oral ca\ it)' from oral admini tration or tolerance from the effect of the drug through 
repeated use. If an individual frequently takes a drug, tolerance to its effects builds up and 
the user needs to tak a higher dose to experience the same effect. This would result in 
high concentration of the drug in oral fluid, without the impairing effect. 
D.9-THC \\as analy ed on th GC- 1 ,results for this are shown in Appendix 1 144. 
, 
I 
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10.4 Comparison of Oral Fluid Collection Devices for the 
Detection of Drugs of Abuse 
Blood, urine and oral fluid amp} s were taken from patients attending a residential 
rehabilitation entre. mp) \ ere collected from the first day of admission for five 
consecutive day . In mo t case blood was taken only in the first couple of days, to 
minimise di comfort to th pati nts. 
10.4.1 Whole Blood Results 
48 whole blood ample \\er anal}' ed from 20 patients. The morphine blood 
concentrations are hown In Tabl 10-3. 
Table 10-3 : Morphine blood concentrations found in patients 
Morphine Blood Concentration (ng/mL) 
Patient 
l-Da) 1 Day 2 I Day 3 Day 4 DayS 
GY31290 0 I ns 0 0 6 
MMG4167 I 12 11 8 3 0 
SL16771 7 I n 0 ns ns 
MT171060 0 n ns 0 0 
BA318l 19 n ns 0 ns 
HD180669 0 I 0 n ns 0 
CL180981 7 n I 0 ns ns 
JC271273 0 4 0 ns ns 
C0221180 28 0 3 ns 0 
MM22676 13 0 0 ns ns 
OT4676 0 0 0 ns ns 
SC191082 n 7 n 1 ns 
JS18981 n n 0 0 ns 
i 
SMOS1273 J I n 0 ns ns 
JMOl1178 0 n ns ns ns 
JL300578 4 n 0 ns ns 
S0220384 3 n~ I n ns ns 
AC290980 16 n_ n ns ns 
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Patient 
Morphine Blood Concentration (nglmL) 
Day 1 I Day 2 I Day 3 Day4 DayS 
I PT020681 I 0 I n I ns ns ns I DMcC-1174 L 3 I n I n 0 ns 
ns : no sample provIded 
From the above re ult it can been that there are many samples missing from the data 
set. In many ca ,coll tion of blood wa found to be either too distressing for the 
patient, or too difficult for the medical practitioner. Many of the results were negative and 
for those \\hich were po itive, I ,eIs '\ 'ere low. Levels ranged from 3-28 nglmL with a 
mean and median of 10 and no mL. respectively. Morphine metabol1ses rapidly and has 
a half-life of 1.3-6.7 ho r On tudy has shown morphine concentrations in plasma to 
decline to the en itivit), of the analytical method (0.6 ng/mL) by 24 hours after 20 mg and 
10 mg dos 0 f mtram u ular morphine 1 .0. The self reported time between the last heroin 
use to blood collection rang d from 7 hours (AC290980) to 4-5days (BA3181). This could 
explain the low po Hive r ult found. The 10\\ positive results for morphine found in later 
days could be e. 'plained by patient re-using within the rehabilitation centre. 6-MAM was 
not detected in any blood ample. Thi i not surprising considering the low 
concentrations of morphme found and the rapid metabolism of 6-MAM to morphine. 
Codeine was al 0 ab nt in the blood amples, codeine is a by-product of the production of 
heroin. It can be found in blood aft r heroin use but levels are a magnitude less than 
morphine. Con id ring th low morphine Ie els, we would not expect codeine to be 
present. 
Dihydrocod in w found in mo t patients. When a patient is first admitted into the 
centre, dihydrocodein 1 gl\en to the patient by the care workers until they are seen by the 
doctor who can th n pre cribe them methadone. The levels of dihydrocodeine found are 
shown in Table 10-4. 
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Table 10-4 : Dihydrocodeine blood concentrations found in patients 
~ Dihydrocodeine Blood Concentration (ng/mL) Patient Da) "l"T Day 2 I Day 3 Day4 DayS 
GY31290 - 0 n I 1 0 0 
MMG4167 375 -3 0 0 0 
SL167 1 0 ns 0 ns ns 
MT171060 269 n I n 0 0 
BA3181 221 n I n 0 ns 
HD180669 0 0 I n ns 0 
CL180981 216 n 0 ns ns 
JC271273 I 3;8 IS 0 ns ns 
CD221180 0 0 0 ns 0 
MM22676 0 24- 339 ns ns I ~ I 
I 
I 
DT4676 0 0 0 ns ns 
SC191082 n 403 ns 221 ns 
JS18981 n n 0 0 ns 
S\1051273 0 n- O ns ns 
JMOll178 235 n n ns ns 
JL300578 I 310 n ~ 1 ns ns 
SD220384 294 I n' n ns ns 
AC290980 0 n ns ns ns 
PT020681 69 n:; ns ns ns 
D\1cCS1174 12 n~ n 0 ns 
ns : no ample provld d 
Dia7epam and its thr e metabolites were all detected in blood. Diazepam was found in 92 
% (n- 4) of sample - and in all but one patient DMcC51174. Results are shown in Table 
10-5. Patient rc pn.: cnbed diazepam if they are suffering from withdrawal symptoms 
from recent u 
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Table 10-5 : Diazepam blood concentrations found in patients 
Patient 
Diazepam Blood Concentration (ng/mL) 
Day 1 Day 2 Day 3 Day 4 DayS 
GY31290 241 ns 672 434 362 
MMG4167 375 420 594 474 342 
SL16771 8 ns 449 ns ns 
MT171060 0 ns ns 26 0 
BA3181 596 ns ns 344 ns 
HD180669 47 21 ns ns 3 
CL180981 247 ns 399 ns ns 
JC271273 312 226 261 ns ns 
CD221180 120 126 146 ns 44 
MM22676 903 854 677 ns ns 
DT4676 309 342 370 ns ns 
SC191082 ns 1787 ns 1266 ns 
JS18981 ns ns 327 472 ns 
SM051273 1538 ns 310 ns ns 
JM011178 385 ns ns os ns 
JL300578 684 ns 774 ns ns 
SD220384 687 ns ns ns ns 
AC290980 301 ns ns ns ns 
PT020681 97 ns ns ns ns 
DMcC51174 0 ns ns 0 ns 
ns : no sample provided 
10.4.2 Discussion 
Blood concentrations of morphine were very low, ifit was present. 6-MAM and codeine 
were not found at all, highlighting the rapid metabolism of heroin. Dihydrocodeine and the 
benzodiazepines were found in many samples at high concentrations, resulting from 
administration within the rehabilitation centre. 
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10.4.3 Oral Fluid Collected by the Modified Omni-SafJ Device 
Results 
95 oral fluid samples collected by the modified Omni-Sal® device were analysed for 
opiates and benzodiazepines. This device was accepted well by the patients, the main 
disadvantage was the time taken to collect a sample. The device has a window at the end 
of the stick which turns blue when 1 mL of oral fluid is collected. Opiate addicts often 
suffer from "dry mouth" prolonging the time taken to collect ImL; it took one patient 30 
minutes. Only 5 samples were not collected, either because the patient left the centre early, 
or the centre had run out of the collection devices. 
Assuming that morphine levels in oral fluid are from the diffusion of morphine from blood 
into saliva, it would be expected that the levels found in oral fluid would be comparable to 
those found in blood. The morphine concentrations found in the oral fluid samples are 
shown in Table 10-6. 
In day 1, 10 samples were found positive for morphine. In whole blood on day 1, 11 
samples were found positive with 4 samples absent from analysis. Although there seems 
to be less positive results in oral fluid, the mean concentration was 83 nglmL with a 
median of 48 ng/mL. The concentrations ranged from 4 - 437 ng/mL. A study showed 
that following intramuscular injection of20 mg morphine sulphate, equilibrium between 
saliva and plasma concentrations was reached after 45 minutes. They found that plasma 
levels were similar or greater than saliva levels". Intramuscular injections of morphine 
ensure no contamination of the oral cavity. The highest level ofmorpbine found in these 
oral fluid samples, was 437 ng/mL (JL300578), this could be as a result of oral 
contamination from smoking heroin. The median in oral fluid is almost 7 times higher 
than that in blood. 
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Table 10-6 : Morphine oral fluid concentrations collected using the modified Omni-Sal® 
device 
Patient 
Morphine Oral Fluid Concentrations (ng/mL) 
Dayt Day 2 Day3 Day 4 DayS 
GY31290 11 0 0 23 306 
MMG4167 0 0 66 0 0 
SL16771 0 0 0 0 0 
MT171060 21 0 0 0 0 
BA3181 0 0 0 0 ns 
HD180669 0 0 0 0 0 
CL180981 0 0 0 0 0 
JC271273 0 0 0 0 ns 
CD221180 98 4 0 0 0 
MM22676 54 0 0 9 0 
DT4676 0 0 0 0 0 
SC191082 52 3 0 9 0 
JS18981 43 0 0 0 0 
SM051273 4 0 0 0 0 
JMOll178 0 0 0 ns ns 
JL300578 437 42 0 0 0 
SD220384 0 0 0 ns 0 
AC290980 99 0 0 0 0 
PT020681 0 0 0 0 0 
DMcC51174 6 0 0 0 0 
ns : no sample provided 
6-MAM was not present in any blood samples, this was not the case with oral fluid 
samples. Using the modified Omni-Sal® device, 6-MAM was found in 9 out ofthe 20 
patients analysed. The full set of results is shown in Table 10-7. JL300578 shows a high 
level of 6-MAM, 282 nglmL which would support the hypothesis of oral contamination 
through smoking. A study evaluating the use of oral fluid testing for the detection of 
opiate use in drug users found high concentrations of 6-MAM which was attributed to the 
breakdown of heroin during smoking rather than the diffusion from the blood. The authors 
also found in a few cases opiates could be detected in oral fluid up to five days after last 
reported use 145. 
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Table 10-7: 6-MAM oral fluid concentrations collected using the modified Omni-Sal® device 
Patient 
6-MAM Oral Fluid Concentrations (ng/mL) 
Day 1 Day2 Day 3 Day 4 DayS 
GY31290 0 0 0 0 0 
MMG4167 0 0 92 0 0 
SL16771 0 11 0 0 0 
MT171060 40 15 0 0 0 
BA3181 0 0 0 0 ns 
HD180669 0 0 0 0 0 
CL180981 0 0 0 0 0 
JC271273 0 0 18 5 ns 
CD221180 0 0 0 0 0 
MM22676 30 0 0 0 0 
DT4676 0 0 0 0 0 
SC191082 36 0 0 0 0 
JS18981 0 0 0 0 0 
SM051273 0 0 0 0 0 
JM011178 0 0 0 ns ns 
JL300578 282 25 3 0 7 
SD220384 0 0 8 ns 0 
AC290980 0 0 0 0 0 
PT020681 0 0 65 10 2 
DMcC51174 0 0 0 0 0 
ns : no sample provided 
Codeine was also found in these oral fluid samples, where none was found in the 
respective blood samples. These could be explained by the oral contamination through 
smoking, or the oral self-administration of an over the counter preparation. The full set of 
codeine results are shown in Table 10-8. Codeine positive samples are consistent with 
morphine positive samples. The median of codeine concentrations was 11 nglmL 
compared with the median morphine concentration of 48 ngimL. Although the detection 
ofmorpbine and codeine is not conclusive of heroin use, the patients were known heroin 
abusers. 
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Table 10-8 : Codeine oral fluid concentrations collected using the modified Omni-Sal® 
device 
Patient 
Codeine Oral Fluid Concentrations (ng/mL) 
Day 1 Day 2 Day 3 Day4 DayS 
GY31290 24 0 0 0 0 
MMG4167 0 0 0 0 0 
SL16771 0 0 0 0 0 
MT171060 0 0 0 0 0 
BA3181 14 0 0 0 ns 
HD180669 3 1 0 0 0 
CL180981 0 0 0 0 0 
JC271273 0 0 0 0 ns 
CD221180 45 0 0 0 0 
MM22676 35 0 0 0 0 
DT4676 0 0 0 0 0 
SC191082 17 10 0 0 0 
JS18981 11 4 0 0 0 
SM051273 4 0 0 0 0 
JM01l178 0 0 0 ns ns 
JL300578 20 6 0 0 6 
SD220384 0 0 0 ns 0 
AC290980 21 0 0 0 0 
PT020681 0 0 0 0 0 
DMcC51174 0 0 0 0 0 
ns : no sample provided 
Dihydrocodeine was found in 43 % (n=41) of samples, with a median of379 nglmL and 
results ranging from 1 - 15058 ngimL. In blood, dihydrocodeine was found positive in 44 
% (n=21) of samples, with a median of235 nglmL and a range of 1 - 570 ngimL. The 
highest blood concentration of 570 nglmL was from GY31290 on day 1, the corresponding 
oral fluid concentration was the highest found. Dihydrocodeine levels are elevated in oral 
fluid samples compared to blood. The full set of dihydrocodeine results are shown in 
Table 10-9. 
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Table 10-9: Oihydrocodeine oral fluid concentrations collected using the modified Omni-
Sal® device 
Patient 
Dihydrocodeine Oral Fluid Concentrations (ng/mL) 
Day 1 Day 2 Day 3 Day 4 DayS 
GY31290 15058 767 17 13 0 
MMG4167 1736 66 0 0 0 
SL16771 0 0 0 0 0 
MT171060 3134 198 0 0 0 
BA3181 836 232 3 0 ns 
HD180669 1598 181 37 1 0 
CL180981 379 57 3 0 0 
JC271273 869 27 5 0 ns 
CD221180 0 0 0 0 0 
MM22676 0 671 715 2541 846 
DT4676 0 0 0 0 0 
SC191082 1069 4610 610 2702 1143 
JS18981 0 0 0 0 0 
SM051273 0 0 0 0 0 
JM011178 707 90 19 ns ns 
JL300578 629 304 0 0 0 
SD220384 1541 121 55 ns 10 
AC290980 0 0 0 0 0 
PT020681 892 24 0 0 0 
DMcC51174 0 0 0 0 0 
In contrast with the opiates, diazepam was found in only 59 % (n=56) of oral fluid 
samples, compared with 92 % (n=44) of blood samples. The number of oral fluid samples 
with a corresponding blood sample was 48. Of these, 92 % (n=44) were positive for 
diazepam in blood, and 52 % (n=25) were positive for diazepam in oral fluid. The blood 
concentrations had a median of 353 nglmL with a range of 3 - 1787 nglmL and the oral 
fluid concentrations had a median of 17 nglmL with a range of2 - 329 nglmL. Oral fluid 
concentrations of diazepam are a magnitude less than blood concentrations. Diazepam is 
highly protein bound in plasma. Therefore it is only the low amount of free drug which is 
able to diffuse into saliva. 
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Similarly, N-desmethyldiazepam, temazepam and oxazepam had considerably lower 
concentrations in oral fluid compared to blood. N-desmethyldiazepam was found in 42 % 
(n=40) of oral fluid samples compared with 92 % (n=44) of blood samples. Temazepam 
was found in 18 % (n= 17) of oral fluid samples compared with 94 % (n=45) of blood 
samples. Similarly oxazepam was found in 20 % (n= 19) of oral fluid samples compared 
with 83 % (n=40) of blood samples. The median concentrations of diazepam and its 
metabolites in blood and oral fluid collected by the modified Omni-Sal® device are shown 
in Table 10-10. 
Table 10-10: Median concentrations of diazepam and Its metabolites In blood and oral fluid 
collected by the modified Omni-Sale device. 
Median (nglmL) 
Diazepam N-desmethyldiazepam Temazepam Oxazepam 
Oral Fluid Blood Oral Fluid Blood Oral Fluid Blood Oral Fluid Blood 
22 353 26 380 3 55 8 51 
10.4.4 Discussion 
The modified Omni-Sal® device was easy to use and generally accepted by the patients. 
However, for some patients it took up to 30 minutes to provide a sample as a result of "dry 
mouth". Morphine concentrations were elevated in the oral fluid specimen compared with 
blood levels, although the number of positive samples was less in oral fluid than blood. 
6-MAM was found in 15 oral fluid samples, but not in any of the corresponding blood 
samples. This could be useful for confirmation of heroin use, as 6-MAM is a unique 
marker, unlike morphine. 
Diazepam and its metabolites were found more frequently in blood compared to oral fluid, 
and concentrations were much higher in blood. This could be as a result of the high 
protein binding capacity of the benzodiazepines in blood resulting in low concentrations in 
saliva. 
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10.4.5 Oral Fluid Collected by the Intercepf® Device Results 
91 oral fluid samples were collected by the Intercept® device. Instead of waiting until a 
specific volume was absorbed like the modified Omni-Sal® device, this collection device 
was placed in the mouth for between 2 - 5 minutes. The pad is impregnated with a salt to 
stimulate saliva production, and placed between the lower gum and cheek. A mixture of 
oral mucosal transudate, saliva and other debris in the mouth is absorbed by the pad. After 
collection, the pad is removed and placed in a tube with buffer, the stick snapped off and 
the tube sealed. Some patients preferred this device to the modified Omni-Sal® device 
because it was quick, but they dido't like the after taste from the salt. 
In day 1 samples, only 6 were found positive for morphine, compared with lOusing the 
modified Ornni-Sal® device and 11 in whole blood with 4 samples missing results. The 
full set of morphine results are shown in Table 10-11. In total 9 samples were found 
positive for morphine with a mean concentration of 60 nglmL and a median of 22 ngimL. 
The results ranged from 2 - 312 ngimL. As before, oral fluid concentrations were greater 
than in whole blood, although the actual number of positives was less. The concentrations 
found in oral fluid samples collected using the Intercept® device were less than those 
obtained from the modified Omni-Sal® device. Morphine has a pKa of 8.1 and 10, and 
therefore its concentration in saliva is greatly affected by a change in saliva pH. By 
stimulating saliva flow, the bicarbonate concentration in the saliva increases making it 
more alkaline. This rise in pH can lower the saliva/plasma ratio and this could account for 
the lower concentrations of morphine found using this device compared to the other oral 
fluid device. Also because the saliva flow is stimulated, more saliva is secreted but drugs 
don't have time to diffuse in, giving a dilution effect. Another possibility is that the 
Intercept® collection device only collects ""'().4 mL of oral fluid compared to 1 mL by the 
modified Omni-Sal® collection device. 
6-MAM was found in 5 % (n=5) of samples, compared with 16 % (n=IS) of samples 
collected with the modified Omni-Sal® device. The mean concentration found was 49 
nglmL with a median of34 nglmL and a range of7 - 133 ngimL. The highest 
concentration of 133 nglmL was found in JL300S78 on day 1, this was also the highest 6-
mam result, 282 nglmL, using the modified Omni-Sa1® device. 
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Codeine was found in only 2 samples at 8 and 9 nglmL, compared with 15 samples using 
the modified Omni-Sal® device with a mean of 15 nglmL and a median of 11 ngimL. In 
the sample with 8 nglmL of codeine morphine was also present at 61 ngimL. 
Dihydrocodeine was found in 35 % (n=32) of samples, with a mean and median of 1002 
and 773 nglmL respectively. Concentrations ranged from 20 - 4598 ngimL. Although the 
number of samples found positive was less than that found using the modified Omni-Sal® 
device (43 %, median 379 nglmL), the median concentration was greater. Dihydrocodeine 
has a pka of 8.8; it therefore, may not be as affected by stimulation than the other opiates. 
Table 10-11 : Morphine oral fluid concentrations collected using the Intercept® Device 
Patient 
Morphine Oral Fluid Concentrations (og/mL) 
Day 1 Day 2 Day 3 Day 4 Day 5 
GY31290 22 0 0 0 0 
MMG4167 ns 0 9 0 0 
SL16771 0 0 0 0 0 
MT171060 0 0 0 0 0 
BA3181 0 2 0 0 ns 
HD180669 0 0 0 0 0 
CL180981 0 0 0 0 0 
JC271273 10 14 0 0 ns 
CD221180 0 0 0 0 0 
MM22676 61 0 0 0 0 
DT4676 0 0 0 0 0 
SC191082 74 0 0 0 0 
JS18981 39 0 ns 0 0 
SM051273 0 0 0 0 0 
JM011178 0 0 0 ns ns 
JL300578 312 0 0 0 0 
SD220384 0 0 0 ns ns 
AC290980 0 0 0 ns 0 
PT020681 0 0 0 0 0 
DMcC51174 0 0 0 0 0 
ns : no sample provIded 
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Diazepam was found in 33 % (n= 30) of samples, with a mean and median of 369 and 65 
nglmL respectively. The concentrations found ranged from 5 - 4216 ngimL. The number 
of positives was less than those found in oral fluid collected by the modified Omni-Sal® 
device (59 %) and less than those found in blood (92 %). The concentrations found in oral 
fluid collected by the Intercept® device were greater than those collected by the modified 
Omni-Sal device. The median concentrations of diazepam and its metabolites are shown 
in Table 10-12 compared with the other oral fluid device and blood. From the table it is 
clear that median concentrations in oral fluid collected by the Intercept® device are greater 
than the Omni-Sal device but still less than blood concentrations. 
Table 10-12 : Median concentrations of diazepam and its metabolites in blood, and oral fluid 
collected by two devices. 
Diazepam Median Concentration (ng/mL) 
Oral Fluid (Omni-Sa~) Oral Fluid (Intercept~) Blood 
22 65 353 
N-desmethyldiazepam Median Concentration (ng/mL) 
Oral Fluid (Omni-Sa~) Oral Fluid (Intercept~) Blood 
26 261 380 
Temazepam Median Concentration (ng/mL) 
Oral Fluid (Omni-Sat~) Oral Fluid (Intercept~) Blood 
3 6,4272 55 
Oxazepam Median Concentration (ng/mL) 
Oral Fluid (Omni-Sa~) Oral Fluid (Intercept@) Blood 
8 24 51 
10.4.6 Discussion 
Morphine, 6-MAM and codeine were found less frequently using the Intercept® device 
compared with the Omni -Sal® device. The concentrations found were also less. This can 
be explained by the stimulation effect produced by the salt impregnated in the Intercept® 
device. Drugs with a pKa close to the pH of saliva i.e. 8.5, are affected greatly by a change 
in saliva pH. The Intercept® device also only collects ~0.4 mL of oral fluid compared with 
lmL using the modified Omni-Sal® device. Therefore samples close to the limit of 
detection using the modified Omni-Sal® device may be missed using the Intercept® device. 
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6-MAM was found in five cases using the Intercept® device compared with fifteen using 
the modified Omni-Sal device and none in blood. 
Dihydrocodeine has a slightly higher pKa (8.8) than morphine, and is therefore not as 
affected by the pH change caused by the device. The number of dihydrocodeine positives 
was less than using the Omni-Sal® device but the concentrations were much greater. 
The number ofbenzodiazepine positives using the Intercept® device was less than using 
the Omni-Sal device, but the concentrations found were greater. 
10.4.7 Urine Results 
87 urine samples were collected and analysed. Morphine was found in all patients on day 
1, and in 90 % (n=78) of all samples analysed. The full set of results is shown in Table 
10-13. Most patients are positive for morphine throughout the 5 days. This result is not 
surprising, and the rehabilitation centre use urine analysis to confirm opiate use before 
prescribing methadone. 
Table 10-13 : Morphine concentrations found in urine 
Patient 
Morphine Urine Concentrations (ng/mL) 
Day! Day 2 Day 3 Day 4 DayS 
GY31290 425 496 293 ns 0 
MMG4167 730 2126 245 181 69 
SL16771 377 107 74 ns ns 
MT171060 30 0 0 0 0 
BA3181 2334 737 163 68 ns 
HD180669 77 203 31 8 4 
CL180981 563 465 116 ns 0 
JC271273 265 521 63 12 ns 
CD221180 16254 968 508 653 190 
MM22676 5208 149 22 26 6 
DT4676 8 ns ns 19 8 
SC191082 988 ns 589 451 63 
JS18981 1690 255 110 14 2 
SM051273 1051 414 188 71 52 
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Patient 
Morphine Urine Concentrations (ng/mL) 
Day 1 Day 2 Day 3 Day 4 DayS 
JMOl1178 172 44 ns ns ns 
JL300578 3830 453 290 43 14 
SD220384 1119 392 192 ns 87 
AC290980 10428 1139 301 75 0 
PT020681 959 291 14 0 0 
DMcC51174 388 970 700 120 37 
ns : no sample provided 
6-MAM was found in 7 % (n=6) of samples. 6-MAM is not usually found in urine 
because it metabolises rapidly to morphine. The median concentration found for 6-MAM 
was 286 nglmL with a range of 12 - 1080 ngimL. In 5 cases where 6-MAM was found, 
the corresponding morphine level was greater than 2000 ngimL. 
Codeine was found in 38 % (n=33) of samples, with a median of 17 nglmL, it was never 
found after day 4. Dihydrocodeine was found in 79 % (n=69) of samples, many of these 
were off the scale of the detector. Diazepam was found in 68 % (n=59) of samples, N-
desmethyldiazepam in 36 % (n=31) of samples, temazepam in 54 % (n=47) of samples and 
oxazepam in 78 % (n=68) of samples. Many of these values were at very high 
concentrations and off the scale of the detector. 
10.4.8 Discussion 
Urine analysis can detect opiate use up to 5 days after admission to the centre. 6-MAM 
was rarely found unless the morphine level was very high. Codeine was also found up to 
day 4 in urine samples. Dihydrocodeine and diazepam and its metabolites were found at 
very high concentrations, most likely because they were given these drugs on admission in 
to the rehabilitation centre. 
10.4.9 Conclusions for Detection of Opiates in Heroin Addicts 
The table below, Table 10-14, shows the morphine concentrations found in samples taken 
on day 1 in the centre. 
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Table 10·14: Overall day 1 results for morphine in all matrices 
Patient 
Day 1 Concentrations (ng/mL) 
Blood Interceptl!!l Omni-Sall!!l Urine 
GY31290 ns 7 11 425 
MMG4167 12 ns 0 730 
SL16771 7 0 0 377 
MT171060 ns 0 21 30 
BA3181 19 0 0 2334 
HDl80669 0 0 0 77 
CL180981 7 0 0 563 
JC271273 0 3 0 265 
CD221180 28 0 98 16254 
MM22676 13 20 54 5208 
DT4676 0 0 0 8 
SC191082 ns 25 52 988 
JS18981 ns 13 43 1690 
SM051273 3 0 4 1051 
JM011178 0 0 0 172 
JL300578 4 104 437 3830 
SD220384 3 0 0 1119 
AC290980 16 0 99 10428 
PT020681 0 0 0 959 
DMcC51174 3 0 6 388 
ns : no sample provided 
It is clear that if the object is to determine opiate use in the last 24 hours then urine analysis 
provides this evidence. Although oral fluid morphine concentrations were often higher 
then morphine blood concentrations, the number of positives was less for oral fluid than 
for blood. 
It has been shown that diazepam and its metabolites do not diffuse into saliva easily, and 
concentrations were a magnitude less in oral fluid than in blood. The Intercept® device 
gave higher concentrations of diazepam and its metabolites because of salt present which 
stimulated saliva flow. This is in contrast to the opiates where concentrations were less 
using the Intercept device than with the modified Omni-Sal® device. This can be 
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explained by the pKa of these analytes and their susceptibility of being affected by a 
change in saliva pH. 
Most patients preferred the Intercept® device because it took less time than the modified 
Omni-Sal® device. The instructions for use of the Intercept® are to leave the device in the 
oral cavity for between 2 and 5 minutes. Most patients left the device in for 2 minutes 
only, which could have led to less sample being collected resulting in fewer positive 
results. Patients did not like the salty aftertaste when using the Intercept® device, but it 
seemed that the time taken was more important to them. The modified Omni-Sal® device 
took between 5 and 30 minutes to collect 1 mL of oral fluid. One of the side effects of 
opiate use is "dry mouth" resulting in a longer time to collect a specified volume. 
The detection of 6-MAM in oral fluid where none was found in blood is significant in that 
it can be used as a specific marker for heroin use. 6-MAM was only found in 6 urine 
samples compared to 15 samples collected with the Omni-Sal® device and 5 with the 
Intercept® device. 
Although oral fluid analysis proved unsuitable for the rehabilitation centre setting, it was 
generally accepted more than urine and blood. The morphine blood concentrations were 
very low, so it is unsurprising that there were many negative oral fluid samples. 
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11 Conclusions 
The potential use of liquid chromatography - mass spectrometry has been investigated for 
its use in forensic toxicology. It has been shown that it is an invaluable tool and 
complements the use of gas chromatography - mass spectrometry. 
The development of a sensitive and specific method for the detection of flunitrazepam in 
blood is essential for the increasing number of drug facilitated sexual assault cases 
submitted to the laboratory. Limits of quantitation of 0.2 and 0.5 nglmL were achieved for 
flunitrazepam and its metabolite 7-aminoflunitrazepam respectively. It was also 
discovered that the use of very concentrated additives in the mobile phase frequently 
suppressed ionisation in the source, and lowered sensitivity. 
In addition to flunitrazepam another method was developed for diazepam and its 
metabolites N-desmethyldiazepam, temazepam and oxazepam. This proved invaluable 
with limits of detection :s 1.1 nglmL for each analyte. The sensitivity of LC-MS is shown 
to be much greater than HPLC with UV detection and it doesn't suffer from the same 
interference from biological samples. With the use of the chlorine atom present in every 
analyte, a qualitative ion was found by looking for the pseudo-molecular ion containing 
35CI and 37 Cl. Not only the additives present in the mobile phase affect ionisation as does 
the organic solvent. Acetonitrile was found to be much more preferential to the 
benzodiazepines ionisation than methanol. 
With the submission of a post-mortem blood sample requiring sildenafil analysis it was 
necessary to develop and validate a suitable instrumental method. LC-MS proved suitable, 
with its in-source collision capable of monitoring the pseudo-molecular ion and ,specific 
daughter ion simultaneously. The method was validated and applied to post-mortem 
blood, eliminating sildenafil overdose as a cause of death. 
The use of oral fluid as an alternative matrix to blood or urine, has come to the forefront of 
forensic toxicology in recent years. In the course of this project it was assessed as a 
roadside collection device and as an alternative to urine in a rehabilitation centre setting. A 
disadvantage of oral fluid testing is the lack of volume obtained from the subject. This 
need not be a problem if a unified extraction method is used to simultaneously extract 
multiple analytes. With the use of this method, analytes were analysed by using both LC 
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and GC-MS. Thermally labile drugs requiring derivatisation for GC-MS analysis were 
analysed on the LC-MS, this included 20 drugs of abuse and their metabolites. The LC-
MS required less maintenance and consequently suffered from much less down-time than 
the GC-MS. In the first project involving oral fluid analysis (Chapter 7), the LC-MS was 
used and further qualitative information was obtained from the GC-MS. There was great 
correlation between the quantitative results from both instruments. Using LC-MS-MS in 
the second project (Chapter 8) made the acquisition of Full MS-MS data possible, negating 
the need for confirmation from the GC-MS. Although three injections were needed for 
each sample, to analyse all 21 analytes, many injections could be placed in a queue running 
the instrument almost continuously because of its reliability. 
Finally the method developed in Chapter 8 was validated for 8 drugs extracted from urine, 
blood and an additional oral fluid collection device. This enabled the detection of analytes 
over various matrices collected at the same time. Unfortunately drugs of abuse do not 
seem to be suited to the prediction of blood concentrations from oral fluid concentrations. 
This is evident from the marked differences between the two oral fluid collection devices. 
Recent drug use can be assessed though; in the case of contamination of the oral cavity 
drug administration can be predicted within the last few hours. 
With respect to benzodiazepine analysis in oral fluid, it is evident that concentrations found 
in oral fluid are considerably less than blood. The use of a collection device with salt 
stimulation resulted in higher concentrations, although these were still less than blood. 
This data provides valuable information on benzodiazepine concentrations found in 
subjects who are known abusers ofValium®. 
In conclusion, the reliability, versatility and specificity of LC-MS and LC-MS-MS are 
unsurpassed and there is a definite need for its use in forensic toxicology. This is not to 
say that GC-MS has lost its place in the laboratory. The parallel use of these two 
instruments in the laboratory will provide a solution to most forensic toxicology problem. 
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12Further Work 
The use of LC-MS for the detection and quantitation for drugs of abuse in blood, urine and 
oral fluid has been shown. With some adaptation of the extraction methods, LC-MS 
analysis could be applied to different matrices including hair. The matrix effects would 
have to be monitored to ensure limits of detection were not compromised. Evaluating the 
matrix effects from different matrices would be useful in determining the optimum sample 
pre-treatment and extraction procedure. This may mean that for urine analysis a simple 
dilution would be sufficient because of the high drug concentrations expected. 
Screening for unknown drugs in LC-MS is more difficult than in GC-MS as the spectra a 
variable with instrument, laboratory, chromatography conditions and voltages applied for 
fragmentation. To overcome this an in-house library would need to be built up with 
different collision energies for each drug. The use of two collision energies, a high and 
low, would give a molecular ion and a more detailed spectra with specific daughter ions. 
The use of data-dependent scanning enables the instrument to select the ion with the 
highest response and carry out an MS-MS scan on it. 
With respect to oral fluid, there are many questions unanswered as to the concentrations 
obtained and their relevance. By doing more controlled research into the collection 
devices available, and their relationship with expectorate, a better understanding would be 
achieved. This could involve the measurement of the pH of oral fluid when it is sampled, 
as this is an important factor when analysing drugs of abuse. Also more work could be 
carried out with the Intercept® device to establish if leaving the pad in for a longer period 
of time greatly effects the final concentrations. Washing the pads from the collection 
devices and extracted the washes may be useful in determining ifbenzodiazepines are 
adsorbed in some way on the pad. By simultaneously collecting expectorate and oral fluid 
using collection devices, a better understanding of the effect of the collection device on 
drug concentrations could be achieved. 
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SIMULTANEOUS DETECTION AND QUANTITATION OF 21 
DRUGS OF ABUSE AND THEm METABOLITES IN ORAL FLUID 
USING LIQUID CHROMATOGRAPHY - ELECTROSPRAY MASS 
SPECTROMETRY 
H. Torrance, F.M. Wylie and J.S. Oliver 
Forensic Medicine and Science, University of Glasgow, Glasgow, UK 
Aims: An LC-MS method has been developed for drug analysis in oral fluid. The method 
was validated for 21 drugs of abuse and their metabolites. Methods: A single quadrupole 
instrument was used in Selected Ion Monitoring (SIM) mode with an electro spray 
interface. Skimmer cone voltages for each drug were optimised and defined, ranging from 
5 V for amphetamine to 40 V for norbuprenorphine. The probe temperature was set at 350 
°C with 5 kVapplied. A Phenomenex Luna C18(2) 150 X 2.0 mm with 3 flm packing was 
used for separation with a guard column of identical packing material. The mobile phase 
composition was investigated to include the use of formic acid in combination with other 
buffers to monitor the effect on response. The use of a basic buffer, 10 mM ammonium 
bicarbonate, was also explored. The optimised mobile phase employed a gradient system 
of acetonitrile and 10 mM ammonium bicarbonate. Oral fluid samples were collected 
using the modified Omni-Sal® device supplied by Cozart and extracted using Bond Elut 
Certify solid phase extraction columns. The analytes were eluted using 4 mL acetone : 
chloroform (50:50) then 4 mL of ethyl acetate with 2 % ammonia. Both fractions were 
blown down under nitrogen, reconstituted in mobile phase and injected into the LC-MS in 
duplicate. Results: Recoveries for all drugs of interest were found to be over 80 %. 
Limits of detection were calculated as 3 times the standard error of the straight line + the 
intercept. They ranged from 0.1 nglmL for buprenorphine to 1.5 nglmL for cocaethylene. 
Limits of quantitation were calculated using 10 times the standard error, they were all 
found to be ~ 5.0 ng/mL. This method was applied to 40 oral fluid samples. Conclusions: 
Ammonium bicarbonate was found to be favourable for the chromatography and ionisation 
of the compounds identified in this method. A single quadrupole LC-MS was successfully 
used to identify and quantify the major drugs of abuse and their metabolites from 1 mL of 
oral fluid. 
Keywords: drugs of abuse, oral fluid, LC-MS 
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THE USE OF LIQUID CHROMATOGRAPHY - MASS 
SPECTROMETRY IN FORENSIC TOXICOLOGY. 
H. Torrance and 1.S. Oliver 
Forensic Medicine and Science, University of Glasgow, Glasgow, UK 
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Gas Chromatography - Mass Spectrometry (GC-MS) has been accepted as the gold 
standard technique for the qualitative and quantitative analysis of drugs in forensic 
toxicology. Unfortunately due to a number of factors including the high temperatures 
involved not all drugs chromatograph well by GC, especially thermally labile analytes. 
High Pressure Liquid Chromatography (HPLC) has proved useful in the analysis of such 
analytes. With only UV detection however it is not as sensitive or specific as MS. HPLC 
has its advantages because of the gentle separation and lack of high temperatures it 
employs. Using a UV detector does not give the structural information ofMS spectra, and 
can suffer from interference if samples are especially dirty e.g. post-mortem blood extracts. 
To separate using liquid chromatography and detect with a mass spectrometer would be 
ideal. Only in the last two decades has LC been successfully interfaced to MS. With the 
use of LC-MS, sensitive and specific methods can be developed to analyse otherwise 
problematic drugs. For example Rohypnol®, the infamous "date rape" drug, is 
administered in very low doses and metabolises rapidly in the body. A very sensitive 
detection technique is required which LC-MS provides. Analysis ofbenzodiazepines by 
GC is not ideal because of thermal decomposition at the high temperatures involved in the 
separation. LC-MS uses gentle separation with no heat and with soft ionisation in the MS. 
Other forensic applications of LC-MS include the ability to quantitate 21 drugs of abuse 
and their metabolites. The advantages of this technique include no derivatisation, analysis 
of thermally labile compounds and little downtime of the instrument. 
Keywords: forensic toxicology, LC-MS 
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ANALYSIS OF SALIVA FOR DRUGS OF ABUSE USING LC-MS 
H. Torrance and F.M. Wylie 
Forensic Medicine and Science, University of Glasgow, Glasgow, UK 
Oral fluid testing for drugs of abuse has become of great interest in a variety of areas such 
as roadside testing of potentially intoxicated drivers, testing of patients involved in drug 
maintenance programmes and drug testing in the workplace. Oral fluid samples can be 
collected using one of several commercially available devices. However, regardless of the 
device, the limitation of this specimen is often in the amount of sample available. In cases 
where the sample has to be tested for a wide variety of drugs ideally a single extraction 
method is preferable. 
The use of Liquid Chromatography - Mass Spectrometry (LC-MS) for the separation and 
detection of drugs means that sensitive and specific methods can be developed to include 
drugs which may otherwise be problematic by Gas Chromatography-Mass Spectrometry. 
This presentation will discuss the use of single quadrupole and ion trap LC-MS 
instruments with electrospray ionisation for the analysis of drugs of abuse in oral fluid 
samples. The drug findings in two projects involving drivers and the relative merits of each 
instrument will be addressed. 
